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Abstract 
A number of growth factors and cytokines involved in the local regulation of bone 
remodelling are either synthesised by osteoblasts or have osteoblasts as their target. 
These include the RANK-L/OPG system, the gp130 cytokine family, including IL-6, and 
insulin like growth factors. In addition, aberrant cytokine signalling is strongly linked 
with pathological states characterised by increased bone resorption, including 
osteoporosis and renal osteodystrophy. The range of action and potency of these 
osteotropic cytokines requires that their actions are tightly regulated. Amongst such 
potential control mechanisms are the suppressors of cytokine signalling (SOCS), the 
presence and role of which in bone has not been studied in detail.  
 
The aim of this thesis was (i) to examine the direct effect of uraemia on cytokine 
release in human osteoblastic cells; (ii) to determine if the regulatory SOCS genes are 
expressed in these cells and, if so, (iii) to characterise their functional significance.  
 
In initial studies, osteoblastic cells were cultured in media containing sera from either 
healthy volunteers or haemodialysis treated chronic kidney disease patients. 
Concentrations of OPG and IL-6 were then measured in harvested supernatants. 
Additionally, individual serum samples collected prior to, and during, a haemodialysis 
(HD) session were assayed for IL-6, IL-1β and soluble IL-6 receptor (sIL-6R). HD 
patients had significantly higher concentrations of IL-6 than normal subjects, but there 
were no significant differences in either IL-1β or sIL-6R. These concentrations did not 
change significantly during HD. There were no differences in OPG production by 
osteoblastic cells after exposure to either normal or uraemic serum. Incubation with 
untreated sera from normal subjects increased IL-6 production by ~6-fold above 
control, whereas sera from uraemic subjects increased it only ~2-3-fold. HD did not 
restore the capacity of uraemic serum to augment IL-6 release to the same degree as 
normal serum.  
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Further work examined a variety of osteotropic stimuli for their ability to induce SOCS1-
3 and CIS expression in human osteoblastic cells. The utility of both conventional RT-
PCR and fluorescence-based kinetic real time PCR for this purpose are compared. 
These SOCS were found to be expressed constitutively and could be induced to a 
variable degree by relevant growth factors. In general, the temporal pattern of SOCS 
expression was consistent with a negative feedback function. Potential functionality 
was explored following transfection with SOCS1 and SOCS3 plasmid DNA. 
Significantly enhanced IL-6 secretion was found in both the basal and stimulated state, 
whilst OPG production was enhanced only in the latter. Function was also studied in 
the context of osteoblastic apoptosis, the regulation of which is highly relevant to 
skeletal disease. Initial experiments developed a framework for subsequent studies: 
serum starvation for 24h produced reproducible cell death that could be attenuated in a 
dose dependent manner by IGF-I. SOCS1 and SOCS3 overexpression had limited 
influence on osteoblast survival, whereas gene knock down experiments using siRNA 
indicated that IL-1β-induced cell death is mediated differentially, depending on the type 
of cell death involved. SOCS1 and SOCS3 are involved in the apoptotic cascade, while 
IL-1β-induced necrosis appears to be independent of SOCS3. 
 
Collectively these studies demonstrate that the augmentation of IL-6 production by 
osteoblastic cells after exposure to normal serum is greater than after uraemic serum. 
HD does not correct this disparity; perhaps indicating a non-dialysable inhibitor of IL-6 
release is involved in the dysregulated bone turnover of uraemic patients. Further work 
establishes the constitutive presence of the SOCS family in human osteoblastic cells, 
as well as their transient inducibility by key osteotropic stimuli. Several novel aspects of 
SOCS function, including influence on IL-6 and OPG production and involvement within 
apoptotic pathways are demonstrated.  
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PPARγ1    peroxisome proliferator-activated receptor-1 
PVDF     polyvinyldifluoride 
RANK     receptor activator of NF-κB 
RANK-L    receptor activator of NF-κB Ligand 
RAS     rat sarcoma 
rhGH     recombinant human growth hormone 
RIP-1     receptor interacting protein 1 
RNA     ribonucleic acid 
ROCK-1    rhokinase isoform-1 
Runx2     runt-related transcription factor 2 
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RRT     renal replacement therapy 
RT-PCR    reverse transcription polymerase chain reaction 
RXR     retinoid X receptor 
SDS     sodium dodecyl sulphate 
SERM selective oestrogen receptor modulator 
SHP Src homology domain 2 -containing protein 
tyrosine phosphatase-1 
SHPT     secondary hyperparathroidism 
sIL-6R     soluble interleukin-6 receptor 
SOCS     suppressors of cytokine signalling 
SSi     STAT inducible STAT inhibitor 
STAT signal transducer and activator of transcription 
Taq     Thermus aquaticus 
TBE     tris borate EDTA 
TBS-T     Tris-Buffered Saline and Tween 20 
TGF-ß     transforming growth factor – ß 
TNF     tumour necrosis factor 
TLR     Toll-like receptor group 
TRAF     TNF receptor associated factor 
TRAIL     TNF-related-apoptosis-inducing-peptide 
TRAP     tartrate resistant acid phosphatase 
VDR     vitamin D receptor 
VDRE     vitamin D response elements 
VEGF     vascular endothelial derived growth factor 
UV     ultraviolet 
Wnt     wingless and Int-1 
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1.0 Introduction 
1.1  Bone 
Bone tissue is not static, it is continually being remodelled according to mechanical and 
metabolic requirements. This process is complex, involving the concerted action of two 
important cell populations, bone forming cells (osteoblasts) and bone resorbing cells 
(osteoclasts), and proceeds under the regulatory influence of both systemic osteotropic 
hormones and local paracrine factors. Remodelling serves several important 
physiological purposes, functioning not just to renew bone as it deteriorates, but to 
redistribute bone matrix along lines of mechanical stress, allow healing of 
injured/fractured bone and permit the skeleton to act as a reservoir for calcium and 
phosphate. During normal remodelling, the development, longevity and interactions 
between cells within skeletal tissue are all critical steps (Coe and Favus, 2002).  
 
Bone is a specialised connective tissue that makes up, together with cartilage, the 
skeletal system. It consists of several dedicated cell types and a distinctive 
extracellular matrix composed of collagen fibres and non-collagenous proteins. The 
ability of this matrix to undergo hydroxyapatite mineralization endows bone with many 
of its unique characteristics (Favus and Christakos, 1999). 
 
Bone serves three important functions: - 
• Mechanical - it is the site of muscle attachment for locomotion. 
• Protection - for vital organs and the bone marrow. 
• Metabolic - it acts an ion reservoir for mineral metabolism. 
 
1.1.1 Macroscopic organisation 
Two types of bone can be distinguished in the skeleton: flat bones (e.g. skull bones, 
scapula, and mandible) and long bones (e.g. tibia, femur and humerus). Long bones 
are composed of two wider extremities (the epiphyses), separated from a cylindrical 
central tube (the midshaft or diaphysis) by a developmental zone (the metaphysis). 
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This is shown schematically in figure 1. In a growing long bone, the epiphysis and the 
metaphysis are separated by a layer of cartilage called the growth plate (epiphyseal 
cartilage). This area of cell proliferation and expanding matrix is the site of longitudinal 
growth. Once growth is completed the epiphyseal cartilage is destined to become 
calcified itself. The outer region of bone is formed by an extremely dense layer of 
tissue, known as cortical or compact bone. This strong layer encloses the medullary 
cavity, which houses the haematopoietic bone marrow. In areas close to the 
metaphysis this internal space is honeycombed by a lattice work of plates called 
trabeculae. These create cavities that can be filled with either haematopoietic marrow 
or adipose tissue. In certain cases, as in the sinuses of the skull, the spaces are filled 
with air. These trabeculated areas constitute cancellous, also termed spongy or 
trabecular, bone. Cortical and trabecular bone are populated by the same cell types 
and have identical matrix elements, though they exhibit important differences. 
Structurally the most significant difference is that 80 to 90% of cortical bone is calcified, 
in contrast to only 15 to 25% of trabecular bone. Functionally, cortical bone has a 
primarily mechanical or protective purpose, while trabecular bone is more actively 
engaged in metabolic processes. 
 
1.1.2 Microscopic organisation 
Bone is formed by collagen fibres, 90% of which are type I collagen, and non-
collagenous proteins. Once secreted, the collagen fibres undergo extracellular 
processing to produce mature three chain type I collagen molecules that are able to 
assemble into fibrils. Individual collagen molecules are interconnected via unique 
pyridinoline cross-links. The orientation of the fibres alternates from layer to layer, 
giving bone a typical lamellar structure. This arrangement permits the highest density 
of collagen per unit volume of tissue. The lamellae form either continuous layers at the 
surface (circumferential lamellae), or concentric cylinders around neurovascular 
channels (Haversian canals). In cases where bone is being formed rapidly, as is the 
case during development, fracture healing and some metabolic bone diseases, 
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including those associated with kidney disease, the preferential organisation of the 
collagen fibres is disturbed, resulting in poorer quality, woven, bone.   
 
                                                                                     
 
 
Figure 1.1: Schematic view of a longitudinal section through a growing long bone. (Adapted 
from Jee W. The skeletal tissues. In Weiss L, ed. Histology, cell and tissue biology. New York: 
Elsevier Biomedical, 1983: 200-255, reproduced in Favus 1999) 
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Osteocalcin and osteonectin constitute 40 to 50% of the non-collagenous matrix 
proteins. Mice deficient in osteonectin exhibit decreased osteoclast and osteoblast 
numbers and profound osteopenia (Delany et al., 2000), suggesting an active role in 
the life cycle of these cells. A number of other proteins such as osteopontin, bone 
sialoprotein, fibronectin, vitronectin, and thrombospondin are present and function as 
attachment factors that interact with integrins. The majority of the non-collagenous 
proteins present in the matrix are synthesised by fully differentiated osteoblasts, though 
some are synthesised elsewhere and preferentially imported; e.g. fetuin (α2-heremans 
schmid glycoprotein), synthesised in the liver. The remainder of the extracellular matrix 
consists mainly of highly anionic glycoproteins and proteoglycans. These have a high 
ion-binding capacity and play an important part in the calcification process. 
Mineralisation occurs via the deposition of hydroxyapatite crystals [3Ca3(PO4)2] (OH)2] 
throughout the collagen fibres. Osteoblasts are thought to regulate local concentrations 
of calcium and phosphate in such a way as to promote the formation of hydroxyapatite 
(Boskey, 1998). Prior to undergoing mineralisation, bone matrix is known as osteoid.  
 
 
1.2 Osteoblasts 
Osteoblasts, the cell type at the centre of this thesis, are cuboidal, basophilic, 
mononuclear cells found on the surface of growing or remodelling bone. They occur in 
clusters and never function in isolation. Osteoblasts occupy a central position in the 
homeostasis of skeletal tissue. Their functions include:- 
• Synthesis and secretion of matrix. 
• Mineralisation of the matrix. 
• Regulation of bone turnover - osteoblasts are the major target of the ‘classical’ 
osteotropic hormones parathyroid hormone (PTH) and 1,25 – dihydroxyvitamin D3 
(1,25(OH)2D3 or calcitriol) as well as the source of many local growth factors and 
cytokines.  
• Control of osteoclastogenesis. 
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1.2.1 Origin and lineage 
 
The precursors of osteoblasts are pluripotent mesenchymal stem cells. These may 
also give rise to chondrocytes, myocytes, fibroblasts, adipocytes and a variety of 
haematopoiesis support cells (Aubin, 2001). Osteoblast precursors most likely reach 
bone by migration from neighbouring connective tissues. Commitment of mesenchymal 
precursors to the osteoblastic lineage is initiated by bone morphogenetic proteins 
(BMPs), particularly BMP -2 and - 4, members of the transforming growth factor ß 
(TGF-ß) superfamily (Abe et al., 2000). BMPs stimulate transcription of the gene 
encoding Cbfa1 (core binding factor a1), a transcription factor that induces osteoblast 
differentiation via the activation of a range of osteoblast specific genes including those 
for alkaline phosphatase, osteopontin, bone sialoprotein, type I pro-collagen and 
osteocalcin (Ducy et al., 1997, Ducy, 2000). Lack of Cbfa1 prevents osteoblast 
development and, because of the dependence of osteoclastogenesis on mesenchymal 
cell differentiation, also reduces the population of osteoclasts (Gao et al., 1998, Komori 
et al., 1997). Other factors such as TGF-ß, platelet derived growth factor (PDGF), 
fibroblast growth factors (FGFs), and insulin like growth factors (IGFs) are able to 
influence the replication and differentiation of committed osteoblast precursors toward 
the osteoblast lineage, though they are unable to induce osteoblast differentiation from 
uncommitted progenitors (Marcus et al., 2001). The relationship between 
osteoblastogenesis and adipogenesis is a particularly intimate one, with peroxisome 
proliferator activated receptor γ1 (PPARγ1) appearing, through its ability to inhibit the 
expression of other lineage specific transcription factors, to act as an important early 
determinant of mesenchymal progenitor cell destiny (Shao and Lazar, 1997, Lecka-
Czernik et al., 1999). In fact, the discovery of communication between cells of 
osteoblast and adipocytes lineage (via leptin and other hormones) and therefore 
between bone remodelling and energy metabolism is an area of increasing interest. It 
may have particular relevance in diabetes mellitus, where disorders of bone 
remodelling are common (Kawai et al., 2009). 
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The isolated mature osteoblast cannot simultaneously perform all the functions needed 
for the initiation and maintenance of bone formation. This is achieved by maintaining a 
pool of osteoblasts populated by cells at various differentiation stages. This phenotypic 
heterogeneity, despite common lineage, provides the diverse functionality required for 
bone generation. The principal forms that mediate bone-forming processes are (i) 
stromal osteoprogenitor cells (contribute to the maintenance of the osteoblast 
population and bone mass); (ii) mature osteoblasts (synthesise bone matrix at the bone 
forming surfaces); and (iii) osteocytes (terminally differentiated cells that support bone 
structure). As a general rule, osteoblastic maturity increases in relation to the proximity 
to the bone surface.  
 
1.2.2 Ultrastructure and properties of the osteoblast 
 
The osteoblast is a highly metabolically active cell, with a large proportion of this 
activity channelled into the production of type I collagen (Bilezikian et al., 2002). It has 
an abundant rough endoplasmic reticulum committed to the production of extracellular 
matrix proteins, including osteocalcin and osteopontin. A number of the growth factors 
and cytokines that are intimately involved in the local regulation of the remodelling 
cycle are also synthesised by osteoblasts. The most important of these are the BMPs, 
the transforming growth factor ßs (TGF-ßs), the insulin–like growth factors (IGFs), the 
gp130 family of cytokines (chiefly IL-6 and IL-11), platelet derived growth factors 
(PDGFs) and osteoprotegerin (OPG) (Heymann and Rousselle, 2000, Hofbauer et al., 
2000). 
 
The cell membrane of the osteoblast is characteristically rich in a specific isoform of 
alkaline phosphatase (ALP), the precise role of which remains unclear. However, 
relevance has always been inferred from the observation that ALP deficiency in 
hypophosphatasia, an inherited systemic disorder, results in defective mineralisation 
and poor dentition (Whyte, 1994). It seems likely that local inorganic pyrophosphate, 
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generated by both the nucleotide pyrophosphatase-phosphodiesterase designated 
NPP1, as well as the transporter ANKH, can inhibit hydroxyapatite formation unless 
hydrolysed by ALP – a process that will also provide free inorganic phosphate for 
mineralisation (Orimo, 2010). The serum concentration of bone specific ALP is used 
clinically as a useful marker of bone turnover.  
 
1.2.3 Control of osteoblast function 
 
Osteoblastic function is controlled by endocrine, paracrine and autocrine influences. 
Expression of receptors for PTH and active vitamin D means that these important 
systemic hormones can exert influence. Furthermore, it is through the mediation of the 
osteoblast that these stimuli are processed and passed on to the osteoclast prior to the 
initiation of bone resorption.  
 
1.2.4 Relationship with osteoclasts: the RANK-L/OPG system 
 
It has long been recognised that, within the bone microenvironment, osteoblasts exert 
an important influence over neighbouring osteoclasts. While the paracrine release of 
cytokines (including IL-1, IL-6, IL-11, TNF and TGF-ß) ostensibly explained this cellular 
cross-talk, it was noticeable that spatial proximity of osteoblast to osteoclast was a 
prerequisite for behavioural change in the latter (Suda et al., 1992, Martin and Ng, 
1994, Martin et al., 1998). Growth factors in isolation provided an inadequate stimulus. 
There seemed to be a concealed line of communication that enabled the osteoblast to 
orchestrate bone homeostasis so effectively. The discovery of two glycoproteins, both 
from the TNF receptor superfamily, termed (after several early nomenclature changes) 
osteoprotegerin (OPG) and the ligand for receptor activator of NF-κB (RANK-L) 
provided the missing link (Simonet et al., 1997a, Yasuda et al., 1998a, Lacey et al., 
1998). These constitute a system that acts as the final effector pathway for a host of 
osteotropic stimuli. RANK-L is expressed in committed pre-osteoblastic cells (as well 
as T lymphocytes), while its receptor (RANK) is found on osteoclastic progenitors. The 
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activation of RANK in osteoclasts results in activation of several intracellular signal 
transduction pathways, particularly TRAF 6, which bind the nuclear factor κB (NF-κB). 
This translocates to the nucleus, where it upregulates cofactors that induce 
osteoclastogenic gene transcription. These promote osteoclastic differentiation, 
activation and survival, thereby increasing the pool of mature, functioning osteoclasts 
able to undertake bone resorption (Suda et al., 1999). RANK-L and macrophage 
colony stimulating factor (M-CSF) alone are sufficient to invoke osteoclastogenesis 
independent of other growth factors. This is summarised in figure 1.2. OPG provides 
an ingenious regulatory mechanism; like RANK-L it is an osteoblastic product, but it 
differs importantly in being secreted rather than membrane bound. Once released it 
acts as a decoy receptor for RANK-L, preventing its interaction with RANK and 
opposing the stimulation of osteoclasts. It is a very potent inhibitor of 
osteoclastogenesis and bone resorption both in vitro and in vivo. In this way, bone 
remodelling becomes intimately related to changes in expression of OPG and RANK-L 
(Hofbauer et al., 2000). When OPG levels decrease, more RANK-L is available to bind 
RANK and induce bone resorption. Conversely, a rise in OPG tips the balance in 
favour of bone formation.  Factors that decrease the OPG/RANK-L ratio, thereby 
favouring bone resorption with higher rates of bone turnover, include TNF-α (Hofbauer 
et al., 1999c), PTH (Yasuda et al., 1998b), PTH related peptide (PTHrP), calcitriol 
(Yasuda et al., 1998b), glucocorticoids (Hofbauer et al., 1999a), gp130 activating 
cytokines (e.g. IL-6, IL-11) (Yasuda et al., 1998b), IL-1 (Hofbauer et al., 1998, 
Hofbauer et al., 1999c) and the immune suppressant drug cyclosporine (Hofbauer et 
al., 2001). This latter observation may provide a possible explanation for the more 
marked effects on osteoblastic proliferation and differentiation of cyclosporine than the 
related immune suppressant tacrolimus (Moreira et al., 2009). Those that increase the 
OPG/RANK-L ratio, thereby decreasing bone resorption and slowing bone turnover 
include oestrogens (Hofbauer et al., 1999b), androgens (Hofbauer et al., 2002), BMP-2 
(Hofbauer et al., 1998) and possibly IGF-I (Rubin et al., 2002).  
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Figure 1.2: A
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atic representation of osteoclast differentiation and function as supported by osteoblasts/strom
al cells. 
A
dapted from
 (S
uda et al., 1999, H
arada and R
odan, 2003) 
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The crucial role of the OPG/RANK-L system in bone remodelling is emphasised by 
observations in transgenic mice, where manipulation of the relevant genes produces 
extremes of skeletal phenotype. OPG over-expression and both RANK-L and RANK 
gene deletion all result in osteopetrosis (characterised by deficient osteoclastic 
resorption, increased bone mass and marked skeletal fragility), while OPG knockout 
leads to severe osteoporosis (Simonet et al., 1997b, Bucay et al., 1998, Mizuno et al., 
1998, Kong et al., 1999). These observations, coupled with the finding that OPG 
administration prevented bone loss in ovariectomised mice (Kostenuik et al., 2001), 
stimulated huge interest in the potential for manipulation of the OPG/RANK-L system in 
the treatment of osteoporosis and/or other pathological conditions involving bone loss. 
Recently, a full year of transgenic overexpression of OPG has demonstrably 
suppressed bone resorption, while increasing vertebral strength, in rats (Ominsky et 
al., 2009) and inhibition of RANK-L has improved bone mass in both healthy rodents 
(Rosen, 1994) and in several animal models of human disease (Kostenuik et al., 2001, 
Samadfam et al., 2007). Encouraging clinical data is also emerging - with the 
demonstration of reduced bone turnover, as inferred from biochemical data, in post-
menopausal women following a single OPG dose (Bekker et al., 2001) and recent 
preliminary clinical studies involving a fully human monoclonal antibody to RANK-L. 
The latter possesses high specificity and affinity for its antigen and acts to neutralise it 
in a similar manner to OPG. (McClung et al., 2006, Cummings et al., 2009, Lewiecki et 
al., 2007) However, it is worth mentioning that the correlation between serum OPG 
levels and fractures or BMD is inconsistent and clinically unhelpful (Browner et al., 
2001). 
 
In addition to skeletal metabolism, the RANK/OPG system may play a significant 
regulatory role in several other biological systems. OPG is produced by many tissues 
in addition to bone, including skin, liver, stomach, intestine, lung, heart, kidney, 
placenta and haematopoietic/immune cells. Of particular note is the observation that 
mice deficient in RANK-L lack lymph nodes as well as osteoclasts (Kong et al., 1999). 
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RANK/OPG is also credited with a role in the regulation of antigen presentation and T 
cell activation (Emery et al., 1998). In addition, OPG also binds with high affinity to the 
cytotoxic ligand TRAIL (TNF-related apoptosis-inducing ligand) and inhibits TRAIL-
mediated apoptosis in lymphocytes (Degli-Esposti, 1999). This, and the realisation that 
antibodies to exogenous OPG could be raised, is one of the principle reasons for the 
deceleration in its development as a therapeutic agent - inhibition of TRAIL-mediated 
apoptosis could conceivably interfere with tumour surveillance.  
 
An additional, unexpected, finding of profound interest was that OPG knockout animals 
developed widespread medial vascular calcification (Bucay et al., 1998), preventable 
by transgenic overexpression of soluble OPG (Min et al., 2000). Recombinant OPG 
has also been shown to prevent the vascular calcification induced by both warfarin and 
vitamin D in rats (Price et al., 2001). The subsequent accumulation of evidence has 
suggested that vascular calcification is intimately related to bone resorption. For 
example, if OPG knockout mice are cross bred with Apolipoprotein E (ApoE) 
knockouts, the latter predisposing to atherosclerosis and vascular calcification, bone 
turnover demonstrably increases in association with accelerated calcification and 
plaque progression (Bennett et al., 2006). Evidence from human studies also supports 
the relationship. An observational study in postmenopausal women has shown that 
aortic calcification is inversely related to bone density and positively associated with 
fractures (Schulz et al., 2004). It therefore seems somewhat counterintuitive that 
several observational studies have demonstrated a positive correlation between serum 
OPG concentration and vascular disease (Ziegler et al., 2005, Browner et al., 2001, 
Jono et al., 2002, Schoppet et al., 2003, Kiechl et al., 2004, Nitta et al., 2003). Possible 
interpretations of this include OPG playing an active role in disease progression, or 
functioning as part of a compensatory mechanism to retard it (Kearns et al., 2008). It is 
possible that while OPG reduces vascular calcification through suppression of bone 
turnover, it may have a neutral effect on atherosclerosis. To support this, LDL receptor 
knockout mice fed on a high-fat diet have a significant reduction in calcified aortic 
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lesions, but not atherosclerotic ones, following treatment with OPG (Morony et al., 
2008).  
 
1.2.5 Osteocytes 
 
The final fully differentiated cells of the osteoblast lineage are known as osteocytes. 
They are the most abundant cell type in mature bone (about ten times more common 
than osteoblasts) and are essentially osteoblasts that have been engulfed by 
mineralised matrix. Despite this incarceration, they are not metabolically inactive and 
continue to synthesise several matrix components. Osteocytes are characterised by a 
striking stellate morphology, reminiscent of the dendritic network of the nervous system 
(Bilezikian et al., 2002). Their contact with other cells, including bone forming 
osteoblasts, through these cellular processes has led to suggestions that they act as 
local sensors, or barometers, of prevailing mechanical and metabolic circumstances 
(Aarden et al., 1994). 
 
1.2.6 Lining cells 
The surface of normal quiescent bone (i.e. bone that is not undergoing remodelling) is 
covered by a layer of unmineralised collagen matrix on top of which there is a layer of 
flat and elongated cells. These ‘lining cells’ are the descendents of osteoblasts (Parfitt, 
1994). Osteoclasts cannot attach to the unmineralised collagenous lining layer and it 
seems to be the responsibility of lining cells to remove it, while sending a signal of 
attraction to the resorbing cells. This is the first step in remodelling and probably 
proceeds under the coordination of osteocytes (Parfitt et al., 1996). 
 
1.2.7  Wnt signalling 
Mention should be made of the emerging importance of the Wnt (Wingless and Int-1) 
signalling pathways for bone over the last decade. Wnt are a family of secreted 
glycoproteins with shared cysteine residues, that signal through members of the 
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Frizzled (Fz) receptor family. Ligand binding induces one of three known downstream 
pathways, but the canonical (Wnt/β-catenin) pathway appears the most relevant in a 
skeletal context (Westendorf et al., 2004). Evidence from several rare hereditary bone 
disorders suggests a role in bone formation (Krishnan et al., 2006) and the pathway 
appears active in many aspects of pre-osteoblast and osteocyte function, including 
differentiation, proliferation and apoptosis (Piters et al., 2008). It also presents an 
attractive target for drugs as it offers several potential targets for intervention (Rawadi 
and Roman-Roman, 2005). 
 
In summary, cells of osteoblastic lineage perform two crucial tasks. Firstly they are 
responsible for the production and subsequent mineralisation of the bone matrix. 
Secondly, they have a pivotal role in the regulation of the bone remodelling cycle 
through (i) their response to endocrine influences such as PTH and active vitamin D 
and (ii) their influence over osteoclastic development and function through the RANK-
L/OPG system. 
 
1.3 Osteoclasts 
The osteoclast is the only cell capable of resorbing bone directly. Unlike osteoblasts, 
they are derived from the monocyte/macrophage lineage. Although the exact stem cell 
is still uncertain, the colony forming unit for the granulocyte-macrophage series is 
considered the most likely (Roodman, 1999). Osteoclasts are giant multi-nucleated 
cells, containing four to twenty nuclei. Their cytoplasm contains abundant Golgi 
complexes and many vacuoles containing lysosomal enzymes. They are usually found 
in close proximity to the bone matrix. The zone of contact between cell and matrix is 
recognisable by a ruffled cellular border. Here the cell membrane is highly folded and 
flanked by a specialised area, known as the clear or sealing zone, containing a ring of 
contractile proteins. These, with the help of specific integrin receptors for matrix 
proteins, serve to attach the cell to the bone surface and provide a tight seal around 
the bone resorbing compartment. This allows secreted enzymes to be contained and 
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controlled within an optimised microenvironment and minimises unwanted effects on 
surrounding cells. The area of the ruffled membrane depends on the state of bone 
resorption, increasing when bone resorption is stimulated; for example by PTH, and 
decreasing (often disappearing) when resorption is inhibited; for example by oestrogen 
(Roodman, 1996). Osteoclasts are motile cells capable of resorbing more than just the 
cavity within which they are identified. After an osteoclast digs a cavity, it can detach 
from bone and move on to a new resorption site. A further characteristic feature of 
mature osteoclasts is their high content of the phosphohydrolase enzyme, tartrate-
resistant acid phosphatase (TRAPase). Measurement of TRAP is commonly exploited 
for the detection of osteoclasts in bone specimens (Udagawa et al., 1990). 
 
1.3.1 Mechanisms of bone resorption 
The proteolytic enzymes that digest bone (chiefly matrix metalloproteinases and 
cathepsins K, B and L) work best at acidic pH (Bossard et al., 1996). Protons are 
generated by carbonic anhydrase type II and pumped across the ruffled border into the 
sealed space between cell and bone. The maintenance of the pH and electrochemical 
balance in this space is dependent on a variety of ion channels, pumps and exchange 
mechanisms, including a Ca2+ ATPase, K+ channel and HCO3/Cl- exchanger (Blair et 
al., 1989, Blair et al., 2002). These features put the osteoclast in the same functional 
category as both gastric oxyntic cells and intercalated cells of the renal tubule, both of 
which are also of epithelial origin and secrete acid in a polarized fashion. The degraded 
bone matrix components are endocytosed along the ruffled border and trancytosed to 
the opposite side of the cell for release (Nesbitt and Horton, 1997, Salo et al., 1997). 
 
1.3.2 Osteoclastogenesis 
In addition to the RANK/OPG system (as shown in figure 1.2) a complex network of 
cytokines is involved in the fine tuning of osteoclastogenesis (Manolagas, 1995). The 
early stages are very similar to haematopoiesis and proceeds under parallel influences. 
These include the interleukins IL-1, IL-3, IL-6, IL-11, leukaemia inhibitory factor (LIF), 
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oncostatin M (OSM), ciliary neurotropic factor (CNTF), tumour necrosis factor (TNF), 
granulocyte macrophage-colony stimulating factor (GM-CSF), M-CSF, and c-kit ligand 
(Manolagas, 1998). IL-4, IL-10, IL-18 and interferon γ all exert a negative influence. In 
the case of IL-18 this effect is mediated through GM-CSF (Udagawa et al., 1997). 
 
 
 
Table 1.1: The positive and negative regulatory influences on osteoclast development in 
addition to the RANK-L/OPG system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stimulate osteoclast development 
 
Inhibit osteoclast development 
 
IL-1, IL-3, IL-6, IL-11 
Leukaemia Inhibitory factor (LIF) 
Oncostatin M (OSM) 
Ciliary neurotropic factor (CNTF) 
Tumour necrosis factor (TNF) 
Granulocyte macrophage-colony stimulating 
factor (GM-CSF), M-CSF and c-kit ligand. 
 
IL-4, IL-10, IL-18, IFN-γ 
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1.4 Bone remodelling cycle 
 
The remodelling cycle is a complex multi-step process consisting of coordinated 
resorption and replacement of bone (figure 1.4) (Marcus et al., 2001). Bone turnover 
begins by conversion of an inactive or quiescent skeletal surface to a remodelling site, 
a process referred to as activation. Activation involves proliferation of new blood 
vessels needed to bring recruited resorbing cells to the site and retraction of the flat, 
pavement-like cells that cover quiescent surfaces to expose the mineralised bone 
surface. New osteoblasts assemble only at sites where osteoclasts have recently been 
active, a process known as coupling. The aim is the maintenance of an ordered 
mineralised matrix under the control of systemic endocrine factors and locally released 
paracrine factors. It occurs as a consequence of the interactions between small groups 
of osteoblasts and osteoclasts grouped into a ‘basic multicellular unit’ (BMU) by virtue 
of close anatomical proximity. In healthy human adults, 3 to 4 million BMUs are 
initiated every year and approximately one million are active at any moment (Parfitt, 
1994). Once activated, the BMU moves over the surface of bone as a resorptive tide. 
The leading edge of the BMU consists of recently recruited and activated osteoclasts, 
and is followed by cells of the osteoblast lineage, reforming fresh matrix as old is 
removed. The process is driven by osteoblastic processing of local and systemic 
resorptive stimuli with subsequent recruitment of osteoclasts from the haematopoietic 
precursor pool. Further regulation occurs as bone dissolution releases mineral ions and 
other factors that feed back directly on the osteoblast and the osteoclast. During the six 
to nine month lifespan of a BMU, the shorter-lived osteoclasts and osteoblasts are 
continually replaced while the same discrete spatial and temporal relationships are 
maintained (Manolagas, 2000).  
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1.5 Endocrine influences on the bone remodelling process 
 
1.5.1 Parathyroid hormone 
 
Parathyroid hormone (PTH) is a single chain polypeptide of 84 amino acid residues 
(molecular weight 9500 D) synthesised in the parathyroid glands in the neck. Biological 
activity resides in the N-terminal 1 to 34 region. It is a crucial hormone for the 
maintenance of bone turnover and calcium homeostasis in man (Schrier, 1997). It acts 
on a wide variety of target cells through a G protein coupled PTH receptor (PTH-1R) 
(Juppner et al., 1991). The effects of PTH on bone, and in the osteoblast in particular, 
are complex and vary widely between in vitro and in vivo systems (Jilka et al., 1999). 
PTH is capable of both stimulation and inhibition of matrix synthesis, though the former 
appears the predominant effect in vivo (Dempster et al., 1993). The response is 
dependent to a degree on whether it is administered continuously or intermittently 
(Tam et al., 1982, Ma et al., 2001). Intermittent administration of PTH stimulates bone 
formation by increasing osteoblast number. PTH directly activates survival signals in 
osteoblasts and induces a delay in osteoblast apoptosis (Jilka, 2007). PTH may also 
cause replicating progenitors to drop out of the cell cycle through decreased 
expression of cyclin D and increasing expression of several cyclin dependent kinase 
inhibitors (Qin et al., 2005). This drop out may allow response to the pro-differentiation 
and survival effects of locally produced growth factors and cytokines (Partridge et al., 
2006). The anabolic effect of PTH appears, in part, to be mediated through the 
production and release of local factors, such as IGF-I and fibroblast growth factor-2, 
and is linked to an increase in cAMP - the classical intracellular messenger for PTH 
(Canalis et al., 1989, McCarthy et al., 1990, Hurley et al., 2006). PTH also stimulates 
the production of RANK-L and the gp130 cytokines IL-6 and IL-11 by stromal and 
osteoblastic cells (Yasuda et al., 1998b, Girasole et al., 1994, Greenfield et al., 1995).  
PTH fragments are also present in the circulation. These include a large C-terminal 
fragment called PTH (7-84). This has a longer half-life and may exert an inhibitory 
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influence on osteoclastic bone resorption (probably via a distinct receptor) (Martin et 
al., 1979, Slatopolsky et al., 2000). 
 
1.5.2 Vitamin D 
 
Vitamin D and its metabolites are transported in the circulation by a specific binding 
protein, vitamin D binding protein (DBP), which is normally present in large excess. 
Active vitamin D, 1α,25-dihydroxyvitaminD3 (1,25(OH)2D3 or calcitriol), is generated by 
hepatic 25-hydroxylation and renal 1α-hydroxylation of inactive precursors. The 25-
hydroxyvitamin D-DBP complex gains access to a 25(OH)D3-1α-hydroxylase in renal 
proximal tubular cells by binding to megalin located on their apical membrane (Nykjaer 
et al., 1999). In target cells, calcitriol alters gene expression by binding with high affinity 
to its intracellular receptor, the vitamin D receptor (VDR), which acts as a nuclear 
transcription factor. Liganded VDR undergoes conformational change and forms a 
heterodimer with a second protein, the retinoid X receptor (RXR). This, in turn, binds to 
DNA elements in the promoter regions of target genes described as vitamin D 
response elements (VDREs). Binding to the VDREs may promote transcription, as is 
the case with osteocalcin in the osteoblast, or inhibit transcription, as for parathyroid 
hormone in the parathyroids, by either enhancing or repressing activity of transcription 
machinery (Darwish and DeLuca, 1996). Calcitriol has complicated effects on 
osteoblast function (Brown et al., 1999), though the predominant influence is to 
increase bone resorption. It is also required for matrix mineralisation, though this does 
not appear to be mediated through the osteoblast, but rather through calcium and 
phosphate homeostasis (van Leeuwen et al., 2001). Indeed, it is interesting to note that 
normalisation of serum levels of calcium and phosphate in VDR knockout mice results 
in normalisation of bone histology (Amling et al., 1999). Additionally, 1,25(OH)2D3 
appears to bind to one or more additional cell surface receptors that, through second 
messenger pathways, mediate certain non-genomic effects (Baran et al., 2000). In 
addition to its ‘classical’ role in mineral metabolism, vitamin D exerts various influences 
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on differentiation, proliferation, and apoptosis across a variety of cell types (Baeke et 
al., 2010). Within bone, physiological doses of 1,25(OH)2D3  protect against 
osteoblastic apoptosis by mechanisms involving non-genomic activation of a 
VDR/PI3K/Akt survival pathway that can generate phosphorylation of multiple p-Akt 
substrates as well as a reduction in caspase activity (Zhang and Zanello, 2008). 
Vitamin D insufficiency has been implicated (based on varying degrees of 
epidemiological and biological evidence) in the pathogenesis of several non-osseous 
disorders, including cancer (Freedman et al., 2007), diabetes mellitus (Mathieu et al., 
2005), hypertension (Rostand, 2010) cardiovascular disease (Swales and Wang, 2010) 
as well as increased overall mortality in patients with kidney disease undergoing 
dialysis (Wolf et al., 2007). 
 
 
Figure 1.5. An overview of vitamin D function (PO4 = serum phosphate, Ca2+ = serum calcium, 
FGF-23 = fibroblast growth factor 23). Reproduced from Steddon et al (Steddon, 2006) 
 
1.5.3 Oestrogens 
After the menopause, the rate of bone remodelling increases sharply. This increase is 
mediated through enhanced local cytokine production with consequent augmentation 
of osteoclastogenesis and osteoblastogenesis (Manolagas et al., 1995). When present, 
oestrogen suppresses the osteoblastic production of IL-6, as well as of its two receptor 
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subunits IL-6Rα and gp130 (Jilka, 1998, Lin et al., 1997). Accordingly, concentrations 
of these are demonstrably higher in oestrogen deficient mice, rats and humans 
(Miyaura et al., 1995, Bismar et al., 1995, Cheleuitte et al., 1998). Oestrogen deficiency 
may also increase osteoblastic sensitivity to IL-6 and other gp130 type cytokines 
(Manolagas, 2000). The production of TNF and M-CSF are also suppressed by 
oestrogen (Srivastava et al., 1999, Srivastava et al., 1998), while the production of 
OPG is enhanced (Hofbauer et al., 1999b). Oestrogen lack also increases osteoclast 
longevity, giving them more time to resorb and erode bone (Hughes et al., 1996, Parfitt 
et al., 1996, Eriksen et al., 1999).  
 
1.6 Local regulatory factors acting on the bone remodelling process 
 
These factors consist of cytokines and growth factors secreted by skeletal cells (mainly 
osteoblasts, with a small contribution from other marrow/stromal cells) and other 
factors embedded in bone at the time of production and released as a result of 
osteoclastic bone breakdown. As discussed above, modulation of osteoclastic activity 
is via the osteoblastic processing of systemic (e.g. PTH), or local (e.g. IL-1) signals, 
predominantly through the RANK/OPG system. Osteoclastic activity can be regulated 
in several ways; (i) an increase in the recruitment and differentiation of pre-osteoclasts 
to expand the active osteoclast pool; (ii) modification of the highly specialised cell 
structure required for active resorption (iii) through the presence, or absence, of 
chemotactic factors required for osteoclastic movement to areas of bone resorption.  
 
1.6.1 Insulin-like growth factors (IGFs) 
The IGFs are a small family of anabolic polypeptides that are structurally related to pro-
insulin. Two have been characterized, IGF-I and IGF-II. They are predominantly 
synthesised in the liver (under the regulation of growth hormone), but are also 
produced locally within bone (Jones and Clemmons, 1995, Middleton et al., 1995). The 
two IGFs vary little in their action on in vitro and in vivo systems, but do vary in their 
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potency, with IGF-I around five times more potent than IGF II (Middleton et al., 1995).  
In utero, linear bone growth appears independent of growth hormone and regulated 
mainly by IGF-I and IGF–II. After birth, however, it is reliant on growth hormone and 
IGF-I (van der Eerden et al., 2003). IGF-I can act as a systemic hormone or as an 
autocrine/paracrine growth factor in the skeleton (Slootweg et al., 1990). In vitro 
studies have demonstrated that IGF-I modestly stimulates bone cell proliferation, 
markedly accelerates osteoblast differentiation, and increases production of several 
components of bone matrix (Canalis, 1993, Birnbaum et al., 1995). It also increases 
transcription of the type I collagen gene (Hock et al., 1988) and inhibits the synthesis 
and release of collagen degradatory enzymes (Canalis et al., 1995). In addition, it may 
also have a role in the prevention of apoptosis (Hill et al., 1997, Neuberg et al., 1997). 
In vivo, IGF-I deficiency, as noted in IGF-I null mice (and in a single human case with a 
point mutation in exon 5 of the IGF-I gene), results in a significant growth retardation 
and extremely low bone mineral density (Bikle et al., 2001, Miyakoshi et al., 2001). 
Furthermore, osteoblast specific deletion of the IGF-I receptor gene in mice leads to is 
a marked decrease in both cancellous bone volume and trabecular number along with 
increased trabecular spacing and decreased matrix mineralisation (Zhang et al., 2002). 
Conversely, genetically manipulated mice with targeted overexpression of IGF-I in 
mature osteoblasts, exhibit increased bone formation and enhanced trabecular and 
cortical bone volume (Zhao et al., 2000). In a large human cohort study of males 
between the ages of 19 and 85 there was a positive correlation between serum IGF-I 
levels and bone mineral density (Szulc et al., 2004). These findings implicate IGF-I as 
a major anabolic factor in the growth and maintenance of skeletal tissue and have 
engendered much interest in a possible role for IGF-I in the treatment of disorders 
characterised by bone loss, including osteoporosis. This interest has been qualified, 
however, by the finding that IGF-I may also stimulate bone resorption. For example, 
mice with targeted overexpression of IGF-I directed by the osteocalcin promoter have a 
demonstrable increase in their number of osteoclasts by age 6 weeks (Zhao et al., 
2000). The major substrates of IGF-I receptor tyrosine kinases are known to be the 
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closely related proteins called insulin receptor substrates -1 and -2 (IRS-1 and IRS-2), 
which become phosphorylated on multiple tyrosine residues following ligand binding 
(Kadowaki et al., 1996). They have significant structural differences which endow them 
with distinct signalling properties. Both are expressed in bone (Yamaguchi et al., 2005). 
It has been proposed that IRS-2 maintains the predominance of bone formation over 
bone resorption, whereas IRS-1 preserves bone turnover – while the fusion of these 
two signals can orchestrate the skeletal anabolic response to IGF-I (Akune et al., 2002, 
Ogata et al., 2000)  
 
Osteoclasts express mRNA for IGF-I, IGF-II, and type I IGF receptor (Middleton et al., 
1995). In vitro, IGF-I promotes formation of osteoclasts from mononuclear precursors, 
stimulates activity of pre-existing osteoclasts and increases resorption activity in bone 
cell cultures (Slootweg et al., 1990, Mochizuki et al., 1992). In osteoblasts from 
osteoporotic subjects, the IGF-I receptor shows increased basal tyrosine 
phosphorylation and a blunted response to stimulation by IGF-I (Perrini et al., 2008). 
Such abnormalities may be responsible for the observed reduction in cell proliferation 
and impaired bone formation that occur in human osteoporosis. In vivo studies with 
recombinant human growth hormone (rhGH) and/or recombinant IGF-I in elderly 
subjects or those with GH deficiency have demonstrated a significant increase in both 
bone formation and resorption, especially within the first twelve months (Johannsson et 
al., 1996, Brixen et al., 1995, Ghiron et al., 1995). More recently it was noted that low 
dose recombinant IGF-I given for one year in older postmenopausal women, was not 
associated with an increase in spine or hip bone mineral density, but was associated 
with higher rates of bone formation than in women receiving both IGF-I and 
concomitant oestrogen replacement therapy (Friedlander et al., 2001). It has been 
shown that IGF-I regulates OPG and RANK-L expression both in vitro and in vivo 
(Rubin et al., 2002). This may explain the dual activation of both bone formation and 
bone resorption; the latter effect mediated through the OPG/RANK-L system. The 
major osteotropic hormones appear to be important in regulating the effects of IGF-I 
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(and vice versa). Both in vitro and in vivo studies suggest that the anabolic effects of 
intermittent PTH are, at least in part, mediated through local increased IGF-I 
expression (Canalis et al., 1989, McCarthy et al., 1989). Osteoblasts produce several 
IGF-binding proteins (IGFBPs). Of these, IGFBP-4 binds to IGF and blocks its action, 
whereas IGFBP-5 promotes IGFs stimulatory effects (Nasu et al., 2000, Marcus et al., 
2001). 
 
Another factor in the growth hormone axis that appears to play a role in skeletal 
metabolism is ghrelin. This 28 amino acid peptide, first identified in the submucosal 
layer of the stomach in 1999, has been found to strongly stimulate growth hormone 
release via the growth hormone secretagogue receptor (GHS-R) (Kojima et al., 1999). 
Ghrelin is widely expressed and has a variety of roles within glucose metabolism and 
energy homeostasis (Pusztai et al., 2008, Nikolopoulos et al., 2010). It also appears to 
influence bone metabolism independently of both growth hormone and IGF-I (Cocchi et 
al., 2005). Expression has been demonstrated in osteoblasts, where it functions to 
stimulate proliferation (Fukushima et al., 2005) and inhibit apoptosis (Kim et al., 2005, 
Maccarinelli et al., 2005). 
 
1.6.2 Interleukin 1 (IL-1) 
Two forms of IL-1 exist, alpha and beta, with broadly similar biological actions. Locally 
produced IL-1 is involved in the initiation of bone resorption (Gowen et al., 1983) 
(Kimble et al., 1994) and like other factors that control resorption, its signal to the 
osteoclast appears to be processed via the osteoblast and the RANK-L/OPG system, 
specifically RANKL expression (Hofbauer et al., 1999c). The bone resorbing activity of 
IL-1β has been associated with osteoporosis, myeloma and rheumatoid arthritis 
(Hofbauer and Schoppet, 2004, Strand and Kavanaugh, 2004, Roodman, 2001). In 
inflammatory situations such as the latter, IL-1β, in combination with the potent 
inflammatory cytokine TNF-α, may play a particularly key role (Kobayashi et al., 2000). 
What has been more difficult to understand is its stimulatory effect on OPG mRNA 
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levels and protein release (Hofbauer et al., 1998, Pantouli et al., 2005), which appears 
to be dependent on the phosphorylation of p38 and ERK, but not the classical NF-κB 
pathway (Lambert et al., 2007). This production of OPG transcripts may be some form 
of counter-regulatory process, or the OPG may act as a survival factor via another 
pathway such as TRAIL. Both remain to be demonstrated, however. 
 
1.6.3 Interleukin-6 (IL-6) 
IL-6 is a multifunctional cytokine of around 20 kD. It consists (in man) of 212 amino 
acids in the precursor form and 183 in the mature form. IL-6 is produced by a wide 
variety of cells including T and B lymphocytes, macrophages, fibroblasts, mesangial 
cells, astrocytes, endothelial cells as well as bone marrow stromal cells and 
osteoblasts. In general it is considered a pro-inflammatory cytokine (Naka et al., 2002, 
Kishimoto, 2005). It exerts its biological effects via a cell surface receptor consisting of 
two components: a ligand binding 80 kD glycoprotein (IL-6 receptor, IL-6R) and a non-
ligand binding, but signal transducing, gp130 protein-coupled component. Binding of 
IL-6 induces dimerisation of the two components and tyrosine phosphorylation of the 
cytoplasmic tail of gp130 (Stahl and Yancopoulos, 1993, Darnell, 1997). This leads 
(with a degree of interdependence) either to activation of the Ras/MAPK cascade or 
the recruitment of STAT1 and STAT3 (Ernst and Jenkins, 2004, Kishimoto, 2005). 
Further regulation is provided by the suppressors of cytokine signalling (SOCS), as 
discussed later. The α subunit of the IL-6 receptor also exists in a soluble form (sIL-
6R), but unlike other soluble cytokine receptors, it functions as an agonist - binding to 
IL-6 and stimulating JAK/STAT signalling via the gp130 subunit (Stahl and 
Yancopoulos, 1993). In this way, it bestows IL-6 responsiveness to cells expressing 
gp130, but missing IL-6Rα. Conversely, the soluble form of gp130 blocks IL-6 action 
(Narazaki et al., 1993). The source of sIL-6R in bone may be non-skeletal; e.g. liver 
derived, but it may also be locally released by osteoblasts (Jones et al., 2001, 
Franchimont et al., 2005a). Many in vitro studies have reported that IL-6 exerts minimal 
influence on osteoblasts unless sIL-6R is present (Franchimont et al., 1997a, 
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Nishimura et al., 1998, Erices et al., 2002, Franchimont et al., 2005b), although 
osteoblastic IL-6 receptor expression has been demonstrated in vivo (Hoyland et al., 
1994). Ligand binding induces progression toward a more mature phenotype and it is 
possible that IL-6 functions to regulate differentiation of osteoblastic cells as well as to 
initiate apoptosis in more mature cells (Bellido et al., 1996, Bellido et al., 1997, Li et al., 
2008).  
 
IL-6 is produced at high levels by cells of osteoblastic lineage in response to a plethora 
of cytokines and growth factors, including IL-1, TNF, TGF-ß, PDGF and IGF-II 
(Girasole et al., 1992, Franchimont and Canalis, 1995, Franchimont et al., 2000, 
Manolagas, 1998). In addition IL-6 is an important (Grey et al., 1999), although 
possibly not essential (O'Brien et al., 2005), downstream mediator of PTH action, the 
effects of which can be antagonised by neutralising IL-6 antibody (Greenfield et al., 
1995). Activation of the gp130/STAT3 pathway by IL-6 can stimulate RANKL 
expression and osteoclastogenesis in vitro (Udagawa et al., 1995, O'Brien et al., 1999). 
However, IL-6 in isolation is insufficient to stimulate osteoclast formation in vivo (de la 
Mata et al., 1995, O'Brien et al., 2005). Furthermore, blockade of either osteoblastic 
gp130/STAT3 signalling or IL-6 action abolishes osteoclastogenesis stimulated by IL-6, 
but not by PTH (Devlin et al., 1998, O'Brien et al., 1999). Transgenic mice 
overexpressing IL-6 demonstrate significant skeletal abnormalities including 
osteopenia and defective ossification (De Benedetti et al., 2006) and inappropriate 
expression of IL-6 appears to play an important role in the pathogenesis of skeletal 
disorders characterised by accelerated bone remodelling and resorption - including 
lytic metastases (Roodman, 2001), malignant hypercalcaemia (Yoneda et al., 1993), 
multiple myeloma (Callander and Roodman, 2001), renal osteodystrophy (Langub et 
al., 1996), hyperthyroidism (Siddiqi et al., 1998, Siddiqi et al., 1999) and osteoporosis 
(Manolagas and Jilka, 1995). However, IL-6 knockout mice have a surprisingly normal 
skeletal phenotype, although they do demonstrate cortical microstructural 
abnormalities, delayed fracture healing and reduced bone resorption following 
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oestrogen depletion (Poli et al., 1994, Yang et al., 2007). They are also protected 
against joint inflammation in both collagen and antigen induced arthritis (Alonzi et al., 
1998, Ohshima et al., 1998). Moreover the number of osteoclasts was found to be 
unexpectedly increased in foetuses where gp130 had been knocked out (Kawasaki et 
al., 1997). It is therefore possible that while IL-6 may not be mandatory for 
physiological bone remodelling under normal circumstances, it may undertake a more 
dominant role when prevailing turnover is high (Franchimont et al., 2005b). This may 
be mediated through regulation of both its receptor and downstream signalling biology. 
For example, mice carrying a point mutation that favours JAK/STAT signalling by 
selectively blocking the Ras/MAPK pathway display increased bone turnover and 
decreased trabecular bone volume. When crossed with IL-6 knockouts, the level of 
bone formation returned to the level of wild type mice (Sims et al., 2004, Sims, 2009).  
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1.7 Renal bone disease 
 
Renal bone disease, or osteodystrophy, is one facet of chronic kidney disease – 
mineral and bone disorder (CKD-MBD). This relatively new term aims to encompass all 
the mineral, skeletal, and related cardiovascular consequences of chronic kidney 
diseases, including bony pathology and vascular calcification (Moe et al., 2006). This 
expanded focus has been driven by observational studies suggesting that CKD-MBD 
(and its treatment) may influence morbidity and mortality in patients with kidney 
disease (Block et al., 1998, Tentori et al., 2008, Covic et al., 2009). Vascular disease is 
common and progresses rapidly in CKD - typically occlusive lesions due to 
atheromatous plaques. However, the full spectrum of arterial disease in these patients 
is broader, including vessel wall calcification with resulting impaired vascular function 
(Moe and Chen, 2008). The prevalence of both soft tissue and vascular calcification far 
exceeds the general population and progression is vastly accelerated. Increasingly, the 
phenomenon appears intimately linked to the well described disturbances in mineral 
and bone metabolism (Moe, 2006a). In fact, a poorly understood association between 
arterial calcification and bone disease is long established in the context of osteoporosis 
(Hofbauer et al., 2007) and the evidence trail in this context has rapidly expanded. It 
includes the observation that calcium deposited in vessels is in the form of 
hydroxyapatite crystals - the same as in the skeleton (Zaheer et al., 2006), and the 
demonstration that several stimuli, including inorganic phosphate and uraemic serum, 
can promote differentiation of vascular smooth muscle cells to an osteoblastic 
phenotype via upregulation of the sodium-dependent co-transporter, Pit-1 (Chen et al., 
2002, Moe, 2006b, Lau et al.). The term renal bone disease (osteodystrophy) is now 
reserved to describe the specific bone pathologies associated with CKD.  
 
The pathophysiology of renal bone disease is extremely complex, but, essentially, a 
reduction in functioning renal mass causes the accumulation of phosphate and a 
deficiency of 1,25(OH)2D. These, in turn, generate a reduction in the serum calcium 
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concentration and all three, will if uncorrected, relentlessly drive the development of 
secondary hyperparathyroidism, with eventual clonal proliferation of parathyroid cells 
(Mondry et al., 2005, Hruska et al., 2007) 
 
 
KDIGO classification of CKD-MBD and renal osteodystrophy 
 
 
Definition of CKD-MBD 
 
 
A systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a 
combination of the following 
 
• Abnormalities of calcium, phosphorus, PTH or vitamin D metabolism 
• Abnormalities of bone turnover, mineralisation, volume, linear growth or strength 
• Vascular or other soft tissue calcification 
 
 
Definition of renal osteodystrophy 
 
 
• Renal osteodystrophy is an alteration of bone morphology in patients with CKD 
• It is one measure of the skeletal component of the systemic disorder that is quantifiable 
by histomorphometry of bone biopsy material 
 
 
Table 1.2 Classification of mineral and bone disorders in chronic kidney disease. Kidney 
Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (Moe, 2009). 
 
These clones express less calcium sensing and vitamin D receptors, further 
constraining the effects of therapy (Steddon and Cunningham, 2005). This later 
situation is termed tertiary or autonomous hyperparathyroidism. In addition there is a 
relative ‘skeletal resistance’ to the effects of PTH, the cause of which is unclear 
(Friedman and Goodman, 2006). The end product is an abnormal bone remodelling 
cycle and, ultimately, diminished bone strength. Within this framework, fibroblast 
growth factor 23 (FGF-23) has recently emerged as an important pathophysiological 
driver (Juppner et al.). FGF-23 is produced in bone and its concentration increases as 
renal function falls. This elevation causes potent suppression of 1α-hydroxylase and 
therefore 1,25(OH)2D production. FGF-23 excess is now known to underlie autosomal 
dominant hypophosphataemic rickets, x-linked hypophosphataemia and tumour 
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induced osteomalacia (all characterized by phosphate wasting, reduced 1,25(OH)2D 
and skeletal abnormalities) (Amatschek et al.). In addition, FGF-23 is also emerging as 
a very powerful biomarker of mortality (Gutierrez et al., 2008).  
 
 
Figure 1.6: The pathogenesis of secondary hyperparathyroidism. Modified from Steddon et al 
(Steddon, 2006) 
 
Renal osteodystrophy is now defined and considered in terms of bone turnover, 
mineralisation and volume (Malluche and Monier-Faugere, 2006). Strictly speaking a 
bone biopsy, usually from the iliac bone, with both histological and histomorphometric 
assessment is required for accurate diagnosis and classification, but, in practice, these 
are very rarely performed (as they are invasive and require considerable – and scarce - 
expertise for their interpretation), so surrogate markers of bone turnover, including 
serum PTH and alkaline phosphatase, are generally utilised. Osteodystrophy 
represents a histological continuum, with high and low turnover disease at opposing 
ends (Favus and Christakos, 1999). High turnover disease corresponds to the clinical 
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entity of secondary hyperparathyroidism. It is characterised by increased numbers of 
osteoblasts and osteoclasts, abnormally high rates of bone formation and a high serum 
PTH (Slatopolsky et al., 1999). Haphazardly organized, weakened bone results, which 
is classically described as osteitis fibrosa cystica. Low turnover disease, or adynamic 
bone disease (ABD), is typified by reduced numbers of osteoblasts and osteoclasts, 
very low rates of bone formation and a serum PTH that is within (or just above) the 
normal range (Malluche and Monier-Faugere, 1992). However, these high and low 
bone turnover states are not mutually exclusive entities; they can, and often do, co-
exist in bone biopsy specimens (Malluche and Monier-Faugere, 1994). This can be 
difficult to conceptualise because they are usually categorised clinically in terms of an 
absolute value of serum PTH, rather than within a histological framework. 
Osteomalacia generally refers to a defect in mineralisation; however, in the context of 
chronic kidney disease, this is a relatively uncommon isolated finding and therefore not 
a particularly helpful clinical description. It is generally related to a deficiency of 
1,25(OH)2D (calcitriol), but aluminium intoxication and uraemic acidosis are also 
important risk factors (Steddon, 2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The spectrum of renal osteodystrophy, including the potential influence of common 
treatments. Reproduced, with modifications, from (Steddon, 2006). SHPT = secondary 
hyperparathyroidism. 
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 Adynamic bone disease is an increasingly common lesion in CKD (Salusky and 
Goodman, 2001, Frazao and Martins, 2009).  Histologically, ABD is characterised by a 
reduction in the numbers of osteoblasts and osteoclasts and a paucity of bone 
formation (Malluche et al., 1997). The appearance of ABD is often viewed as the cost 
of striving to normalise bone turnover through suppression of PTH, though it almost 
certainly has a more complex pathophysiological basis (Salusky and Goodman, 2001, 
Ferreira, 2006). Although historically linked with aluminium toxicity, this association has 
depreciated in contemporary relevance. The major associations of ABD are treatment 
with active vitamin D, calcium overload and, possibly, choice of peritoneal dialysis as 
modality of renal replacement therapy (RRT) (Frazao and Martins, 2009). In addition, in 
a significant proportion of the CKD population, the coexistence of other low turnover 
states, including age related, or post-menopausal, osteoporosis and diabetes mellitus, 
may predispose to the adynamic lesion (Rigalleau et al., 2007, Miller, 2009).  As 
discussed, a low serum PTH, often in combination with a high serum calcium, is used 
clinically as a surrogate marker for ABD. Though useful, this may serve to exaggerate 
the importance of PTH in the evolution of the disorder. The occurrence of ABD in those 
with persistent elevations of PTH despite administration of active vitamin D implies a 
degree of PTH independence (Qi et al., 1995, Wang et al., 1995). Calcitriol itself may 
be culpable through an inhibitory influence on osteoblast function (Brown et al., 1999). 
Support for this comes from the differential properties, at the level of bone, of the 
newer analogues of vitamin D (or so called vitamin D receptor analogues, VDRAs). 
These have demonstrable differences in their ability to stimulate the production of IL-6 
(McIntyre et al., 1999). In addition, the analogue 22-oxacalcitriol has been shown to 
suppress PTH in the uraemic dog without increasing the risk of adynamic bone 
(Monier-Faugere et al., 1999). Despite these, and other, findings, ABD cannot be 
regarded solely as a by-product of calcitriol therapy; the appearance of ABD in biopsy 
specimens prior to calcitriol administration militates strongly against this (Malluche et 
al., 2008). PTH and calcitriol coordinate the latter steps in osteoblast and osteoclast 
differentiation, while other growth factors and cytokines coordinate the early stages. It 
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may be that anomalies in the synthesis and secretion of the latter may be more 
relevant to the development of ABD.  
 
1.7.1 Effects of chronic kidney disease on skeletal biology 
 
Given the preceding discussion concerning the relatively recent expansion of our 
understanding of the complex physiology within bone – and, in particular, the 
recognition that a multitude of growth factors and cytokines occupy important roles in 
the remodelling cycle – it seems almost certain that the heterogeneous manifestations 
of renal bone disease will not be explained exclusively within a framework of aberrant 
PTH and vitamin D metabolism. Abnormalities in several other pathways are likely to 
occur during the progression of CKD and require exploration for their potential 
contribution to the abnormal bone biology found in the uraemic state. In general, it has 
been inferred from abnormal serum concentrations of cytokines that their coordination 
of the remodelling cycle may be disturbed in CKD (Hory and Drueke, 1997) (Gonzalez, 
2000). For example, high levels of IL-1β have been consistently demonstrated in 
dialysis patients (Herbelin et al., 1990, Ferreira et al., 1996), as have high levels of the 
IL-1 receptor antagonist (IL-1Ra), which opposes IL-1β’s cellular effect (i.e. a high 
serum concentration of the IL-1Ra makes the skeleton relatively insensitive to 
circulating IL-1β) (Moutabarrik et al., 1995). In addition, concentrations of TNF-α, 
another promoter of remodelling, are demonstrably higher in the circulation of uraemic 
patients (Herbelin et al., 1990). Elevated levels of IL-6 and the sIL-6R have been 
reported in both pre-dialysis CKD patients and patients on dialysis (Herbelin et al., 
1991, Le Meur et al., 1999), as has a relationship between IL-6 concentration and other 
markers of bone turnover (Montalban et al., 1999). There also appears to be an inverse 
correlation between the sIL-6R:IL-6 ratio and the surface area of osteoclast activity 
(Ferreira et al., 1996). IL-6 receptor mRNA is present in osteoclasts of CKD patients, 
with the level of expression corresponding to their bone resorbing activity (Langub et 
al., 1996). Recently, several cytokines, including IL-1, TNF-α and IL-6 and were shown 
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to be positively correlated with bone formation rate in prevalent dialysis patients by 
histomorphometric criteria (Ferreira et al., 2009). This association was particularly 
strong for IL-6. 
 
Increased circulating levels of IGF-I have also been reported, and there is evidence to 
suggest that bone formation rate correlates with IGF-I concentration in these patients 
(Andress et al., 1989). There is also robust evidence that individuals with kidney failure 
have relative IGF-I resistance. This resistance appears to be multilayered; there is an 
elevation of IGF binding protein-1 which in itself is likely to reduce IGF-I activity (Jain et 
al., 1998). There may also be an IGF-I receptor defect (Feld and Hirschberg, 1996). In 
addition, IGF-I production by a variety of tissues appears to be reduced in uraemic 
animals, with demonstrably less mRNA levels in the steady state in liver (Tonshoff et 
al., 1997), skeletal muscle (Ding et al., 1996) and growth plate cartilage (Hanna et al., 
1995). Studies utilising in situ hybridisation have analysed IGF-I expression in uraemic 
bone (Picton et al., 2000, Hoyland and Picton, 1999). Expression was found 
predominantly in osteoblasts with semi-quantitative analysis showing a decrease in 
mRNA in renal bone compared to normal and non-uraemic high turnover bone (healing 
fracture callus and bone from patients with Paget’s disease). Levels of expression were 
significantly lower in adynamic bone that in high turnover hyperparathyroid bone. This 
implies that there is a downregulation of osteoblast IGF-I in renal bone. Comparison of 
IGF-I mRNA signal density with serum biochemical markers showed a significant 
correlation with intact PTH levels in patients with adynamic bone. This is consistent 
with studies demonstrating lower levels of osteoblastic IGF-I mRNA expression in older 
bone where similarities with adynamic bone might be expected (Tanaka et al., 1996, 
Wakisaka et al., 1998).  
 
Although the OPG/RANKL system has only come under scrutiny in the context of renal 
bone disease relatively recently, aberrations might have been expected as it is, at least 
in part, regulated by osteotropic hormones known to be affected in kidney failure. High 
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circulating levels of OPG are now well documented in CKD patients (Kazama et al., 
2002, Gonnelli et al., 2005, Wittersheim et al., 2006), and it seems likely they will have 
some impact on remodelling (Padagas et al., 2006, Fahrleitner-Pammer et al., 2009). 
They also act as biomarkers of cardiovascular risk (Mikami et al., 2008, Sigrist et al., 
2009). 
 
Epidermal growth factor is also known to affect osteoblast development, and the 
uraemic state may affect the actions of EGF on bone by regulating the expression of its 
receptor (Drake et al., 1994). A member of the TGF-β family, bone morphogenetic 
protein-1 (BMP-1), crucial for osteoblast differentiation, is normally manufactured in the 
kidney, therefore a deficiency as renal mass declines could potentially influence 
osteoblast development and contribute to the low turnover bone (Ozkaynak et al., 
1991). Furthermore, deficiency of other bone morphogenetic proteins in CKD may 
contribute in additional ways to disordered remodelling. Of particular note, treatment 
with BMP-7 in the relevant animal models results in normalisation of both high and low 
turnover states (Hruska et al., 2004) 
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1.8  Cytokine signalling 
Growth factors and hormones are clearly extremely important effectors of the 
communication network necessary for the well being of bone in health and disease. At 
the core of this network is a cytokine receptor superfamily, consisting of cell surface 
receptors and receptor coupled intracellular signalling mechanisms. These determine 
the timing, nature and strength of the cellular response to an external cytokine 
stimulus. The basic components of this cellular apparatus are receptor associated 
Janus tyrosine kinases (JAK) and cytoplasmic transcription factors called ‘signal 
transducers and activators of transcription’ (STATs).  
 
1.8.1  STAT Transcription Factors 
STATs were first discovered as mediators of interferon-induced gene expression 
(Darnell et al., 1994). They comprise a family of latent proteins within the cytoplasm 
that facilitate gene regulation after cell receptors encounter various extracellular 
peptides. The STAT family consists of seven members that are activated by many 
cytokines and growth factor (Table 1.4). Their role in cell signalling and development 
has been elucidated through analysis of transgenic mice lacking individual STAT genes 
(Akira, 1999, Aaronson and Horvath, 2002).  
 
The STAT proteins are unique among transcription factors, in that they contain an Src 
homology-2 (SH2)-binding domain (Shuai et al., 1994). Tyrosine phosphorylation is 
essential for their dimerization and subsequent nuclear translocation. Receptors that 
catalyze this phosphorylation include those with intrinsic tyrosine kinase activity, such 
as epidermal growth factor (EGF), and platelet-derived growth factor (PDGF) as well as 
those that lack such intrinsic activity but have Janus kinases (JAKs) non-covalently 
associated (Leaman et al., 1996, Ihle et al., 1995). Phosphorylated STAT monomers 
form dimers that translocate to the nucleus and bind to specific DNA target sequences 
to regulate gene transcription (Ihle et al., 1997, Ihle et al., 1998, Ihle, 2001b). JAK 
associated receptors often have a cytokine ligand, including IFN-α, -β and -γ; 
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interleukins -2, -7, -10 -13, and -15, as well as EPO, growth hormone and other 
polypeptides (Schindler et al., 2007). STAT dimers and heterodimers, but not 
monomers, are capable of DNA binding. The known DNA binding heterodimers are 
STAT1:2 (requires the presence of another protein, p48) and STAT1:3. Homodimeric 
DNA binding STATs include STAT 1, 3, 4, 5 (STAT5A and 5B interact in a manner 
equivalent to a heterodimer) and 6 (Schindler and Darnell, 1995). In most cases, STAT 
activation is transient. Inactivation is carried out by several mechanisms, including 
dephosphorylation of STAT proteins in the nucleus and degradation through the 
ubiquitin-proteosome pathways (Kim and Maniatis, 1996). 
 
 
Factor 
 
Mass 
(kDa) 
 
Activating Cytokine 
 
Reference 
 
STAT1  
 
91 
 
IFN-α, IFN-γ, EGF, PDGF, FGF, ACRII, 
 
(Darnell et al., 1994) 
 
STAT2  
 
113 
 
IFN-α/β (with STAT1) 
 
(Darnell et al., 1994)  
 
STAT3 
 
92 
 
IL-6, LIF, CNTF, OM, CT-1, EGF, G-CSF, 
IL-10, leptin 
 
(Darnell et al., 1994)  
(Zhong et al., 1994)  
 
STAT4  
 
 
89 
 
IL-12 
 
 
(Zhong et al., 1994)  
(Ihle and Kerr, 1995) 
 
STAT5A 
& 5B  
 
77, 80 
 
IL-2, IL-3, IL-5, IL-7, IL-15, GM-CSF, 
Prolactin, Epo 
 
(Pallard et al., 1995)  
(Azam et al., 1995) 
 
STAT6  
 
94 
 
IL-4, IL-13 
 
 
(Lin et al., 1995) 
(Quelle et al., 1995) 
 
Table 1.4 The STAT family and their activating cytokines 
 
 
 
 62 
1.8.2.  The suppressors of cytokine signalling 
 
The range of action and potency of cytokines mandate that their actions are tightly 
regulated to avoid detrimental consequences (Yasukawa et al., 2000). A variety of 
counter-regulatory measures exist to control the magnitude and duration of cytokine 
activity. At the extracellular level, these include specific cytokine antagonists, such as 
IL-1Ra, and soluble receptors, such as sIL-6R. Control can also be exerted within the 
cell; for example specific phosphatases, such as SHP1 and SHP2, can 
dephosphorylate JAK/STAT proteins (Matozaki and Kasuga, 1996). In addition, a 
relatively recently discovered family of cytokine inducible proteins can downregulate 
cytokine-activated JAK/STAT signalling pathways. These proteins, which represent an 
important mechanism for self limiting the cellular cytokine response have been 
designated the suppressors of cytokine signalling (SOCS) (Krebs and Hilton, 2001). 
The first member of the SOCS family to be discovered, cytokine-induced SH2 domain 
containing protein (CIS), was described as an immediate early-response gene, the 
expression of which could be induced by several cytokines (Yoshimura et al., 1995). 
The second family member was discovered, independently, in three different 
laboratories and given the names SOCS1, JAK-binding protein (JAB) and STAT 
induced STAT-inhibitor (SSI) (Endo et al., 1997, Starr et al., 1997, Naka et al., 1999). 
This confusing nomenclature has been resolved - with SOCS now the most widely 
used description. At present, the SOCS family contains eight members, SOCS1-
SOCS7 and CIS. Each member contains a characteristic central SH2 domain and a 
carboxy-terminal 40 amino acid ‘SOCS box’. Database inspection has revealed a large 
number of SOCS- related proteins in humans and mice. While these proteins all 
contain the 40-residue C-terminal motif SOCS box, their physiological significance is 
unclear (Hilton et al., 1998). SOCS1 and SOCS3 also contain a conserved 12-residue 
sequence – the kinase inhibitory region (Yasukawa et al., 1999). 
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Generally, the SOCS genes are not highly expressed in unstimulated tissues, but can 
be induced rapidly by various cytokines, including those belonging to the interferon, 
interleukin, and colony-stimulating factor families (table 1.4). In addition, growth 
hormone, prolactin, leptin, lipopolysaccharide, angiotensin II and growth factors, such 
as epidermal growth factor (EGF) have been shown to induce the expression of 
various SOCS (Alexander and Hilton, 2004, Yoshimura, 2009). Individual SOCS 
proteins are able to inhibit multiple cytokines, although it is not yet apparent how the 
specificity of SOCS inhibition is regulated. Of interest is the structural homology 
between SOCS pairs such as SOCS1/SOCS3, CIS/SOCS2 and SOCS6/7 (Dalpke et 
al., 2008). 
 
 
Gene 
 
Main Affected Cytokine 
 
CIS 
 
STAT5 signalling (EPO, IL-2, IL-3) 
 
SOCS1 
 
IFN-γ, IFN-α, IL-4, IL-12, LPS 
 
SOCS2 
 
GH, IGF-I 
 
SOCS3 
 
Gp130, IL-2, IL-6, G-CSF, leptin, EPO 
 
SOCS4 
 
Unknown 
 
SOCS5 
 
IL-4, EGF 
 
SOCS6 
 
?insulin 
 
SOCS7 
 
?insulin 
 
Table 1.5. Differential inducibility of the SOCS genes by various cytokines 
 
The most well characterised SOCS family members, CIS, SOCS1, SOCS2 and 
SOCS3, act in a classical negative feedback loop to inhibit cytokine signal 
transduction. Both in vitro and in vivo studies show that cytokine induced SOCS 
expression is usually dependent on the JAK/STAT signalling pathway (Starr et al., 
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1997). Indeed, the promoters of many SOCS genes contain STAT- responsive DNA 
elements (Naka et al., 1997). However, it is also becoming clear that non-JAK/STAT-
dependent regulation of SOCS expression can occur, as has been described in the 
case of IL-10 stimulated SOCS3 expression in neutrophils (Cassatella et al., 1999). IL-
10 upregulation of SOCS3 expression in monocytes is linked to the ability of this 
cytokine to suppress the actions of many pro-inflammatory cytokines, such as IFN-γ, 
serving to highlight the potential for cross-regulation between different cytokine 
signalling pathways via the regulation of SOCS proteins (Ito et al., 1999, Alexander et 
al., 1999). Furthermore, SOCS1 is highly induced by LPS, implying that SOCS1 also 
inhibits the toll-like receptor (TLR)-NF-κB pathway (Mansell et al., 2006). 
 
The ability of the SOCS molecules to inhibit cytokine-activated JAK/STAT signalling 
involves several distinct mechanisms, including receptor interaction, direct JAK 
inhibition and targeting receptor complex and other signalling proteins for proteasomal 
degradation. SOCS1 can directly associate with high affinity with all four JAK 
molecules directly inhibiting their catalytic ability (Nicholson et al., 1999, Yasukawa et 
al., 1999, Alexander, 2002). The SH2 domain is responsible for the association 
between SOCS1 and JAK2, and the N-terminal amino acid region possesses kinase 
inhibitory activity. SOCS3 may function through an interaction with activated cytokine 
receptors, though it does not appear to interfere with STAT recruitment. For example, it 
has been shown to associate with the activated GH receptor and inhibit STAT5 
signalling without preventing STAT5: receptor binding (Hansen et al., 1999). It has 
been shown to bind the gp130 receptor at a specific phosphorylated receptor tyrosine 
identical to that used by the SH2-domain containing tyrosine phosphatase-2 (SHP2), 
so it may compete for receptor phosphotyrosine docking sites (Schmitz et al., 2000, 
Nicholson et al., 2000). Finally, the conserved SOCS box domain interacts with 
elongins B and C to target proteins for degradation through ubiquitination (Zhang et al., 
2001, Kamura et al., 1998). So, the SOCS proteins seem to combine specific and 
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direct inhibitory actions on components of the signalling cascade with a generic 
mechanism that targets these components for ubiquitin mediated proteasomal 
degradation. Consistent with this model, the activation of JAKS and STATS can be 
prolonged in the presence of proteasome inhibitors (Verdier et al., 1998). 
 
It might be inferred from the above discussion that that the SOCS proteins negatively 
regulate a variety of non-specific, and often unrelated, cytokines. However, in vivo data 
indicate a much more restricted and refined role. The most direct evidence of SOCS 
function comes from studies utilising gene deletion or overexpression of individual 
SOCS genes (table 1.6).  
 
 
Gene 
 
Phenotype in knockout mice 
 
Phenotype when overexpressed in 
transgenic mice 
 
 
CIS 
 
Not extensively examined, but reported to have 
few abnormalities (Marine et al., 1999a). 
Possible increased haematopoiesis and 
disturbed lactation. 
 
Widespread overexpression: low body weight, 
lactation failure, fewer splenic γδ T cells, NK cells 
and NKT cells, preferential TH2 differentiation, 
reduced IL-2 signalling (Matsumoto et al., 1999). 
 
T-cell-targeted overexpression: little effect in vivo, 
altered T-cell receptor responses in vitro (Li et al., 
2000). 
 
 
SOCS1 
 
Neonatal fatality caused by fatty degeneration of 
the liver with haematopoietic infiltration of 
multiple organs, lymphopenia, apoptosis in 
lymphoid organs and aberrant T-cell activation. 
Primarily associated with deregulated responses 
to IFN-γ (Marine et al., 1999b, Starr et al., 1998, 
Naka et al., 2001). 
 
 
T-cell-targeted overexpression: suppression 
signalling by multiple cytokines. T-cell developmental 
abnormalities with relative increase in CD4+ T cells, 
fewer γδ t cells and spontaneous T-cell activation 
(Fujimoto et al., 2000). 
 
 
SOCS2 
 
Gigantism with evidence of deregulated GH 
and/or IGF-I signalling (Metcalf et al., 2000). 
 
Gigantism 
 
SOCS3 
 
Mid-gestational embryonic lethality due to 
placental insufficiency (Roberts et al., 2001), 
embryonic lethality with erythrocytosis (Marine et 
al., 1999a). 
 
Haematopoietic cell-targeted overexpression: 
embryonic lethality with increased TH2 differentiation 
and anaemia (Marine et al., 1999a). 
 
Table 1.6: The biological functions of the best-characterised SOCS proteins: evidence from 
SOCS gene manipulation in mice 
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Figure 1.8 
In unstimulated cells JAKs and STATs are inactive and, typically, SOCS genes are not 
expressed.  After binding of cytokines, receptor aggregation occurs, bringing receptor 
associated JAKs together and allowing cross-phosphorylation and activation. These kinases 
then phosphorylate multiple target proteins, including tyrosine residues in the cytoplasmic 
domains of the receptor and receptor associated STAT monomers. Phosphorylated STAT 
monomers form dimers that translocate to the nucleus and bind to specific DNA target 
sequences to regulate the transcription of biological response genes, including SOCS.  The 
ability of the SOCS molecules to influence signalling involves several disparate mechanisms. In 
essence, they combine direct inhibitory actions on specific components of the signalling 
cascade with more generic mechanisms that target components for ubiquitin mediated 
proteasomal degradation. The disappearance of SOCS proteins once they have acted to shut 
down signalling allows the cycle of cytokine stimulation to be completed and the cell to return to 
its cytokine-responsive state. See text for references and (Alexander and Hilton, 2004, Dalpke 
et al., 2008, Yoshimura, 2009) for detailed reviews. 
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1.8.3  SOCS in immune, infectious and inflammatory disease 
The regulation of cytokine signalling by differential SOCS expression is implicated in 
the pathogenesis of various immune, infectious and inflammatory diseases. Evidence 
is emerging for the particular involvement of SOCS1 and SOCS3 in the latter, including 
rheumatoid arthritis, dermatitis and inflammatory bowel disease. In many 
circumstances, SOCS expression appears to exert a negative influence on 
inflammation (Chen et al., 2004, Fujimoto et al., 2004). For example, in a mouse model 
of colitis, colonic expression of SOCS3 is increased, as it is in intestinal T cells from 
patients with Crohn’s disease (Suzuki et al., 2001, Niemand et al., 2003). SOCS3 
inhibition causes STAT3 overactivity and increases disease. However, in asthma, 
disease severity correlates with the magnitude of SOCS3 expression (Tang and 
Raines, 2005), perhaps indicating a role in promotion as well as inhibition of 
inflammatory processes.  
 
1.8.4 The suppressors of cytokine signalling in bone  
The presence and function of the SOCS family of cytokine regulators within skeletal 
tissue has not been studied in detail. In the rat osteosarcoma cell line, UMR106, 
SOCS1 and CIS appear to play a role in GH signalling (Morales et al., 2002). Pre-
treatment with 1,25(OH)2D3 allows a prolonged response to subsequent JAK2/STAT5 
mediated GH signalling as well as permitting a response to repetitive GH stimulation. 
Since pre-treatment with 1,25(OH)2D3 is also associated with the inhibition of 
subsequent GH induced expression of SOCS3 and CIS, it has been suggested that the 
release of the JAK2/STAT5 pathway from the negative influence of SOCS proteins 
explains the effects of 1,25(OH)2D3. The smaller size of SOCS1 knockout mice has 
prompted further skeletal evaluation (Abe et al., 2006). Undercalcified areas were 
found in the skull, sternum and certain regions of cortical bone in SOCS1 knockouts 
and the mineralisation activity of primary cultured calvarial cells from these animals 
was significantly impaired. Furthermore in situ hybridisation demonstrated a significant 
decrease in osteocalcin, a late marker of osteoblastic differentiation, although early 
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markers were comparable. Recent genome wide association staudies have identified 
SOCS2 as one of the 20 loci that influence human adult height (Weedon et al., 2008). 
An insight into how SOCS may be involved in the counterbalance of positive and 
negative signals in bone, and on the osteoclast in particular has previously been 
demonstrated. Expression of SOCS, predominantly SOCS3, can be induced in 
osteoclast progenitors by exposure to RANK-L and M-CSF, both of which are positive 
influences on progenitor recruitment. In turn, SOCS3 inhibits STAT-1 phosphorylation 
and suppresses the signalling of the potentially negative influence of IFN-ß (Hayashi et 
al., 2002). 
 
 
A possible role for SOCS in inflammatory skeletal diseases has been inferred from 
animal models of arthritis (Rottapel, 2001). Overexpression of SOCS3 in joint 
macrophages and fibroblasts blocks STAT3 activation and attenuates disease severity 
(Shouda et al., 2001). Recently, a role for SOCS1 as a negative regulator in the 
experimental methylated BSA/IL-1 arthritis model has been demonstrated in double 
knockout SOCS1-/- IFN-γ -/- mice (Egan et al., 2003). These animals do not develop 
the severe spontaneous inflammation and perinatal lethality manifested by single 
knockout SOCS1 -/- mice and have been developed to explore the in vivo role of 
SOCS1. Induction of this particular form of arthritis, which is known to proceed 
independently of IFN-γ, in these mice led to disease of similar duration, but markedly 
increased severity. This has created interest in SOCS1 as a possible therapeutic target 
in inflammatory disease (Ivashkiv and Tassiulas, 2003). 
 
1.8.4 The suppressors of cytokine signalling in uraemia  
The uraemic state is associated with resistance to the action of growth hormone (GH). 
This manifests clinically as impaired growth and short stature in children with chronic 
renal disease. The basis of this resistance remains unclear, though several 
mechanisms have been suggested, including decreased GH receptor (GHR) gene 
expression (Tonshoff et al., 1994, Tonshoff et al., 1997), increased IGF-I binding to 
 70 
serum proteins (Tonshoff et al., 1995) and post-receptor defects in IGF-I action (Ding et 
al., 1996). Partial GH resistance is reproducible in the uraemic rat (Chan et al., 1993). 
Binding of GH to its membrane receptor induces intracellular signalling via the 
JAK2/STAT5 (and to a lesser degree STAT3 and STAT1) pathways. The concomitant 
induction of SOCS expression allows negative feedback at the level of the GHR-JAK2 
complex (Ram and Waxman, 1999, Tollet-Egnell et al., 1999). Whereas SOCS1 and 
SOCS3 appear to be stronger inhibitors than SOCS2 or CIS in transfection models, in 
vivo evidence indicates a clear role for the latter; deletion of SOCS2 causes IGF-I 
hyper-expression and gigantism in mice (Metcalf et al., 2000), while CIS 
overexpression causes severe growth retardation (Matsumoto et al., 1999). This makes 
the JAK-STAT signalling pathway an attractive target for developing a post-receptor 
paradigm to explain to uraemic GH resistance. This has been further explored in the 
5/6th nephrectomy uraemic rat model, where the response to GH treatment, in terms of 
weight gain and hepatic IGF-I and IGFBP-I mRNA levels, appears abrogated in 
comparison to sham operated pair fed controls (Schaefer et al., 2001). To determine 
the basis of this resistance, both ligand/receptor binding and downstream signal 
transduction through the JAK-STAT pathway were further investigated. Hepatic GHR 
mRNA levels were significantly decreased in the uraemic animals, though there was no 
difference in GHR protein level. GH binding to microsomal and plasma membranes 
was unchanged. Amounts of JAK2, STAT1, STAT3, and STAT5 protein were also 
unchanged. However, GH induced tyrosine phosphorylation of JAK2, STAT5, and 
STAT3 was significantly lower in the uraemic animals. This was associated with a two-
fold increase in SOCS2 expression in GH treated uraemic animals and a 60% elevation 
in SOCS3, independent of GH treatment. Thus there appeared to be a post-receptor 
defect in GH signal transduction characterised by impaired phosphorylation of and 
nuclear translocation of GH activated STAT proteins. This was mediated, at least in 
part, by overexpression of the SOCS proteins. The authors speculated that the 
persistent proinflammatory cytokine release and sub-clinical inflammation associated 
with the uraemic state might contribute to GH resistance through an increase in SOCS 
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protein production. The mechanism for the increase in SOCS mRNA levels in the 
presence of impaired GH-activated JAK2/STAT signalling in uraemia raises important 
questions. It is possible that SOCS gene expression is induced through cytokine 
signalling via a different Janus kinase. Alternatively, the increase in SOCS expression 
in uraemia might itself be mediated by GH, but through a non-STAT pathway. In this 
regard, there is evidence that nuclear STAT-binding sites are not essential for GH 
activation of the SOCS3 promoter (Paul et al., 2000). A similar molecular basis has 
been proposed for the resistance to erythropoietin therapy seen in many ESRD 
patients, suggesting uraemia may exert an influence beyond GH in terms of JAK/STAT 
dependent cytokines (Allen et al., 1999).  
 
SOCS have also been implicated as modulators of cell function in experimental models 
of immune complex glomerulonephritis, where increased glomerular and 
tubulointerstitial expression of SOCS3 corresponds to proteinuria (Gomez-Guerrero et 
al., 2004). In addition SOCS2 is demonstrably upregulated in the skeletal muscle of 
ESRD patients undergoing haemodialysis treatment (Raj et al., 2005). There is also 
evidence to suggest that SOCS may act as negative regulators of angiotensin II 
signalling in cultured mesangial and tubular epithelial cells and therefore potential 
regulators of renal injury (Hernandez-Vargas et al., 2005). Increased monocyte SOCS3 
has been demonstrated in CKD patients and appears to correlate with progressive loss 
of estimated GFR, while lymphocyte SOCS1 expression correlates with other markers 
of cardiovascular disease such as systolic hypertension and pulse wave velocity 
(Rastmanesh et al., 2008). There is also an early indication of differential expression 
according to dialysis modality, with CIS expression significantly increased in 
lymphocytes of pre-dialysis and peritoneal dialysis, but not haemodialysis patients 
(Rastmanesh et al., 2009). However, multiple potential confounding factors, such as 
concurrent inflammation, mean this observation requires further study. 
 
 
 72 
1.9 Apoptosis 
1.9.1  Introduction 
Apoptosis, or programmed cell death, is the process by which cells commit to their own 
demise (Kerr et al., 1972). Accordingly, it is sometimes referred to as cellular suicide 
(Kidd et al., 2000). It is a highly regulated, often endogenously driven, process affecting 
cells of diverse lineage and it plays a critical role in both development and homeostasis 
of most tissues. Defects in apoptotic cell death regulation are thought to contribute to 
many diseases, including disorders of cell accumulation, incorporating cancer, as well 
as cell loss, such as stroke, left ventricular failure and neurodegenerative diseases 
(Reed, 2000). The term apoptosis is primarily a morphological one. Characteristic 
features of an apoptotic cell include chromatin condensation, nuclear fragmentation, 
plasma membrane blebbing and cell shrinkage. The cell eventually breaks into small 
membrane enclosed fragments, termed apoptotic bodies. These are cleared, without 
producing an inflammatory response, by phagocytosis (Hock et al., 2001). The nuclear 
changes are particularly distinctive; DNA fragmentation occurs under the action of an 
endogenous deoxyribonuclease, specific for nuclear, rather than mitochondrial, DNA. 
Oligonucleosomal fragmentation results, with degraded DNA forming a 200-bp ladder 
pattern when separated by gel electrophoresis (Wyllie, 1980).  
 
The effector processes underpinning apoptosis are now mostly known and involve 
activation of both the caspase and Bcl-2 families in response to both physiological and 
noxious stimuli (Hotchkiss et al., 2009). The term caspase is derived from cysteinyl-
directed aspartate-specific protease (Wyllie, 1980) and it is activation of this family that 
underlies the majority of the apoptotic phenotype. At present, 12-14 mammalian 
caspases are known, although not all function during apoptosis. These proteases are 
present as inactive zymogens in virtually all animal cells and are triggered into an 
active state through proteolytic processing at preserved aspartic acid residues. 
Cleavage generates large (20kDa) and small (10kDa) subunits that organise into an 
active heterotetramic (two large and two small subunits) structure (Thornberry and 
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Lazebnik, 1998). The caspases essentially form a cascade in which initiator caspases 
are either activated following cytokine-receptor interaction at the cell membrane, or in 
response to signals within the cell. Thus, caspases 8 is activated when ligands of the 
TNF family bind to their receptor (often termed the extrinsic pathway), while caspase 9 
is activated at the mitochondrial membrane (often termed the intrinsic pathway). 
Initiator caspases then activate, by cleavage, a set of effector caspases, principally 
caspase 3, but also caspases 6 and 7, which proceed to cleave proteins at many 
intracellular locations. This process accounts for much of the distinctive morphology; 
for example, apoptotic cellular blebbing is caused by cleavage of ROCK-1, a rhokinase 
isoform (Coleman et al., 2001) and cell shrinkage by cleavage of focal adhesion kinase 
(FAK) (Wen et al., 1997). Caspases may also be responsible for releasing nucleotides 
that serve as migration signals for macrophages that engulf apoptotic cells (Elliott et al., 
2009). 
 
Bcl-2 family members possess related domains that facilitate interactions within the 
group (Adams and Cory, 2007). Bcl-2 and its closest relatives, including Bcl-xL, 
possess four such domains, designated BH 1,2 and 4. These define a hydrophobic 
groove, while BH3, a short region within the groove, is able to facilitate binding. These 
molecules all support cell survival, whilst shared BH domains permit interaction with the 
pro-death molecules, Bax and Bak. These can punch a wide pore through 
mitochondrial membranes, allowing leakage of critical molecules (Kuwana et al., 2002). 
Among those escaping molecules are cytochrome c and dATP, which can activate 
caspase 9, which itself is held in the vicinity through association with APAF-1 (Van 
Cruchten and Van Den Broeck, 2002). It is the concentration of Bax or Bak relative to 
the Bcl-2 - Bcl-xL or other pro-survival molecules that determines whether this rise in 
mitochondrial permeability will occur, with subsequent activation of the intrinsic 
pathway (Rosse et al., 1998). The remaining members of the Bcl-2 family only possess 
the BH3 domain (Willis et al., 2007). These proteins (including bid, bad, bim and bmf) 
all promote cell death and may act as sensors of the various forms of cellular injury 
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(Wyllie, 2010). In addition to the above, a degree of interdependence between the 
pathways is recognised; for example, caspase-8, classically a feature of the extrinsic 
pathway, can, like caspase-9, activate the bcl2 protein bid in the outer mitochondrial 
membrane with release of cytochrome c (Li et al., 1998). Under certain circumstances, 
cells utilise a different set of proteases to initiate caspase activation. These include the 
aspartic protease cathepsin D, the serine protease AP24 (apoptosis protease 24), and 
calpain. Much like the caspases, calpain is a cysteinyl protease, but it does not 
recognise a defined cleavage site within target substrates (Reed, 2000). Instead it acts 
on the cellular proteins responsible for the maintenance cytoskeletal integrity and is 
regulated by Ca2+ (Harwood et al., 2005). 
 
Until recently, apoptosis was considered the only form of regulated death during 
cellular homeostasis, with necrosis regarded as an uncontrolled process. However, 
accumulating evidence suggests that necrosis can also occur in an ordered fashion 
(Laster et al., 1988, Vandenabeele et al., 2010). The initiation of programmed necrosis, 
or ‘necroptosis’, by death receptors, such as tumour necrosis factor receptor 1, 
requires the kinase activity of receptor-interacting protein-1 (RIP1, also known as 
RIPK1) and RIP3 (also known as RIPK3). Its subsequent execution involves the 
destruction of mitochondrial, lysosomal and plasma membranes (Holler et al., 2000, 
Declercq et al., 2009, Vanlangenakker et al., 2008). Necroptosis may have a role in the 
in the pathogenesis of various diseases, including ischaemic injury, neurodegeneration 
and viral infection (Vandenabeele et al., 2010). Furthermore, an additional death 
pathway is now recognised for the recycling of cellular contents. During this process, 
intracellular materials are packaged into vesicles and targeted to the lysosome or 
vacuole for turnover. This process, termed autophagy, is currently thought to be 
predominantly cytoprotective (Galluzzi et al., 2007, Kroemer et al., 2009). 
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Figure 1.9 continued 
The extrinsic apoptotic pathway is activated following ligand binding to death receptors (TNFR1, 
TRAILR1, TRAILR2, Fas). All death receptors contain a death domain (DD), a conserved 
domain of ~60 amino acids, in their cytoplasmic tail (Feinstein et al., 1995). The DD interacts 
with adapter proteins, including Fas associated death domain (FADD) (Chinnaiyan et al., 1995). 
TNFR1 may also promote survival signalling through activation of NF-κB via IκB (Hsu et al., 
1995).  
 
The intrinsic pathway involves release of mitochondrial factors including cytochrome c, which 
forms a molecular complex called the apoptosome with Apaf-1 and pro-caspase 9 and leads to 
the generation of active caspase 9 (Li et al., 1997). Several factors influence mitochondrial 
permeability; for example, p53 induces Bax to oligomerise and translocate to mitochondria 
where it antagonises the anti-apoptotic effects of Bcl2 and BclXL and disrupts mitochondrial 
integrity. 
 
The extrinsic and intrinsic pathways converge to a caspase cascade that results in cell 
shrinkage, DNA fragmentation and the other morphological features of apoptosis. 
 
IAPs (inhibitor of apoptosis proteins) are a group of cytoplasmic proteins that add another layer 
of regulation through potent caspase inhibition. They are regulated by proteins released from 
mitochondria, including SMAC/Diablo (Chai et al., 2000).  
 
See text for further detail and references. 
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1.9.2 The role of apoptosis in skeletal tissue 
Skeletal mass can be influenced either through regulating the proliferation and 
activation of osteoblast/osteoclast precursors or by modifying cellular longevity through 
apoptosis (Weinstein and Manolagas, 2000). During bone formation and fracture 
healing, osteoblasts can be seen to undergo an organised developmental progression 
concluding with apoptotic cell death. This is most marked in areas of rapid bone 
turnover. The molecular pathways, regulation and overall significance of cell death in 
mature bone remain poorly understood (Xing and Boyce, 2005). 
 
The rate of bone synthesis is to a large extent determined by the number of functioning 
osteoblasts. As these cells complete the task of matrix synthesis and leave the 
remodelling site many undergo progressive phenotypic change, with some becoming 
lining cells and others osteocytes. The majority of the cells, however, cannot be 
accounted for in this way and it is probable that these ‘missing’ cells die by apoptosis 
(Weinstein et al., 1998). Osteoclasts also die by apoptosis and are removed by 
phagocytosis once the resorbing cycle is completed (Hughes and Boyce, 1997). This 
fine balance between cell proliferation and dropout determines the amount of cells 
available to performed the work of bone formation. 
 
The same cytokines and growth factors that stimulate osteoclast and osteoblast 
development appear to exert influence over their subsequent apoptosis. TGFß 
promotes osteoclast apoptosis while inhibiting osteoblast apoptosis. IL-6 and other 
gp130 family cytokines are anti-apoptotic for osteoblasts and antagonise the pro-
apoptotic effects of glucocorticoids.  IGF-I, PDGF and both acidic and fibroblast growth 
factors (FGFs) have all been linked to osteoblast survival in vitro (Hill et al., 1997, Jilka 
et al., 1998, Debiais et al., 2004). IGFs and FGF upregulate calbindin-D28k, which 
binds to, and inhibits, caspase-3, blocking TNF induced apoptosis in osteoblastic cells 
(Bellido et al., 2000). One study found that IGF-II induces apoptosis in osteoblasts, 
which can be overcome by overexpression of Bcl-2 protein (Gronowicz et al., 2004). 
 78 
TNFα is another of the few factors shown to be pro-apoptotic in cell culture systems 
(Tsuboi et al., 1999). Furthermore, an in vivo role is suggested by its involvement in the 
regulation of bone loss following ovariectomy (Kimble et al., 1997). The relationship of 
RANK-L, RANK and OPG to the death receptor family has engendered speculation as 
to their role in the apoptotic process. RANK-L and OPG have been implicated as 
regulators of cell survival in other situations. Indeed, RANK-L was initially discovered 
by two groups attempting to identify and clone genes involved in the regulation of 
apoptosis in dendritic cells (Suda et al., 1999). RANK-L has been shown to promote 
the survival of T-cells (Wong et al., 1997), dendritic cells (Wong et al., 1997), mammary 
epithelial cells (Fata et al., 2000) and osteoclasts (Lacey et al., 2000). In dendritic cells 
this appears to involve a Bcl-XL–dependent mechanism. OPG both promotes and 
inhibits cell survival depending on the model studied. It protects endothelial cells from 
apoptosis induced by serum withdrawal or activation of NF-κB (Malyankar et al., 2000), 
while eliciting death signals in others through its two death domain homologous regions 
(Yamaguchi et al., 1998). In addition, OPG is the only known soluble receptor for 
TRAIL and has been shown to inhibit TRAIL-mediated apoptosis in Jurkat cells (Emery 
et al., 1998, Holen and Shipman, 2006). In addition, OPG appears to be a survival 
factor, in vitro, for prostate cancer cells (Holen et al., 2002), breast cancer cells (Holen 
et al., 2005) multiple myeloma cells (Shipman and Croucher, 2003) and colon cancer 
cells (De Toni et al., 2008). It remains unclear how relevant such findings are to cells of 
osteoblastic lineage. 
 
Several widely used drugs exert their skeletal effects through the manipulation of 
apoptosis in bone cells. In particular, the promotion of osteoclast apoptosis is an 
important therapeutic goal in disorders characterised by excessive bone resorption, of 
which osteoporosis is the most important (Weinstein and Manolagas, 2000). Oestrogen 
promotes osteoclast apoptosis and has undoubted efficacy for the prevention of bone 
loss in postmenopausal osteoporosis (Hughes et al., 1996, Prestwood et al., 1994). 
Bisphosphonates also have the promotion of osteoclastic apoptosis at the core of their 
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mode of action in bone (Luckman et al., 1998) and this stimulated interest in their utility 
in other situations, where they have been shown to induce tumour cell apoptosis, inhibit 
tumour growth and encourage immune reactions against tumour cells (Sun et al., 
2010). The osteoblast is also an important therapeutic target. Protection from the 
induction of, or a reduction in, the amount of osteoblastic apoptosis would increase the 
pool of mature bone forming cells. A decrease in both TNFα and dexamethasone 
induced apoptosis has been achieved with both bisphosphonates and calcitonin 
(Plotkin et al., 1999). PTH is particularly interesting, since constant high concentrations 
induce bone resorption, while intermittent low concentrations promote bone formation 
and increase bone mineral density. These latter, anabolic, effects may be explained by 
the inhibition of osteoblast apoptosis (Jilka et al., 1999). 
 
1.9.3 SOCS in the regulation of apoptosis 
There is evidence that the suppressors cytokine signalling, through their privileged 
position in intracellular signalling, may play a significant role in the processing and 
regulation of apoptotic and anti-apoptotic signals. The abolition of SOCS gene 
expression in SOCS1 null mice was noted to produce apoptosis in liver and lymphoid 
tissue (Naka et al., 1998). In addition, SOCS protein appears to play a role in 
leukaemia inhibitory factor (LIF) dependent survival of embryonic stem cells (Duval et 
al., 2000). Forced overexpression of SOCS1 or SOCS3 in this system leads to a 
reduction in cell viability. LIF activates at least two pathways: the JAK/STAT pathway 
and the ras/mitogen activated protein (MAP) kinase pathway; the JAK/STAT system 
has been shown to be relevant to cell proliferation and differentiation (Hoey and 
Schindler, 1998), while the MAP kinase pathway is also important for apoptotic 
signalling (Kummer et al., 1997). It is likely that there is a degree of interdependence 
between the pathways, with nuclear translocation of STATS leading to the 
transcriptional increase of early response genes such as c-Fos, c-Jun, JunB, JunD and 
c-Myc. In other cell systems SOCS appear to have a protective role. For example 
SOCS3 ameliorates cytokine induced apoptosis in pancreatic ß-cells (Karlsen et al., 
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2001, Bruun et al., 2009) and SOCS1 suppresses TNFα induced cell death, with the 
latter regulated through p38 MAP kinase rather than JAK-STAT signalling (Morita et al., 
2000). SOCS1 suppresses TNFα dependent apoptosis in cardiomyocytes via ERK1/2 
pathway activation (Yan et al., 2008) and SOCS3 has been shown to be an important 
regulator of involution, tissue remodelling and apoptosis that is required after the 
cessation of lactation (Sutherland et al., 2007). In addition, SOCS3 appears to be a key 
component of the survival apparatus of prostate cancer cells (Puhr et al., 2009, 
Horndasch and Culig, 2011b). It is overexpressed in castration-resistant tumours and 
its knockdown results in increased cell death, mediated through both apoptotic 
pathways. Overexpression of Bcl-2 protects those cells with reduced SOCS3 from 
harm. Suppression of SOCS3 increases the susceptibility of renal cell carcinoma to 
IFN-α, raising the possibility that reducing SOCS expression may be a potential future 
strategy for augmenting the effects of anti-tumour therapy (Tomita et al., 2011). 
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Figure 1.10. A summary of the interrelated processes contributing to skeletal mass and 
discussed in detail in this chapter. 
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1.10 Hypotheses 
Chapter 2 
Uraemic toxins contained in uraemic serum obtained from kidney failure patients will 
alter osteoblastic IL-6 and OPG release from human osteoblastic cells. These effects 
may be modifiable by subjecting the serum to heat treatment (to denature 
peptides/proteins), charcoal stripping (to remove hydrophobic molecules) and 
haemodialysis (to remove molecules by size).  
 
Chapter 3 and 4 
Given the relevance of cytokine signalling to their function in both health and disease, 
human osteoblastic cells will express the suppressor of cytokine signalling (SOCS) 
genes SOCS1, SOCS2, SOCS3 and CIS and their pattern of expression following 
stimulation with relevant osteotropic stimuli will provide an insight into their role. The 
functional importance of SOCS will be elucidated through the study of two key 
pathways for osteoblastic cells; namely cytokine secretion, specifically IL-6 and OPG, 
and cell death pathways. 
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Chapter 2 
Cytokine release from human osteoblastic cells in uraemia 
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2.1 Background 
Since bone remodelling requires coupling of osteoclastic bone resorption and 
osteoblastic bone formation, disruption of these linked processes may play a role in the 
aetiology of renal bone disease. A large number of osteotropic factors influence the 
principal mediators of osteoclastic resorption, namely osteoprotegerin (OPG) and 
RANK-L (Aubin and Bonnelye, 2000, D'Amelio et al., 2009). Amongst these, 
interleukin-6 (IL-6) plays a key role in the initiation and maintenance of 
osteoclastogenesis (Adebanjo et al., 1998, Sims and Walsh, 2010) and it has been 
implicated in the pathogenesis of a wide variety of pathologies characterised by 
accelerated remodelling and resorption, including renal bone disease (Langub et al., 
1996, Ferreira et al., 2009). 
 
To explore the hypothesis that the uraemic toxins contained in uraemic serum may 
increase osteoblastic cytokine release, the effect of human uraemic serum on the 
release of OPG and IL-6 from human osteoblast-like cells was examined. MG-63 cells 
were cultured for 24h in media containing sera pooled from either healthy male 
volunteers or haemodialysis (HD) patients alongside matching charcoal stripped sera. 
The concentrations of OPG and IL-6 were then measured in harvested supernatants. In 
other experiments, individual serum samples collected from patients prior to, and 
during, a dialysis session were assayed for IL-6, interleukin-1β (IL-1β) and soluble IL-6 
receptor (sIL-6R) using specific enzyme-linked immunosorbent assays (ELISAs). The 
capacity of charcoal stripping of serum and both sham and therapeutic HD to modify 
osteoblastic IL-6 release was investigated. 
 
In order to study the effects of a uraemic environment on SOCS expression, MG-63 
cells were incubated with pooled serum from either male haemodialysis patients or 
healthy volunteers. mRNA was isolated from the cells prior to PCR amplification with 
SOCS specific primers. 
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2.2  Materials and methods 
2.2.1 Osteoblast-like cell lines 
MG-63 
MG-63 is an osteoblast-like cell line cloned from a human osteosarcoma. It has the 
phenotype of a immature osteoblast. Constitutively the cells have relatively low levels 
of alkaline phosphatase, do not express osteocalcin and do not form a mineralised 
matrix in vitro, though these functions can be stimulated by 1,25 dihydroxyvitamin D3. 
The cells are able to show a cAMP response to PTH stimulation and are high 
constitutive producers of growth factors and cytokines. 
 
SaOS-2 
The SaOS-2 cell line is also derived from a human osteosarcoma. It has many of the 
features of a well-differentiated osteoblastic cell, including constitutive expression of 
high levels of alkaline phosphatase, cAMP response to PTH stimulation, and 
expression of osteonectin and bone sialoprotein. These cells can form bone when 
implanted in vivo and a mineralised matrix in long-term cultures in vitro. However, they 
do not appear to express osteocalcin at any stage of their development. 
 
2.2.2 Cell culture 
MG-63 cells were cultured in Modified Eagles Medium α with 10% (v/v) fetal bovine 
serum (FBS) and antibiotics (benzylpenicillin 100units/mL, streptomycin 10 µg/mL, 
amphotericin 2.5 µg/mL (all Invitrogen, Paisley, UK) [hereafter called medium] in sterile 
T75 culture flasks (Merck, Darmstadt, Germany) and incubated at 37ºC in a humidified 
atmosphere of 95% air and 5% CO2 (IR 1500 Automatic CO2 incubator, Flow 
laboratories Ltd). SaOS-2 cells were cultured in Roswell Park Memorial Institute (RPMI, 
Invitrogen) with 10% (v/v) FBS (plus antibiotic). When confluent, the cells were 
subcultured; i.e. the medium was removed and the cells washed with 10mL of 
Phosphate Buffered Saline pH 7.4 (PBS). Two mL of PBS solution containing 0.05% 
Trypsin (Life Technologies, Paisley, UK) was then added to the cells, which were 
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incubated at 37ºC for approximately 5min until they had detached from the culture 
flask. Eight mL of culture medium was added and mixed gently using a 10 mL stripette 
(Merck, Darmstadt, Germany) to ensure a homogeneous suspension and prevent 
further action of trypsin. The cells were then harvested by centrifugation at 1200 x g for 
5 minutes (Megafuge 2.0R, Heraeus Equipment Ltd). The supernatant was removed 
with care so as not to disturb the pelleted cells, which were then resuspended in culture 
medium and aliquoted into fresh culture flasks. 
 
 
2.2.3 Cell count 
After being harvested by trypsin treatment and centrifugation (see above), an aliquot of 
pelleted cells was resuspended in 10 mL of culture medium and a 1:1 dilution of the 
cell suspension made with 0.1% v/v of Trypan blue (Sigma Aldrich Co, Dorset, UK). 
100 µL of cell suspension-trypan blue mixture was transferred to a haemocytometer 
chamber over which a cover slip was placed. Using one chamber of the 
haemocytometer, the number of dead and viable cells were counted in the middle 
1mm2 square and at least two of the four corner squares. Each square on the 
haemocytometer (with the cover slip in place) represents a total volume of 0.1mm3 (10-
4 mm3). Therefore,  
 
 
Live cells per ml = mean number of unstained cells per square x 104 x 2 
Total cells  = cells per ml x volume in which cells suspended x 2 
 
Cell viability  =  number of unstained cells      x 100 
Total number of cells 
 
 
2.2.4 Cell freezing 
After being harvested, cells were gently washed with 5 mL of PBS, recentrifuged, and 
the buffer removed. The pelleted cells were then resuspended in 1 mL of Cell Culture 
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Freezing Medium (GIBCO Life Technologies, Paisley, UK) and transferred to a cryovial 
(Merck, Darmstadt, Germany), which was placed in a polystyrene container at -20ºC 
for 2h, followed by a minimum of 2 hours at -70ºC, and finally, transferred to liquid 
nitrogen for long term storage. 
 
2.2.5  Human blood samples 
Normal serum samples were obtained from ten healthy male volunteers with no history 
of febrile illness in the preceding four weeks. Males alone were chosen, so that 
important differences in sex steroid concentrations were not introduced. Uraemic 
serum was obtained from ten male ESRD patients receiving HD treatment (renal 
diagnoses: - small kidneys - uncertain cause 3; hypertensive nephrosclerosis 2; 
renovascular disease 1; membranous glomerulonephritis 2; focal and segmental 
glomerulosclerosis 1; adult polycystic kidney disease 1). All patients had been on HD 
for at least one year (mean 26 months, range 13-62 months) and had a mean age of 
39 years (range 28-67 years). All patients underwent three, 4h dialysis sessions per 
week using cellulose acetate dialysers and bicarbonate buffering. Venous access in all 
subjects was by primary arteriovenous fistulae. Blood was sampled from the arterial 
access port prior to passing through the dialyser at the start of a HD treatment session. 
Serum was obtained from blood samples taken into plain glass tubes and allowed to 
stand upright at room temperature for 20min before separation by centrifugation at 
2000 rpm and removal of serum with a sterile pipette and immediate storage at -200 C. 
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2.2.6  Sham dialysis procedure 
Blood samples were also obtained from five additional patients during an individual HD 
session using a modified cellulose dialysis membrane. The characteristics of these 
patients are shown (table 1). Samples were taken prior to dialysis and at 30, 60, 120, 
180, 240 and 300min into their treatment. The first 60min comprised extra-corporeal 
circulation alone, with no dialysate flow and no programmed ultrafiltration (hereafter 
referred to as sham dialysis). After 60min, dialysate flow was introduced and continued 
for the remainder of the dialysis treatment (figure 2.1).  During HD treatment, blood is 
exposed to dialysate, a solution containing physiological concentrations of electrolytes, 
across a semi-permeable membrane. Pores in this membrane allow small molecules 
(e.g. urea – MW 60Da) and electrolytes, but not larger ones (e.g. plasma proteins such 
as albumin – 60,000 Da), or blood cells to pass through. Concentration differences 
across the membrane allow molecules to diffuse down a gradient. This allows waste 
products to be removed and desirable molecules or electrolytes to be replaced. Water 
can be driven through the membrane by hydrostatic force, termed ultrafiltration 
(Steddon, 2006). 
 
 
 
Figure 2.1. Protocol for blood sampling during ‘sham’ and ‘standard’ dialysis 
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Patient 
 
Cause of 
ESRD 
 
Years on 
dialysis 
 
PTH 
(Pmol/L) 
 
CRP 
(mg/L) 
 
1 
 
Reflux 
 
4 
 
136 
 
24 
 
2 
 
Stone disease 
 
2 
 
3.6 
 
<5 
 
3 
 
Hypertension 
 
12 
 
0.3 
 
<5 
 
4 
 
Hypertension 
 
4 
 
30.9 
 
13 
 
5 
 
Hypertension 
 
1 
 
56.7 
 
27 
 
Table 2.1 Characteristics of the five patients who underwent serum sampling throughout an 
individual dialysis treatment. 
 
Individual normal and uraemic serum samples were assayed for IL-6, soluble 
interleukin-6 receptor (sIL-6R) and interleukin-1 beta (IL-1β). IL-1β is known to increase 
the release of IL-6 from both MG-63 and SaOS-2 cells and was measured to assess 
any contribution to the differences in measured IL-6. SIL-6R is a 50 kDa ligand protein 
derived from the surface shedding of the gp80 component of the IL-6 receptor 
(Kishimoto, 2005). Its ability to bind free IL-6 means it is a potential source of 
interference with the measured concentration of IL-6. Some aliquots of human sera 
were ‘inactivated’ by charcoal stripping; a process that removes hydrophobic structures 
including steroids and growth factors. Two grams of activated charcoal were added to 
50 mL of serum and mixed at room temperature for 4h. Serum was recovered by 
centrifuging for 30min at 3500 rpm. The supernatant was re-centrifuged for a further 
20min at 20,000 rpm at room temperature. Prior to use the serum was filtered through 
0.45 µm and then 0.2 µm filters (Minisart, Sartorius AG, Göttingen, Germany). 
Additional aliquots were heat treated in a water bath (65ºC for 30min) as an alternative 
method of growth factor and hormone inactivation.  
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2.2.7  Ethical approval  
Ethical approval for these procedures was obtained from the relevant local body (East 
London and the City Health Authority, reference P/00/241). All patients provided written 
informed consent. 
 
2.2.8  Experimental design 
Cells were seeded into 24 well plates at a density of 200,000 cells/well. They were 
allowed to adhere for 24h before aspiration of media, washing with sterile phosphate 
buffered saline (PBS) and incubation with α-MEM buffer containing antibiotics (as 
before) and 10% charcoal stripped (CS) foetal calf serum (CS-FCS) to provide a non-
stimulating (growth arrested) environment for a further 24h. To examine the effects of 
human sera on IL-6 secretion, cells were then incubated for 24 hours in media 
supplemented with antibiotics and the human sera of interest at a 10% concentration. 
Negative controls were provided by refreshing cells with 10% CS-FCS and positive 
controls (for IL-6) by using 10% CS-FCS to which IL1-β (R&D Systems, Abingdon, 
Oxon, UK) had been added (at 100 IU/ml). At the end of the 24h incubation period 
media were collected and stored at -200C for no longer than one month before assay. 
Cells were washed with PBS and centrifuged before being subjected to three 
freeze/thaw cycles between -700C and room temperature to allow cell lysis for the 
measurement of cellular protein. All samples were assayed in at least quadruplicate 
and individual experiments repeated three or more times. In separate experiments the 
concentration of OPG in pooled 10% normal and 10% uraemic serum was determined 
and the effect of these sera on OPG secretion from both MG-63 and SaOS-2 examined 
and compared to serum free controls. 
 
2.2.9  Alkaline Phosphatase detection 
Alkaline phosphatase (ALP) activity of the cultured cells was confirmed by staining 
confluent flasks with 5-bromo-4-chloro-3-indoyl phosphate (BCIP). Positive blue 
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staining occurs in the presence of ALP and the colour is intensified by oxidation with 
nitroblue tetrazolium chloride (NBT) (Roche Diagnostics, Burgess Hill, UK).  
 
2.2.10  Cytokine assays 
IL-6, OPG, IL1-β and soluble interleukin-6 receptor (sIL-6R) were assayed using the 
relevant DuoSet ELISA Development kits (R&D Systems, Abingdon, UK). Each 
contains the components required for the development of a sandwich ELISA to 
measure a particular cytokine or growth factor in cell culture supernatants. The 
supplied capture antibody is diluted to working concentration in PBS and added in a 
volume of 100 µL per well to a 96 well microplate (e.g. mouse anti-human IL-6 at a 
working concentration of 2µg/mL). The plate is then sealed with an adhesive strip and 
incubated overnight at room temperature. Each well is then aspirated and washed 
three times with 400 µL of wash buffer. After the last wash, residual wash buffer is 
removed by blotting vigorously against paper towels. The plates are ‘blocked’ by 
adding 300 µL of reagent diluent containing 1% BSA to each well, with a 1h incubation 
at room temperature. The wash step is repeated prior to the addition of sample (100 µL 
per well), or standard (e.g. recombinant human IL-6 in two fold serial dilutions from a 
high standard of 600 pg/mL), in reagent diluent. The plate is covered and incubated for 
two hours at room temperature before further washing x 3. Detection antibody (e.g. 
biotinylated goat anti-human IL-6 in a working concentration of 200ng/mL) is added 
(100 µL/well). The plate is re-covered and incubated for a further 2h at room 
temperature, followed by a further wash. Streptavidin conjugated to horseradish-
peroxidase (streptavidin-HRP) is added (100 µL/well) and the plate is covered and 
incubated away from direct light for a further 20 minutes at room temperature. 
Following a final wash (x 3), substrate solution (100 µL/well) is added prior to a further 
20min incubation at room temperature and away from direct light. A stop solution (50 
µL/well) is added and the plate gently tapped to ensure mixing. The optical density of 
each well is determined immediately at 450nm using a microplate reader.  Examples of 
standard curves for the IL-6 and OPG Duosets are presented in appendix 1 (figure..). 
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2.2.11  Protein assays 
Cellular protein in the experiments presented in this chapter (section 2.2.8 and 2.3.6) 
was assayed using the Bradford dye-binding protein assay (Bio-Rad, Hemel 
Hempstead, Hertfordshire, UK) in a spectrophotometric microtitre based format. 
Absorbance was measured at 595 nm and samples quantified with a standard curve 
prepared from known concentrations of bovine serum albumin.  
 
2.2.12 Isolation of total RNA from MG-63 and SaOS-2 cells 
Total RNA isolation was carried out using the RNeasy Mini Kit (Qiagen, Crawley, UK), 
which is designed to isolate total RNA from small quantities of starting material. The 
principle of this method involves a specialised high-salt buffer system, which allows up 
to 100 µg of RNA longer than 200 bases to bind to the RNeasy silica gel membrane. All 
reagents were supplied with the kit and the protocol was followed as in the 
manufacturers handbook. 
 
Cells were disrupted in the presence of 350 µL of a highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer, which immediately inactivates RNases to 
ensure isolation of intact RNA. 10 µL of ß-mercaptoethanol (ß-ME) 14.5M (Sigma-
Aldrich Co) was added to 1 mL of buffer prior to use. The lysate was then homogenised 
to shear genomic DNA and reduce the viscosity of the lysate by centrifugation for 2 
minutes at maximum speed through a QIAshredder column. 
 
One volume of 70% ethanol (Merck, VWR Inc, Leicestershire, UK) was added to the 
homogenised lysate and mixed, in order to create conditions that promote selective 
binding of RNA to the RNeasy membrane. The sample was then applied to an RNeasy 
spin column, where the total RNA binds to the membrane, and centrifuged for 15s at 
9500 x g. Contaminants were washed away with 350 µL of buffer RW1 (containing 2.5-
10% chaotropic salts), followed by centrifugation for 15 seconds at 9500 x g. At this 
stage, an incubation mix of 10 µL of RNase-free DNase I solution and 70 µL of buffer 
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RDD (RNase free DNA digest buffer) was added directly onto the spin-column 
membrane, which was incubated at room temperature for 15 minutes. DNase I was 
used to provide efficient on-column digestion of DNA during RNA purification. 
 
The DNase was then removed by a second wash with 350 µL of buffer RW1, followed 
by centrifugation for 15s at 9500 x g. Next, the spin column was washed twice with 500 
µl of ethanol based buffer RPE to remove all contaminants, and centrifuged for 15s at 
9500 x g and for 2min at maximum speed to dry the silica gel membrane. Finally the 
RNA was eluted by applying 50 µL of RNase free water directly onto the silica gel 
membrane, followed by centrifugation at 9500 x g for 1min.  
 
2.2.13 RNA quantitation for cDNA synthesis 
The concentration of the isolated RNA was determined using a UV spectrophotometer. 
RNA was diluted 1:50 with RNase-free water and the absorbance measured at 260 and 
280nm. The spectrophotometer was blanked against a cuvette containing only RNase 
free water. The RNA concentration was calculated from the formula 
 
40 x dilution factor x A260 = [RNA] µg/ml 
 
The purity of the RNA was estimated from the ratio of A260/A280 with a value of between 
1.8 and 2.0 indicating little or no contamination by protein.  
 
 
2.2.14 First-strand complementary DNA (cDNA) synthesis 
This procedure was carried out using the first-strand cDNA synthesis kit (Amersham 
Biosciences, UK), which has been designed to provide all the reagents necessary to 
generate full-length first strand cDNA from an RNA template, using a variety of primers. 
First strand cDNA synthesis is catalysed by Moloney Murine Leukaemia virus (M-
MuLV) reverse transcriptase. All reagents were supplied with the kit and the protocol 
was followed as in the manufacturer’s handbook. 
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The mRNA or total RNA sample, purified as described, was heat denatured at 65ºC for 
10min, and immediately placed on ice. The bulk first strand cDNA reaction mix 
(containing reverse transcriptase, RNase/DNase free BSA and dNTPs) was gently 
mixed by pipetting to obtain a uniform suspension. 11 µL of the above reaction mix was 
added to a sterile microfuge tube together with 1 µL of dithiothreitol (DTT) solution (200 
mM), 1 µL of a 1 in 25 dilution of Not I-d(T)18 bifunctional primer (5 µg/µL) and 20 µL of 
heat denatured RNA. The solution was mixed by pipetting and then, incubated for 1h at 
37ºC, resulting in a double stranded RNA:cDNA heteroduplex, which was stored at -
70ºC until amplified by PCR.  
 
2.2.15 Polymerase chain reaction 
Intron spanning primers for the house keeping glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) gene were used in the PCR reaction as an internal control 
and to normalise for variable quantities of cDNA used in each amplification. These 
primers were designed to produce a 762 bp product. Primers for the suppressors of 
cytokine signalling genes SOCS 2, 3 and CIS were selected from the available 
literature. Intron spanning primers for SOCS 1 were designed using Primer 3 
(www.genome.wi.mit.edu/cgi-bin/primer/primer3-www.cgi) and subjected to a Blast 
search (www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi). All primers were ordered at 
MWG (https://ecom.mwgdna.com/register/index.tcl) (Eurofins MWG Operon, 
Ebersberg, Germany).  
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Primer name 
 
Length (bp) 
 
Direction 
 
5’-3’ sequence 
 
 
GAPDH 
 
762 
 
Forward 
Reverse 
 
TCC CAT CAC CAT CTT CCA 
GTC CAC CAC CCT GTT GCT 
 
SOCS1 
 
470 
 
Forward 
(Alternative Forward) 
Reverse 
 
GGC AGC TGC ACG GCT CCT 
(AGC ATG CGC GAG AGC CGC) 
CTG TCG CGC ACC AGG AAG 
 
SOCS2 
 
375 
 
Forward 
Reverse 
 
ACA GAG ATG CTG CAG AGA TG 
CTC GGT CAG ACA GGA TGG TA 
 
SOCS3 
 
313 
 
Forward 
Reverse 
 
TGC GCC TCA AGA CCT TCA GC 
CAG CTT GAG CAC GCA GTC 
 
CIS 
 
314 
 
Forward 
Reverse 
 
CAG TGC AGG AGG CCA CAT AG 
GGA GGA TCT GCT GTG CAT AG 
 
 
Table 2.2: Primer details 
 
A master mix of PCR reaction components was set up on ice, based on a final reaction 
of 100 µl per sample. The final concentrations were as follows:  
 
 
Components     Volume Final Concentration 
10 x PCR buffer minus Mg   10 µL   1x 
10mM dNTP mixture     2 µL   0.2 mM each 
25 mM MgCl2     12 µL   3.0 mM 
Primer mix (10µM each)   4 µL   0.5 µM each 
Template cDNA    2 µL   ----- 
Taq DNA polymerase    0.5 µL   2.5 U 
Autoclaved distilled water to   100 µL 
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In the case of multiple reactions, a master mix was prepared to minimise reagent loss 
and enable accurate pipetting. The contents of each tube were mixed and overlaid with 
50 µl of mineral oil. A negative control (without template DNA) was used in each 
amplification. Thermal cycling parameters for GAPDH and SOCS primers were 
optimised for use with a Techne PHC-3 thermal cycler as shown below. 
 
 
 
Primers 
 
T (ºC) 
Duration (secs) 
 
Cycles 
 
 
GAPDH 
 
94        55       72        72 
60s      90s     90s      10min 
 
28 
 
 
SOCS1 
 
94        55       72        72 
60s      90s     90s      10min 
 
28 
 
SOCS2 
 
94        55       72        72 
60s      90s     90s      10min 
 
28 
 
SOCS3 
 
94        60       72        72 
60s      90s     90s      10min 
 
28 
 
CIS 
 
94        55       72        72 
60s      90s     90s      10min 
 
28 
 
Table 2.3: Thermal cycling conditions 
 
2.2.16 Agarose gel electrophoresis 
The PCR product was run on a 1.5% Agarose gel (RNase and DNase-free Agarose, 
Life technologies Ltd) containing 0.2 µg/mL ethidium bromide (Sigma-Aldrich Co) in 1 x 
TBE (Tris-Borate EDTA) buffer. The gel was poured into a gel former (Horizon 58, Life 
technologies) and after setting at room temperature, covered in 1 x TBE buffer. Two µL 
of loading dye (Sigma-Aldrich Co) were added to each sample before loading. 
Horizontal gel electrophoresis was carried out at 80 V for approximately 40min. A 
100bp DNA ladder molecular weight marker (Amersham Biosciences, UK) was used 
for size determination. The resulting DNA bands were visualised using a UV 
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transilluminator (Hoefer Scientific Instruments, Holliston, MA, USA) and images were 
taken using a Polaroid direct screen instant camera DS34 loaded with Polaroid 667 
film. 
 
2.2.17 Scanning densitometry 
Scanning densitometry was carried out using a commercial system (GDS 7500 and 
GelBlot Pro Software; Ultraviolet Products Ltd, CA, USA). Saved images were 
transferred to a remote desktop computer where analysis was performed. Each lane of 
the Agarose gel was scanned individually and a common background subtracted. 
Results, corresponding to the peak areas of specific bands, are expressed as a ratio of 
the specific SOCS to GAPDH. 
 
2.2.19  Statistical analysis 
Comparisons between normal and uraemic serum cytokine concentrations were 
analysed by unpaired t-test while other results of more than two groups were analysed 
by one-way or repeated measures ANOVA with Tukey's post-hoc test for inter-group 
comparisons. P<0.05 was considered significant (NS = not significant) and all results 
are expressed as mean ± standard error of the mean (S.E.M.). 
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2.3  Results 
2.3.1  Serum cytokine concentrations 
The serum concentrations of IL-6 were lower in normal subjects than in serum taken 
before dialysis from stable HD patients (0.4 ± 0.1 pg/mL vs. 7.0 ± 1.6 pg/mL 
respectively P=0.003). However, no significant differences in the concentrations of sIL-
6R or IL-1β were seen in sera taken from normal subjects compared with ESRD 
patients (sIL-6R: 65 ± 26 µg/L vs. 96 ± 24 µg/L, NS; IL-1β: 7.6 ± 1.6 pg/mL vs. 8.7 ± 2.5 
pg/mL, NS). In those subjects followed through a dialysis session, no significant 
changes in the serum levels of IL-6, sIL-6R or IL-1β were found (table 2.4).  
 
 
 
Table 2.4 Effect of haemodialysis on serum cytokines in eight subjects followed for 80 minutes 
during a single haemodialysis session (results are expressed as mean±S.E.M.). The serum 
concentrations of IL-6 were lower in normal subjects than in serum taken before dialysis from 
stable HD patients (P=0.003). No significant differences in the concentrations of sIL-6R or IL-1β 
were found and no significant changes in the serum concentrations of IL-6, sIL-6R or IL-1β were 
seen during 80 min HD treatment. 
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2.3.2  Serum effects on osteoblast OPG release 
The concentration of OPG was significantly higher in 10% uraemic serum than in 10% 
normal serum (2199.3 ± 31.2 pg/mL vs. 1767.704 ± 46.3 pg/mL, p<0.0001). Figure 2.2.  
 
There were no significant differences in OPG secretion following the incubation of MG-
63 cells with 10% normal or uraemic sera (7558.65 ± 193.7 pg/mL and 7764.52 ± 214.5 
pg/mL respectively, NS) or serum free controls (7662.43 ± 140.0 pg/mL).  Figure 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. The concentration of OPG was significantly higher in pooled 10% uraemic 
serum than in pooled 10% normal serum (p<0.0001). The release of OPG from MG-63 
following 24 hours incubation with these sera was similar and not significantly different 
from serum free controls 
 
There were also no significant differences in secretion of OPG from SaOS-2 cells 
following incubation with either sera of interest (2233.88 ± 76.1 pg/mL vs. 2120.46 ± 
62.08 pg/mL, NS).   
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2.3.3  Serum effects on osteoblast IL-6 release 
Significant differences in IL-6 secretion were seen in MG-63 cells when incubated with 
the various sera (P<0.0001 by one-way ANOVA, figure 2.3). Serum that had been 
charcoal-stripped, from either normal or uraemic subjects, resulted in similar amounts 
of basal IL-6 release (1134 ± 127 pg/mL vs. 853 ± 78 pg/mL, NS). Untreated normal 
serum augmented IL-6 release by ~6-fold (to 6878 ± 595 pg/mL) over basal (charcoal-
stripped) concentrations. This increase was significantly attenuated with untreated 
uraemic serum, which increased release by ~2-3-fold (to 2579 ± 169 pg/mL) over basal 
concentrations. The augmentation of IL-6 release by normal sera was significantly 
greater than that by uraemic sera (6878 ± 595 pg/mL vs. 2579 ± 169 pg/mL, P<0.001). 
Heat treatment of uraemic serum had no effect on the release of IL-6 from MG-63 cells 
(1952 pg/mL ± 172 heat treated vs. 1872 pg/mL ± 165 non-heat treated) (figure 2.4). 
IL-1β (100IU/mL) was by far the most powerful stimulus to IL-6 production (31802 ± 
3250 pg/mL), whilst serum free media was the weakest (187 ± 33 pg/mL). 
  
Quantitatively similar results were observed with SaOS-2 cells after incubation with 
human sera (figure 2.5). The augmentation of IL-6 release was 6-fold greater with 
normal serum compared to uraemic serum (374 ± 6 pg/mL vs. 61 ± 4 pg/mL, 
respectively). 
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Figure 2.3: IL-6 release from MG-63 cells after 24h incubation with media containing normal and 
uraemic serum. CS = charcoal stripped. Significant differences between treatments were found 
(P<0.0001 by one-way ANOVA; for each group n=12). The data were reproduced in two further 
experiments. 
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Figure 2.4: The heat treatment (via incubation in a water bath at 65ºC for 30min) of uraemic 
serum did not induce a significant difference in the release of IL-6 following subsequent 24h 
incubation with MG-63 cells as compared to non-heat treated uraemic serum (n=6, p=ns). 
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Figure 2.5: The incubation of SaOS-2 cells with media containing uraemic serum release 
caused a significant reduction in the release of IL-6 release at 24h compared to incubation with 
normal serum (n=3, p<0.001). 
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2.3.4  Effect of haemodialysis on osteoblastic IL-6 release in response to 
uraemic serum 
Having found significant differences in IL-6 production, further experiments were 
designed to explore the capacity of haemodialysis to restore the ability of uraemic 
serum to promote IL-6 production to the same degree as normal serum (figure 2.6). 
The initial period of sham dialysis was necessary to explore the possible consequences 
of both heparinisation and extracorporeal circulation of blood for subsequent effects in 
cell culture. Therapeutic dialysis aided the investigation into the potential removal of 
mediators of the effect. Although for some individual patients there was variability in 
osteoblastic IL-6 secretion at different time points, no significant differences or trends 
were evident.  
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Figure 2.6 IL-6 release from MG-63 cells after 24h incubation with media containing sera 
harvested from five individual patients during a single haemodialysis session. The first 60 min 
represent ‘sham’ dialysis, with no dialysate flow. The abscissas depict the time of blood 
sampling. No significant differences or trends were evident. 
 
 
HD	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2.3.5  Alkaline phosphatase activity 
Positive staining after exposure to NBT and BCIP, confirmed the osteoblastic 
phenotype of both cell lines (see section 2.2.9). 
 
2.3.6 Cellular protein 
There were no significant differences in extracted cellular protein concentrations in any 
of the groups under study (figure 2.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: There were no significant differences in extracted cellular protein concentration 
between the different groups under study (n=6, p=ns). CS denotes charcoal stripping of the 
relevant serum. 
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2.3.7  Expression of SOCS mRNA in MG-63 cells 
 
After harvesting and counting, MG-63 cells were plated at a density of 0.5 x 106 cells 
per well of a 6-well plate in 3 mL medium and incubated at 37ºC for 24h. mRNA was 
extracted from the cells with subsequent cDNA synthesis and PCR amplification using 
SOCS specific primers. Results, indicating constitutive expression of SOCS2, SOCS3 
and CIS mRNA, are shown in figure 2.8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Constitutive expression of SOCS mRNA in unstimulated MG-63 cells. 
SOCS3, SOCS2 and CIS are shown with products corresponding to expected 
sizes. The failure to detect a product corresponding to the expected size of 
SOCS1 is discussed in the text. In the case of SOCS3 product identity was further 
confirmed by restriction enzyme digest (data not shown). 
 
The difficulty in amplifying human SOCS1 is unexplained but widely recognised. It 
seems to be restricted to human sequence as mouse primers for SOCS1 amplify the 
murine gene consistently and reproducibly. 
 
100 base pair 
ladder 
500bp 
300bp 
SOCS3
313bp
500bp
300bp
SOCS2
375bp
CIS
314bp
100bp 
ladder
SOCS1
470bp
 108 
2.3.8 Effect of normal and uraemic serum on SOCS expression 
In order to explore the effects of a uraemic environment on SOCS expression, serum 
was collected from male haemodialysis patients prior to a routine dialysis treatment. All 
patients were medically stable, had no evidence of intercurrent infection and gave 
express verbal consent. The serum was pooled and filtered before use. Serum was 
also collected from healthy non-uraemic control subjects.  
 
After being harvested and counted, MG-63 cells were plated at a density of 0.5 x 106 
cells per well of a 6-well plate in 3 mL medium and incubated at 37ºC for 24h. The cells 
were then growth arrested in serum-starved media for 12h, before stimulation with 
either 10% pooled uraemic serum (in media) or 10% normal serum for 4 hours. As 
before, mRNA was isolated from the cells followed by cDNA synthesis and PCR 
amplification with SOCS specific primers. The integrity of RNA for each specimen was 
verified using human GAPDH primers. Results for SOCS3 are shown in figure 2.8 
below. Uraemic serum did not increase expression of SOCS3 in comparison to normal 
serum after 120 minutes, but did increase expression at 240min. No consistent pattern 
of expression of SOCS2 or CIS was seen in response to either normal or uraemic 
serum.  
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Figure 2.9: SOCS3 expression following stimulation of MG-63 cells with 10% uraemic 
serum. Results (n=2) are shown as fold of expression compared to cells incubated with 
10% normal serum for an identical time. 
GAPDH 
SOCS3 
120min 240min 
Normal          Uraemic Normal          Uraemic 
120min 240min 
 2 
3 
5 
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4 
 110 
2.4  Discussion 
These studies demonstrate that the release of IL-6 from human osteoblastic cells is 
substantially greater during exposure to media containing serum from non-uraemic 
subjects than during incubation with charcoal stripped sera from the same individuals. 
The release of IL-6 is substantially attenuated in the presence of media containing 
serum from uraemic patients established on maintenance haemodialysis, even though 
uraemic serum significantly augmented IL-6 release in comparison to charcoal stripped 
serum. Charcoal stripped serum from normal and uraemic subjects yielded similar 
results. These findings suggest that uraemic serum itself might be able to influence 
bone turnover. In agreement with previous observations (McIntyre et al., 1999, Herbelin 
et al., 1991), the constitutive release of IL-6 from SaOS-2 cells was significantly (~10-
fold) lower than from MG-63 cells; however, the effect of both normal and uraemic sera 
on the more mature osteoblast phenotype (SaOS-2) paralleled those seen in the less 
mature (MG-63) cells. In both these cell lines, IL-6 release was not augmented with the 
negative control (CS-10%FCS) but strongly augmented (>10-fold) with 100 IU IL-1β. 
 
Charcoal stripping is a commonly utilized means of removing steroid hormones, 
including androgen and oestradiol metabolites, cortisol and thyroid hormones from 
serum (Darbre et al., 1983). The process is also likely to remove other growth factors 
and cytokines, although its exact quantitative effect in this regard is ill defined. In 
contrast, heat inactivation denatures serum proteins and peptides, but has minimal 
effect on steroid hormones. In the present studies, IL-6 production after exposure to 
uraemic serum was enhanced with respect to exposure to normal or uraemic sera 
depleted of cytokines and growth factors by charcoal stripping (figure 2.2). 
Haemodialysis did not have any consistent effect of on the capacity of uraemic serum 
to augment IL-6 release (figure 2.3). Sequential samples taken from 5 patients during 
sham dialysis for 60 minutes, followed by conventional haemodialysis for 240min, 
evoked a similar and near constant level of augmentation. These results imply that, in 
contrast to charcoal stripping, the factor(s) in uraemic serum affecting IL-6 release 
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were not removed by haemodialysis. This may be a clue to nature of the molecules 
involved, as charcoal stripping is able to remove larger, often more complex, molecules 
than haemodialysis can across standard modified cellulose membranes. Furthermore, 
heat treatment of uraemic serum had no effect on the release of IL-6, suggesting that 
the factors removed by charcoal stripping were not simply proteins or peptides. 
 
The difference in IL-6 concentration in media harvested from MG-63 cells cultured with 
the various sera is not due to pre-existing circulating IL-6. Even though a disparity in 
the concentration of IL-6 in normal and uraemic sera was present, similar to those 
previously reported in patients with chronic kidney disease on or off haemodialysis 
treatment (Herbelin et al., 1991), these were trivial compared to those in the 
supernatants at the completion of the experiments. Furthermore, the uraemic and 
normal serum were diluted ten-fold in media before use. Also consistent with previous 
reports, there was no effect of haemodialysis itself on circulating IL-6 concentrations 
(Herbelin et al., 1991). IL-6, in the presence of sIL-6R, is known to induce its own 
synthesis in osteoblasts (Franchimont et al., 1997b) and if an effect from pre-existing 
IL-6 in the sera were present, then it might be anticipated that uraemic, rather than 
normal, serum would increase osteoblast IL-6 secretion. 
 
IL-1β is known to increase the release of IL-6 from the cell lines under study (Siddiqi et 
al., 1998) and, indeed, addition of IL-1β to the media as a positive control led to a 
dramatic increase in IL-6 secretion. There were no significant differences in the 
concentration of IL-1β in any of the sera used in the incubation experiments and, as 
haemodialysis had no effect on the serum concentrations of IL-1β ((table 2.2), it 
therefore seems unlikely that this cytokine played a significant confounding role. The 
ability of dialysis membranes to influence IL-6 release has previously been reported. 
Both circulating IL-1β and IL-1β release from harvested peripheral blood monocytes 
have been shown to be elevated by dialysis involving bioincompatible (cuprophane) 
membranes (Lin et al., 1996), though not by the modified cellulose membranes similar 
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to those used in this study (Qian et al., 1995). Thus, not only is IL-1β unlikely to have 
contributed to differences in the release of IL-6, but it is also unlikely to have had any 
tonic effects. The final concentrations that the MG-63 cells were exposed to were all 
less than those previously reported as having an effect on IL-6 release from this cell 
line (McIntyre et al., 1999). 
 
SIL-6R is a 50 kDa ligand binding protein derived from surface shedding of the gp80 IL-
6 receptor (Mullberg et al., 1993) and might be expected to interfere with measured IL-
6 levels by binding to free IL-6, possibly through interference with immunoassay 
detection. Artefacts of this kind seem unlikely as we found no significant differences in 
the concentrations of sIL-6R in any of the sera from patients or control subjects and 
dialysis did not influence the circulating concentrations of sIL-6R in the uraemic 
patients.  
 
Receptor activator of NF-κB (RANK) is a membrane bound receptor found on 
osteoclast surfaces, while its ligand, RANK-L, is inducibly expressed on osteoblast cell 
membranes. Binding of ligand to receptor promotes osteoclastic differentiation and is a 
key step in the initiation of bone resorption. OPG, also an osteoblast product, is a 
secreted decoy receptor of RANK-L and functions as an ingenious regulatory 
mechanism (Suda et al., 1999, D'Amelio et al., 2009). When OPG levels decrease, 
more RANK-L is available to bind RANK and induce bone resorption and turnover. On 
the other hand, a rise in OPG tips the balance in firmly in favour of bone formation. 
Factors that decrease the OPG/RANK-L ratio, thereby favouring bone resorption with 
higher rates of bone turnover, include TNFα (Hofbauer et al., 1999c), PTH (Yasuda et 
al., 1998b), calcitriol (Yasuda et al., 1998b), gp130 activating cytokines (e.g. IL-6, IL-
11) (Yasuda et al., 1998b) and IL-1 (Hofbauer et al., 1998, Hofbauer et al., 1999c). 
Those that increase the OPG/RANK-L ratio, thereby decreasing bone resorption and 
slowing bone turnover include oestrogens (Hofbauer et al., 1999b), and androgens 
(Hofbauer et al., 2002).   
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The current results, while consistent with previous observations of elevated circulating 
OPG levels in uraemic patients (Gonnelli et al., 2005, Sigrist et al., 2009), differ from 
those obtained for IL-6 and do not support our hypothesis that uraemic serum might 
differ from normal serum in its ability to promote or inhibit osteoblastic OPG secretion. 
However, it might have been expected that the amount of OPG measured in the cell 
supernatants would increase by as least as much as that present in the 10% dilutions 
of serum in comparison to serum free controls. This was indeed the case for SaOS-2, 
but not for MG-63, perhaps indicating that both normal and uraemic serum partially 
abolish the synthesis of OPG in this particular cell line. 
 
There are precedents for components of the uraemic milieu affecting cellular function. 
In 1976 Wills and Jenkins reported that pre-dialysis serum from uraemic patients was 
able to inhibit the resorptive effect of parathyroid extract on bone, a phenomenon that 
was not reproducible by the addition of known uraemic metabolites. Furthermore, this 
effect could be removed by dialysis, following which there was a net increase in 
resorption (Wills and Jenkins, 1976). Uraemic toxins have been shown to affect the 
normal functioning of calcitriol by inhibiting the binding of calcitriol receptors to vitamin 
D response elements in a uraemic rat model (Patel et al., 1995). It has previously been 
reported that calcitriol does not have an effect on IL-6 transcription or release from MG-
63 cells at concentrations less than 10-9 M, far higher than those encountered in the 
cell culture media (McIntyre et al., 1999). Thus, calcitriol is unlikely to be responsible 
for the effects on IL-6 release in this cell system. Many small proteins in uraemic serum 
may have profound effects on cellular functions (Haag-Weber et al., 1994) and it might 
be expected that some of these, for example PTH, may exert influence in the current 
model.  The previous observation that PTH has no effect on IL-6 production in MG-63 
cells at concentrations below 10-9 M (McIntyre et al., 1999), coupled with the 
demonstration that concentrations as high as 10-7 M did not increase IL-6 release in 
primary cell osteoblast cultures (Littlewood et al., 1991) suggests that this is unlikely to 
be the case. The PTH concentrations in the culture media fell below the lower of these 
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concentrations. Furthermore, heat treatment would have been expected to destroy 
PTH and no such effect was observed. Srivastava et al reported that uraemic serum 
contains a humoral substance capable of modulating colony forming unit counts in 
mice, an effect that could be modified by dialysis (Srivastava et al., 1990). In the 
current study, an effect of the various sera on cellular proliferation is unlikely to be of 
relevance as there were no differences in the levels of total cellular protein extracted 
from the various experiments. This is compatible with, although not proof of, a neutral 
effect on proliferation. Furthermore, Picton et al reported that a variety of uraemic 
toxins exerted no effect on the proliferation of SaOS-2 cells, despite incubation times 
up to three times longer than those used in this set of experiments (Picton ML, 1999).  
 
The constituitive expression of mRNA for SOCS2, SOCS3 and CIS indicates that this 
important group of regulators of cytokine signalling may be operative in MG-63 
osteoblatic cells. This further exploration of this observation is a major focus of the 
studies presented in chapters 2 and 3 of this thesis. The increase in SOCS3 
expression in the presence of uraemic serum is consistent with previous data 
demonstrating impaired GH-activated JAK2/STAT signalling and EPO signalling in 
uraemia (Schaefer et al., 2001) (Allen et al., 1999). The elevation of SOCS3 in 
osteoblastic cells raises important questions, as the over expression of SOCS3 could 
potentially cause some of the aberrations of cytokine signalling seen in uraemic bone.  
 
In conclusion, IL-6 release is attenuated by uraemic serum in comparison to normal 
serum in human osteoblast-like cells. This was not the case for OPG, where secretion 
remained the same in both settings. The removal of small molecules, including 
cytokines and growth factors, through charcoal stripping, removes the ability of serum 
to augment IL-6 production, though it remains unaffected by either sham or therapeutic 
haemodialysis. This suggests there may be a common factor(s) in uraemic serum, 
apparently not influenced by the primary renal diagnoses, causing reduced stimulation 
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of IL-6 release from osteoblasts and therefore potentially involved in the aberrant local 
signalling and cellular kinetics in uraemic bone.  
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Chapter 3 
Expression and function of the suppressors of cytokine 
signalling (SOCS) in human osteoblastic cells 
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3.1 Background 
 
Uraemia is a highly complex and multi-faceted state and one that is, at best, only partly 
represented in in vitro work by uraemic serum. In particular, uraemic serum is 
susceptible to multiple confounding factors; including concurrent inflammation, differing 
concentrations of circulating hormones as well as the possible effects of co-existing co-
morbid conditions and drug treatments. These limitations guided subsequent 
experiments toward exploration of the cellular regulation of osteoblastic cytokine 
signalling, rather than toward attempts to identify those factors in the uraemic milieu 
that may interfere with it. 
 
The potency of cytokines require that their effects are closely regulated to avoid 
harmful consequences. Amongst the measures that control cytokine activity are a 
family of inducible proteins that downregulate the cytokine-activated JAK/STAT 
signalling pathway - the suppressors of cytokine signalling or SOCS (Yasukawa et al., 
2000). In unstimulated cells JAKs and STATs are inactive and SOCS genes are 
typically not expressed.  After cytokine binding, receptor aggregation occurs, bringing 
receptor associated JAKs together for cross-phosphorylation and activation. These 
kinases can then phosphorylate multiple target proteins, including tyrosine residues in 
the cytoplasmic domains of the receptor and receptor associated STAT monomers 
(Ihle, 2001a). Phosphorylated STAT monomers form dimers that translocate to the 
nucleus where they bind specific DNA target sequences to regulate the transcription of 
biological response genes, including SOCS (Krebs and Hilton, 2001).  
 
The ability of the SOCS proteins to influence signalling involves several disparate 
mechanisms. In essence, they combine direct inhibitory actions on specific 
components of the signalling cascade with more generic mechanisms that target 
components for ubiquitin mediated proteasomal degradation (Piessevaux et al., 2008). 
The clearance of SOCS proteins once they have acted to shut down signalling allows 
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the cycle of cytokine stimulation to be completed and the cell to return to its cytokine-
responsive state (Hilton, 1999).  
 
While both in vitro and in vivo studies show that cytokine induced SOCS expression is 
usually dependent on the JAK/STAT signalling pathway, it is increasingly apparent that 
non-JAK/STAT-dependent regulation of SOCS expression may also occur (Alexander 
et al., 1999, Yoshimura, 2009). 
 
The function of SOCS within bone tissue is still only partially understood (Ahmed and 
Farquharson, 2010). The aim of the studies described in this chapter was to built on the 
observation of constituitive expression of SOCS2, SOCS3 and CIS in human 
osteoblastic cells presented and to attempt to determine their functional significance.  
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3.2  Materials and methods 
3.2.1  Osteoblast-like cell lines and cell culture techniques 
Cell lines and cell culture protocols were followed as described in section 2.2.1. 
 
3.2.2 RT-PCR  
The techniques for isolation of total RNA, RNA quantitation, first-strand complementary 
DNA (cDNA) synthesis, polymerase chain reaction, agarose gel electrophoresis and 
scanning densitometry are detailed in sections 2.2.12- 2.2.17. 
 
3.2.3 Western immunoblotting  
Sub-confluent MG-63 cells were incubated in medium with and without additional 
growth factors of interest for either 4 or 24h. At the end of the experiment, the 
incubation was stopped by the addition of an excess of ice cold PBS. Cells were 
pelleted by scraping with a cell lifter followed by centrifugation for 5min at 1200 g. Cell 
pellets were then lysed by the addition of ice-cold lysis buffer (pH 7.4):  
 
 
 
Lysis buffer 
20 mM Tris (pH 7.4) 
150 mM NaCl 
1% NP-40 
0.5% w/v Na deoxycholate 
0.1% SDS (Promega Corporation, USA)  
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Protease inhibitors were added immediately prior to cell lysis at the following final 
concentrations: 
 
  1 mM PMSF (10 mg/mL stock solution in isopropanol) 
  1 mM orthovanadate (100 mM stock solution) 
  30 µL of a 5-10 U/mL solution of aprotinin from bovine lung 
 
 
Typically, 100 µL of lysis buffer was added per 2 x 106 cells. This was left on ice for 
15min with regular vortex mixing and then centrifuged at 15,000 g for 10min at 4ºC.  
 
The protein content of the supernatant was measured using the bicinchoninic acid 
(BCA) protein quantitation assay (Pierce, Thermo Scientific) in a 96-well plate format. 
Working reagent was made according to the kit insert. To construct a standard curve, a 
set of protein standards was made by diluting 2.0 mg/mL BSA stock solution in dH20. 
Eight dilutions were made ranging in concentrations between 25 to 2000 µg/mL. 25 µL 
of each BSA standard was pipetted into the appropriate wells. 200 µL of the working 
reagent was added to each well, taking care that the samples were mixed well. The 
microplate was placed on a plate shaker for 30s and then put in an oven at 37°C for 30 
minutes. Absorbance was then measured at 550nm on a Dynex MRX II (Dynex, 
Virginia, USA) plate reader. 
 
3.2.4 Immunoprecipitation of SOCS proteins 
SOCS proteins were immunoprecipitated from cell lysates. Lysates (500 µg cell 
protein) were incubated with 2 µg of polyclonal antibody to SOCS1 through 3 or CIS 
(Santa Cruz Biotech, CA, USA) for 2h at 4ºC with end over end agitation.  The bound 
SOCS proteins were then immunoprecipitated by incubation with 20 µl protein A-
agarose (Santa Cruz Biotech) for 4h at 4ºC with end over end agitation. 
Immunoprecipitates were collected by centrifugation at 2,500 g for 5 min at 4ºC and 
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pellets washed three times with 500 µL of lysis buffer containing protease inhibitors and 
each time collected by centrifugation at 2,500 g for 5min. After the final wash pellets 
were resuspended in 40 µL of sample buffer (0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol), boiled for 5min, and a proportion subjected to SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) as described below. The remaining 
immunocomplex in sample buffer was stored at -70ºC for future analysis. 
 
3.2.5 SDS-PAGE 
 
Fifty µg of protein from each sample (whole cell lysate) or a proportion of 
immunoprecipitated protein was electrophoresed on a 10% polyacrylamide gel in the 
presence of SDS. The composition of the solutions for SDS-PAGE are shown below: 
 
 
Stacking gel 
Protogel (30% w/v acrylamide; 0.8% w/v bis-acrylamide)   0.33 mL 
Resolving buffer (1.44M Tris-HCl; 0.384% SDS; pH 8.8)  0.63 mL 
10% Ammonium persulfate (APS)     12.5 µL 
dH20          1.54 mL 
TEMED         2.5 µL 
 
Resolving gel 
Protogel (National Diagnostics, UK)     1.67 mL 
Resolving buffer (0.5M Tris-HCl; 0.4% SDS; pH 6.8)  1.30 mL 
10% APS        50 µL 
dH20         1.98 mL 
TEMED         5 µL 
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Samples were mixed with an equal volume of sample buffer heated to 95ºC for 5 
minutes and placed on ice. 10-20 µL (corresponding to 10 or 20 µg of protein) per well 
was loaded onto the gel. Electrophoresis was carried out at 25 mA per gel for 
approximately 45 minutes at room temperature in a buffer containing 0.025 M Tris (pH 
8.3), 0.192 M glycine, 0.1% SDS. 
 
3.2.6 Immunoblotting and detection of SOCS protein 
 
Acrylamide gels were carefully removed from the electrophoresis apparatus and laid on 
top of a piece of polyvinyldifluoride (PVDF) membrane (Immobilon P; Millipore, MA, 
USA) which had been cut to size and pre-wetted in 100% methanol and dH20. Air 
bubbles were smoothed out with a sterile glass rod and the gel and membrane 
sandwiched between two sponges soaked in transfer buffer (10mM CAPS [3-
cyclohexylamino-1 propane sulfonic acid] pH 11.0, 10% methanol in dH20). The 
sandwich was then placed in the transfer apparatus with the membrane facing the 
anode and electroblotting carried out at 400 mA for 40 mins at room temperature. 
Following electroblotting the membrane was separated from the gel and any residual 
acrylamide washed off by soaking in tris-buffered saline-tween 20 (TBS-T) for 2 
minutes. Non-specific sites on the membrane were blocked with 3% non-fat dry milk in 
TBS-T overnight at 4ºC. After washing in TBS-T for 10min at room temperature, the 
membrane was probed with polyclonal SOCS1-3 or CIS antibody (1:500 v/v in TBS-T + 
1% BSA w/v; Santa Cruz Biotech) for 2h at room temperature with constant agitation. 
The membrane was then washed 5 times for 10 minutes each with TBS-T and 
incubated with a polyclonal anti-rabbit IgG antibody conjugated to horse radish 
peroxidase (1:2000; Santa Cruz Biotech) for 1h at room temperature with constant 
agitation. The membrane was washed as before but with the addition of a final wash 
with TBS. SOCS protein bands were visualised by chemiluminescence (ECL 
Chemiluminescence Detection System, Amersham, UK). Equal volumes (~2 mL) of 
ECL solutions (A and B) were mixed and gently pipetted onto the membrane and left 
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for one minute without agitation. The solutions were then drained off and the 
membrane placed onto a lint-free tissue to remove excess solution. The membrane 
was then immediately covered with Dow Saran wrap (Fisher Scientific UK, 
Loughborough UK) and exposed to light–sensitive film (Kodak Biomax Light) for 
various exposure times. The film was developed using an X-ray developer. 
 
3.2.7 Real time PCR with Taqman ® technology 
Fluorescence-based kinetic RT-PCR procedures significantly improve the reproducible 
quantification of mRNAs and overcome many of the limitations of RT-PCR, which is 
only a semi-quantitative technique. The Taqman assay (Perkin-Elmer/Applied 
Biosystems, CA, USA) utilises the 5’-nuclease activity of DNA polymerase to hydrolyse 
a hybridisation probe bound to a target amplicon. Three oligonucleotides are required. 
Two template-specific primers define the endpoints of the amplicon (and provide the 
first level of specificity). The third oligonucleotide probe hybridises to the amplicon 
during the annealing/extension phase of the PCR (and provides additional specificity). 
This probe contains a fluorescent reporter dye at its 5’ end, the emission spectrum of 
which is quenched by a second fluorescent dye at its 3’ end. If no amplicon 
complementary to the probe is amplified during the PCR, the probe remains unbound. 
If the correct amplicon is amplified, the probe can hybridise after the denaturation step. 
It then remains hybridised while the polymerase extends the primers until reaching the 
probe. It is then displaced and hydrolysed, separating the reporter and quencher dyes 
and releasing quenching of reporter fluorescence emission. As the polymerase will 
cleave the probe only while it remains hybridised to its complementary strand, the 
temperature conditions of the polymerisation phase of the PCR must be adjusted to 
ensure probe binding. Most probes have a Tm of around 70ºC; therefore, the Taqman 
system uses a combined annealing and polymerisation step at 60ºC to ensure the 
probe remains bound to its target during the primer extension step. It also ensures 
maximum 5’-3’ exonuclease activity of the polymerase. 
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3.2.8 Extraction of RNA for real time PCR 
The RNeasy 96 procedure (Qiagen) was used to provide the high throughput isolation 
of high quality RNA. The procedure has been validated for use with sensitive 
quantitative techniques such as Taqman. RNeasy combines the selective binding 
properties of a silica gel based membrane with vacuum technology. Cells are lysed 
with guanidine isothiocyanate (GITC) to inactivate RNases. Ethanol is added to provide 
appropriate binding conditions and the sample applied to the wells of a RNeasy 96 
plate sitting in the QIAvac vacuum manifold. Total RNA binds while contaminants are 
washed away. High quality RNA is then eluted in a small volume of water, ready for 
use in complementary DNA synthesis.  
 
3.2.9 RNA quantitation for real time PCR 
The most commonly used technique for measuring nucleic acid concentration (as 
described in section 3.2.3) is the determination of absorbance at A260. This method has 
several disadvantages, including the relative contribution of proteins and free 
nucleotides to the signal, the interference caused by contaminants and the relative 
insensitivity. The use of sensitive, fluorescent nucleic acid stains lessens many of these 
problems. RiboGreen ® RNA quantitation reagent (Molecular Probes, Invitrogen, 
Paisley, UK) is an ultrasensitive fluorescent nucleic acid stain for quantitating RNA in 
solution; based on fluorescein excitation and emission wavelengths, it enables the 
quantitation of as little as 1ng/mL RNA in a fluorescent microplate reader.   
 
TE assay buffer (10 mM Tris-HCL, 1mM EDTA, pH 7.5) is used for diluting the 
RiboGreen reagent and RNA samples. A 20×TE stock solution is supplied and can be 
diluted in diethyl pyrocarbonate (DEPC) water. On the day of the use, an aqueous 
working solution of the RiboGreen reagent is prepared via the 1 in 2000 dilution of an 
aliquot of concentrated DMSO stock solution into TE. The working solution is protected 
from light by covering with foil. An RNA standard curve is prepared from supplied top 
standards as shown in figure 3.1. RNA samples are diluted 1 in 1000. 100 µl of diluted 
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sample (or standard) are added in duplicate to a 96-well plate. 100 µL of diluted 
RiboGreen is then added to all wells. The plate is wrapped in foil and left at room 
temperature for 5min. Fluorescence is read in a fluorescence plate reader (BMG 
Fluorostar, BMG Labtechnologies Ltd, Aylesbury, UK) at standard fluorescein 
wavelengths (excitation ~ 480 nm, emission ~ 520 nm). 
 
 
TE volume  Volume (µL) of 
100ng/mL RNA stock 
 
Volume (µL) of 2000 fold 
diluted RiboGreen 
reagent 
 
Final 
concentration 
 
 
300 
 
0 
 
100 
 
0 
 
294 
 
6 
 
100 
 
1ng/mL 
 
270 
 
30 
 
100 
 
5ng/mL 
 
150 
 
150 
 
100 
 
25ng/mL 
 
0 
 
300 
 
100 
 
50ng/mL 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: standard curve generated by the ribogreen assay. Concentration of RNA (x axis) is 
plotted against fluorescence (y axis) 
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3.2.10 First-strand complementary DNA (cDNA) synthesis for real time PCR 
Reverse transcription was performed using the Omniscript reverse transcription kit 
(Qiagen) as recommended by the manufacturers, in which 0.5 µg of RNA and oligo-dT 
primer were used. Controls with no reverse transcriptase were included. 
    
3.2.11  Primer and probe design 
A summary of the primer and probe design is shown in the tables. Primer design for the 
Taqman is performed to specification through the use of a specialist primer design 
program, Primer Express (Applied Biosystems, Life Technologies Corp, USA).  
 
 
 
 
Taqman primer guidelines 
 
 
Select the probe first and design the primers as close as possible 
to the probe without overlapping it (amplicons of 50-150 base 
pairs recommended) 
 
Keep the G/C content in the 20-80% range 
 
Avoid runs of an identical nucleotide. This is especially true for 
guanine, where runs of four or more Gs should be avoided. 
 
The Tm should be 58-60ºC 
 
The 5 nucleotides at the 3’ end should have no more than 2 G 
and/or C bases 
 
  
 
Table 3.1: Primer guidelines 
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Table 3.2: Probe guidelines 
  
An important default parameter in Primer Express software is the selection of 
amplicons in the 50-150 base pair range. Small amplicons are favoured because they 
amplify more efficiently and are more likely to be denatured during the 92-95ºC step of 
the PCR, allowing the probes and primers to compete more efficiently for binding to 
their complementary targets. 
  
 
Primer  
 
Length 
(bp) 
 
Direction 
 
5’-3’ sequence 
 
Taqman Probe 
 
 
GAPDH 
 
226 
 
 
Forward 
Reverse 
 
GAAGGTGAAGGTCGGAGTC 
GAAGATGGTGATGGGATTTC 
 
CAAGCTTCCCGTTCTCAGCC 
 
SOCS1 
 
134 
 
Forward 
Reverse 
 
CGCCCTTAGCGTGAAGATG 
GGCGCCGCCACGTA 
 
TTCAGGCCGGCCGCTTTCA 
 
SOCS2 
 
108 
 
Forward 
Reverse 
 
GCTCGCATTCAGACTACCTACTAACA 
CATATGATAGAGTCCAATCTGAATTTTCC 
 
CTGGACCAACTAATCTTCGAATCGA
ATACCAAGA 
 
 
SOCS3 
 
134 
 
Forward 
Reverse 
 
CCAGCCTGCGCCTCAA 
CGGCACTGAGCAGCAGGT 
 
CAGTGCGCAAGCTGCAGGAGAGC 
 
CIS 
 
94 
 
Forward 
Reverse 
 
GTCCAGCCGAGTCCCCAC 
AGTCCGCTCCACAGCCAG 
 
TCCTCTGCGTTCAGGGACCTCGTC 
 
 
Table 3.3: Taqman primer and probe details 
 
Taqman probe guidelines 
 
Select the probe first and design the primers as close as possible 
to the probe without overlapping it (amplicons of 50-150 base 
pairs recommended) 
 
Keep the G/C content in the 20-80% range 
 
Avoid runs of an identical nucleotide. This is especially true for 
guanine, where runs of four or more Gs should be avoided. 
 
The Tm should be 68-70º 
 
No G on the 5’ end 
 
Select the strand that gives the probe more C than G bases 
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By independently varying forward and reverse primer concentrations, the 
concentrations that provide optimal assay performance can be identified. Primers are 
always in large molar excess during the exponential phase of PCR amplification, and 
by adjusting their initial concentration their effective Tms can be adjusted to reduce the 
amount of non-specific primer binding. An initial concentration range of 50 nM-900 nM 
is tested for each primer. A probe optimisation experiment, in which the probe 
concentration is varied from 50-250nM, determines the probe concentrations that will 
provide acceptable results, without using the probe at unnecessary excess (so 
minimising running costs). Table 3.6 shows the optimised primer and probe 
concentrations. 
    
   SOCS1   SOCS2 SOCS3 CIS GAPDH 
    300/300 300/300 300/900 900/900 200/200 
          
Master Mix 5 5 5 5 5 
Forward 0.6 0.6 0.6 1.8 0.4 
Reverse 0.6 0.6 1.8 1.8 0.4 
Probe   0.2 0.2 0.2 0.2 0.2 
Water   1.6 1.6 0.4 0 2 
              
 
 
Table 3.4: Taqman master mix with optimised primer and probe concentrations 
  
 
3.2.12 Construction of standard curves for real time PCR 
SOCS are inducible genes not expressed in the steady state. To obtain cDNA to 
construct SOCS standard curves, DNA from the leukaemic cell line TF-1 after GM-CSF 
stimulation (previously shown to induce SOCS - unpublished data from our laboratory) 
was extracted and amplified using our standard RT-PCR primers. However the 
resulting level of expression was not sufficiently high to generate standard curves. As 
an alternative approach, plasmids containing the cDNA for the entire coding region of 
each human SOCS gene were obtained. These were a generous gift of Professor A. 
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Yoshimura, Fukuoka, Japan. SOCS 1 was contained in the pBluescript II SK + plasmid 
and SOCS 2,3 and CIS in the pcDNA3.1 plasmid. 
 
Transformation 
10 ng of plasmid DNA was added to a 200 µL suspension of JM109 E Coli competent 
cells (Promega). The mixtures were heat shocked at 42ºC for 45s and then chilled on 
ice for 10min. One mL of SOC medium was added followed by an agitated 1h 
incubation at 37ºC. 200 µL of this suspension was streaked onto LB (Sigma Aldrich Co, 
Dorset, UK) containing agar plates (Agar noble; Difco) containing ampicillin (Merck), X-
GAL (Promega) and IPTG (Promega) and left overnight at 37ºC. White colonies were 
selected and grown overnight in 5 mL of LB broth containing ampicillin at 37ºC. 
 
 
DNA purification 
 
Small scale purification of plasmid DNA was carried out using the Wizard Plus DNA 
purification system (Promega). All reagents were supplied with the kit and the protocol 
was followed as in the manufactures instructions. The bacterial culture was centrifuged 
for 2min at 10 000 x g. The pelleted cells were resuspended in 200 µL of cell 
resuspension solution (50 mM Tris, 10 mM EDTA, 100 µg/ml RNase A) and transferred 
to a microcentrifuge tube. The bacteria were lysed with 200 µl of alkaline cell lysis 
solution (0.2M NaOH and 1%SDS) that was subsequently neutralised with 200 µL 
neutralisation solution (1.32M potassium acetate). The resulting lysate was centrifuged 
at 10 000 x g for 5 minutes. The supernatant containing plasmid DNA was transferred 
to the barrel of a syringe containing Minipreps DNA purification resin and the resulting 
mixture injected into a Minicolumn. The syringe was reused to push 2 mL of Column 
Wash Solution (80 mM potassium acetate, 8.3 mM Tris-HCl, pH 7.5, 40 µM EDTA and 
55% ethanol) into the minicolumn. The minicolumn was then transferred to a 1.5 mL 
centrifuge tube and at 10 000 x g for 2 minutes to dry the resin. The plasmid DNA was 
finally eluted in 50 µL of water. 
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To ensure that the plasmid preparation contained the correct size fragments, restriction 
endonuclease digestion of the plasmid DNA with EcoRI was performed. The purified 
plasmid DNA was quantitated and serially diluted to construct standard curves for each 
of the SOCS genes. 
 
Standard curves for GAPDH 
cDNA from unstimulated MG-63 cells was amplified using primers specific for human 
GAPDH yielding a 312 bp product (table 3.5). The primers were designed such that the 
5’ and 3’ ends of the PCR product flanked the sites of the Taqman GAPDH primers. 
This PCR product was run on an agarose gel before excision for gel purification using 
the Wizard SV Gel and PCR clean-up System (Promega). The gel slice is transferred 
to a microcentrifuge tube and Membrane Binding Solution added at a ratio of 10µl of 
solution per 10 mg of agarose gel slice. The resulting mixture is vortexed and 
incubated at 65°C for 10min (until the gel slice dissolves). The dissolved gel mixture is 
then transferred to an SV Minicolumn sitting in a collection tube and incubated for 1 
minute at room temperature followed by centrifugation at 10 000 x g for 1min. The flow-
through is discarded. The column is then washed by the addition of 700µl of Membrane 
Wash Solution (diluted with 95% ethanol) and the minicolumn assembly centrifuged for 
1min at 10 000 x g. The flow-through is again discarded and the wash step repeated. 
The column is then recentrifuged into an empty collecting tube to ensure drying. The 
DNA is eluted from the column into 50 µl of nuclease-free water. Once purified the 
GAPDH DNA is quantitated and serially diluted for use as a template for the standard 
curve. 
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3.2.13 The Taqman assay 
The ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems) is a high-
throughput real-time PCR system that allows the detection and quantitation of nucleic 
acid sequences. It operates in a 384-well plate format and is able to detect 
fluorescence between 500nm and 660nm. 
 
A generic master mix is used for all assays. Assays are run using the same universal 
thermal cycling parameters. This eliminates the need for optimisation of the thermal 
cycling parameters and allows multiple assays to be run on the same plate. These 
thermal cycling parameters are shown in table 3.7. 
 
 
Times and Temperatures 
 
Initial steps 
 
Each of 40 cycles 
 
Melt 
 
Anneal/extend  
Hold 
 
Hold 
 
Cycle 
 
2 min 
50ºC 
 
10 min 
95ºC 
 
15 sec 
95ºC 
 
1 min 
60ºC 
 
Table 3.5: Taqman assay thermal cycling conditions 
 
 
 
3.2.14 Relative quantitation of gene expression 
Accurate and reproducible quantification of mRNA using fluorescence-based PCR is 
based on the concept of the threshold cycle. During the Taqman assay, fluorescence 
values, representing the amount of product amplified to a particular point in the 
amplification reaction, are recorded as the cycle progresses. The more template 
present at the beginning of the reaction, the fewer number of cycles are needed to 
reach a point in which the fluorescent signal becomes statistically significant above 
background. This point is defined as the Ct. It always occurs during the exponential 
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phase of amplification so quantification is not affected by limitation of reaction 
components during the plateau phase. 
 
Quantification of mRNA transcription can be either relative or absolute. Relative 
quantification determines the changes in steady state transcription of a gene and is 
often adequate. A relative standard consists of a sample, the calibrator, which is used 
to create a dilution series with arbitrary units. During the PCR assay, the target Ct is 
compared directly with the calibrator Ct and is recorded as containing either more or 
less mRNA. For normalisation to an endogenous control (GAPDH in this instance), 
standard curves are prepared for both the target and the endogenous reference. For 
each experimental sample, the amount of target and endogenous reference is 
determined from the appropriate standard curve. Then, the target amount is divided by 
the endogenous reference amount to obtain a normalised target value. 
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Plate setup 
Figure 3.2 shows the 384-well plate setup for the relative quantitation of the SOCS 
mRNA. The target and endogenous reference (GAPDH) are amplified in separate 
tubes. Dilutions of cDNA prepared from SOCS DNA (in either the pcDNA3.1 or 
pBluescript II SK plasmids) was used to construct SOCS standard curves. Dilutions of 
purified GAPDH cDNA from MG-63 cells was used to construct the standards for 
GAPDH. Standards are placed in the wells on the left of the plate (coloured in the 
template). 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A       SOCS-1 SOCS-1 SOCS-2 SOCS-3 CIS GAPDH
B
C CIS
D
E
F
G                SOCS-2
H
I GAPDH
J
K
L
M               SOCS-3
N
O
P  
Figure 3.2: Plate setup for the Taqman assay 
 
The unknown samples to the right of the plate are cDNA prepared from total RNA 
isolated from either MG-63 or SaOS-2 cells. 
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Setting thresholds 
After performing the PCR, a threshold is set for fluorescence detection by examining 
the semi-log view of the amplification plots (fluorescence versus cycle number). This is 
above the noise, but still in the linear region of the semi-log plot (horizontal red line in 
the figure 3.3 below). 
 
 
 
 
 
 
Figure 3.3: An amplification plot (fluorescence vs. cycle number) for GAPDH of several cDNA 
samples. The horizontal red line shows the threshold for fluorescence detection 
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Constructing a relative standard curve 
To analyse the experiment, results are exported to an Excel (Microsoft) spreadsheet 
and plotted as an XY scatter graph on the worksheet with the log input amount (DNA 
standard) as the X values and the Ct as the Y values. A linear regression trendline is 
added with intercept, slope and R2 values displayed. 
 
 
 
 
Figure 3.4: an amplification plot of serial (1 in 5) dilutions of CIS DNA 
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Figure 3.5: An XY scatter plot of log DNA input amount (x) against Ct (Y) 
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For the line shown in the figure, the log input is calculated by entering the following 
formula in one cell of the work sheet: 
 
 
= ([cell containing Ct value] – b)/m 
 
where   b = y-intercept of standard curve line 
and  m =  slope of standard curve line 
 
 
The input amount for samples is calculated by entering the following formula in an 
adjacent cell (where ^ represents ‘to the power of’): 
 
 
=  10^ [cell containing input amount] 
 
 
These steps are repeated to construct a standard curve for the endogenous reference 
(using the Ct values determined with the labelled GAPDH probe). The input amount is 
calculated for each sample cDNA from both SOCS and GAPDH standard curves. The 
value for SOCS input amount is then divided by the GAPDH input amount that yields 
the relative input amount. 
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3.2.15 Regulation of SOCS expression by cytokines: interrogation by real time 
PCR 
Poor reproducibility and the failure to detect SOCS1 mRNA proved to be significant 
limitations of standard semi-quantitative RT-PCR methods for the investigation of 
SOCS expression. In view of this, a fluorescence-based kinetic PCR technique using 
Taqman® technology (Applied Biosystems) was used in all subsequent expression 
experiments. The specificity of the Taqman assay is such that the confirmation of 
product identity by sequencing is considered unnecessary (Bustin, 2002, Nolan et al., 
2006).  
 
3.2.16 Experimental design 
After being harvested and counted, MG-63 cells were plated at a density of 0.5 x 106 
cells per well of a 6-well plate in 3 mL medium and incubated at 37ºC for 24h. The cells 
were then placed in serum free media for 12h, before incubation with the growth factor 
or cytokine of interest (IGF-I, IL-1ß, LPS or GM-CSF), for time points between 0 and 
8h. An additional untreated sample was collected at each time point. mRNA was 
isolated from the cells and used in subsequent cDNA synthesis and (real time) PCR 
amplification with SOCS specific primers. All stimulation experiments were performed 
on three separate occasions. An identical experimental paradigm was used for SaOS-2 
cells. 
 
Each cDNA specimen was divided so that subsequent PCR amplifications could be 
performed in triplicate, with subsequent calculation of the mean. Each reaction is 
corrected for GAPDH, expressed as a fold of its own unstimulated control and 
normalised to time zero (i.e. relative expression at time zero = 1). Data are shown as 
the mean ± SEM for each treatment and analysed using one-way ANOVA (analysis of 
variance), and applying a post hoc Bonferroni test. p<0.05 was considered statistically 
significant 
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Table 3.6: concentrations of growth factors and cytokines used in real time PCR SOCS 
expression studies 
 
 
3.2.17 Functionality: transfection of MG-63 cells with SOCS 1 and SOCS 3 DNA 
 
In these experiments the effects on cytokine production of SOCS1 and SOCS3 over 
expression in MG-63 cells was examined. MG-63 cells were seeded into 6 well tissue 
culture plates and allowed to reach 50% confluence. For each well to be transfected, 3 
µL GeneJuice Transfection Reagent (Novagen, Merck, Darmstadt, Germany) was 
added drop wise to 100 µL serum free medium in a sterile tube, before vortexing. 
Following incubation at room temperature for 5min, either 1 µg SOCS pcDNA3 plasmid 
(containing the full length SOCS gene) or empty vector was added for each well to be 
transfected and combined by gentle pipetting. This mixture was incubated at room 
temperature for 10 minutes before careful drop wise addition to the 6 well plates where 
cells remained in complete growth medium. The drops were distributed over the entire 
surface of the dish and the plates gently rocked to ensure even delivery to the adherent 
cell monolayer. 
 
After 8h the transfection mixture was removed and replaced with complete medium. 
The cells were then incubated for a further 24h at 37˚C, before washing and either (i) 
simple media refreshment, (ii) stimulation with IL-1β, or (iii) stimulation with IGF-I for a 
further 24h. Successful transfection was confirmed by PCR.  
 
 
 
Growth Factor 
 
Concentration 
 
IGF-I 
 
10 ng/mL 
 
IL-1ß 
 
100 ng/mL 
 
Lipopolysaccharide (LPS) 
 
100 ng/mL 
 
GM-CSF 
 
2.5 ng/mL 
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3.2.18 Cytokine assays 
IL1-β and OPG were assayed in cell culture supernatants using the relevant DuoSet 
ELISA Development kit (R&D Systems, Abingdon, UK), as described in section 2.2.10. 
 
3.3.19  Functionality: JAK/STAT signalling pathway 
In this experiment, 3 separate clones of SOCS3 transfected cells - designated 3.1, 3.2 
and 3.3 - were stimulated with IL-6 and the sIL-6R. The sIL-6R is the soluble form of 
the α subunit of the IL-6 receptor. Unlike other soluble cytokine receptors, it is an 
agonist - binding to IL-6 and stimulating JAK/STAT signalling via the gp130 subunit. It 
is added in this experiment as MG-63 cells respond poorly to IL-6 alone. Whole cell 
lysates were assessed for the activation of STAT3 to examine whether signalling via 
gp130/STAT3 remained intact.  
 
3.3.20 Assay for activated STAT3  
STAT3 activation was assayed using a TransAM Kit (Active Motif). This comprises a 
96-well plate coated with an immobilised oligonucleotide containing the consensus 
binding site of the activate form of STAT3. A primary STAT3 antibody recognises an 
epitope that is accessible only when it is activated and bound to its target DNA. An 
HRP-conjugated secondary antibody provides a colorimetric readout that can be 
quantified by spectrophotometry. Briefly, 10 µg of sample extract is diluted in lysis 
buffer, with 20 µL added to each well. The plate is sealed and incubated for 1 hour at 
room temperature with continuous gentle mixing. Following a wash x 1, STAT3 
antibody (100 µL of a 1:500 dilution in binding buffer) is added and a further 1 hour 
incubation undertaken. After a further wash, 100 µL of HRP-conjugated antibody 
(1:1000 dilution in binding buffer). After a further hour, developing solution is added. 
Stop solution is added when the sample wells turn blue (2-10min). Absorbance is read 
on a spectrophotometer at 450 nm with a reference wavelength of 650 nm.  
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3.3 Results 
The preliminary data generated by initial studies using conventional RT-PCR are 
presented in appendix 2. 
  
3.3.1 Results of Taqman SOCS expression studies (figures 3.6-3.11)  
IL-1ß 
There was a trend to increased expression of all four SOCS genes in MG-63 cells 
following stimulation with 100 IU/mL IL-1ß, this became significant at 4h for SOCS1 
and SOCS3 and at 8h for SOCS2. The response to IL-1ß in SaOS-2 cells, with the 
exception of an absent SOCS2 response, was similar, with a trend to increased 
SOCS1, SOCS3 and CIS expression.  
 
GM-CSF 
SOCS3 expression was increased at 1h and had doubled by four hours. This effect 
was not significant however. Effects of GM-CSF on SOCS1 expression were very small 
and those on SOCS2 and CIS negligible. 
 
LPS 
The effect of LPS on SOCS expression in MG-63 cells was most evident for SOCS3 
and CIS, though neither reached statistical significance. The effect of LPS on SOCS 
expression generally became apparent at later time points than for the other stimuli 
studied. 
 
IGF-I 
SOCS1 was induced by IGF-I in MG-63 cells (significant after 2h) as well as CIS 
(significant after 1h). A trend to increased SOCS2 and SOCS3 expression was seen in 
SaOS-2 cells.  
 
The pattern of expression of the SOCS genes after stimulation with the above factors in 
MG-63 and SaOS-2 cells is shown in figures 3.6 – 3.11. 
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Figure 3.6: SOCS1 expression at 0, 1, 2, 4 and 8 h following stimulation of MG-63 cells 
with selected growth factors and cytokines, as determined by real time PCR. A 
statistically significant difference (p<0.05) in expression in comparison to time 0 is 
denoted by *. Expression of SOCS1 increases post IGF-I exposure, reaching statistical 
significance at 2h and following IL-1ß, reaching significance at 4h. For each treatment 
n=3. All PCRs were performed in triplicate. 
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Figure 3.7: SOCS2 expression at 0, 1, 2, 4 and 8 h following stimulation of MG-63 cells 
with selected growth factors and cytokines, as determined by real time PCR. A 
statistically significant difference (p<0.05) in expression in comparison to time 0 is 
denoted by *. Expression of SOCS2 post IL-1ß exposure reached statistical significance 
at 8h. For each treatment n=3. All PCRs were performed in triplicate. 
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Figure 3.8: SOCS3 expression at 0, 1, 2, 4 and 8 h following stimulation of MG-63 cells 
with selected growth factors and cytokines, as determined by real time PCR. A 
statistically significant difference (p<0.05) in expression in comparison to time 0 is 
denoted by *. Expression of SOCS3 post IL-1ß exposure reached statistical significance 
at  4h. For each treatment n=3. All PCRs were performed in triplicate. 
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Figure 3.9: CIS expression at 0, 1, 2, 4 and 8 h following stimulation of MG-63 cells 
with selected growth factors and cytokines, as determined by real time PCR. A 
statistically significant difference (p<0.05) in expression in comparison to time 0 is 
denoted by *. Expression of CIS post IGF-I exposure reached statistical significance 
at 1h. None of the exposures led to a statistically significant difference in CIS 
expression compared to time zero. For each treatment n=3. All PCRs were 
performed in triplicate. 
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Figure 3.10: SOCS1 and SOCS2 expression at 0, 1, 2, 4 and 8 h following 
stimulation of SaOS2 cells with IGF-I and IL-1ß, as determined by real time PCR. 
For each treatment n=3.  All PCRs were performed in triplicate.  
 
 
 
 
 
 
 
 
0     1     2      4      8 0      1     2      4     8
hours hours
IGF-1 IL-1β
SOCS1
0.0
0.5
1.0
1.5
2.0
2.5
3.0
R
el
at
iv
e 
Ex
pr
es
si
on
R
el
at
iv
e 
Ex
pr
es
si
on
0     1     2      4      8 0      1     2      4     8
hours hours
IGF-1 IL-1β
SOCS2
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e 
Ex
pr
es
si
on
R
el
at
iv
e 
Ex
pr
es
si
on
 146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: SOCS3 and CIS expression at 0, 1, 2, 4 and 8 h following stimulation of 
SaOS2 cells with IGF-I and IL-1ß, as determined by real time PCR. For each treatment 
n=3. All PCRs were performed in triplicate. 
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3.3.2 Detection of SOCS Protein in MG-63 cells 
 
The detection of SOCS protein in whole cell lysates has proved difficult due to the 
paucity of good quality commercially available antibodies. This experience has been 
shared with other laboratories with an interest in this area. Immunoprecipitation has 
been attempted (see 3.2.9) and not appreciably enhanced SOCS protein detection. 
Due to these difficulties it cannot be viewed as an adequate technique for quantitative 
purposes. New antibodies are now available but relatively untested for Western blotting 
applications. Figure 3.12 shows representative Western blots of whole cell lysates from 
MG-63 cells, in this instance incubated with 10 ng/mL IGF-I for 4 or 24 hours. Small 
bands were seen at expected molecular weight for SOCS2, SOCS3 and CIS although 
these tended to be quite faint and often masked by non-specific bands, whilst no band 
was visible at the expected position of SOCS1. 
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Figure 3.12: The detection of SOCS protein in MG-63 cells. Four western blots prepared 
from whole cell lysates are shown. Lane 1: 5 µL of Perfect Protein Marker (Novagen). 
Lane 2: 5 µL of Rainbow Marker (Amersham). Lane 3: 50µg whole cell lysate from MG-
63 cells following 6 hours incubation with 10ng/mL IGF-I. Lane 4: 50µg whole cell lysate 
from MG-63 cells following 24 hours incubation with 10ng/mL IGF-I. Membranes were 
probed with the appropriate rabbit anti-SOCS antibody at 1:500 dilution. The arrows 
show the size and position of the expected SOCS protein bands. The bands were very 
faint and the long exposure time required led to overexposure of markers. 
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3.3.3  Functionality: IL-6 production following stimulation of SOCS1 DNA 
transfected MG-63 cells with IL-1β 
Basal IL-6 production was dramatically increased in MG-63-SOCS1 cells (see section 
3.2.22) compared with MG-63-Empty Vector (EV) cells (n=6, p<0.001). MG-63 SOCS1 
cells also demonstrated enhanced production of IL-6 following IL-1β (100IU/mL) 
stimulation in comparison to MG-63-EV (n=6, p<0.001). These results are summarised 
in figure 3.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Basal IL-6 production was significantly increased in MG-63-SOCS1 cells 
compared with MG-63-EV cells (n=6, p<0.001). MG-63 SOCS1 cells also demonstrated 
enhanced production of IL-6 following IL-1β stimulation (100IU/mL) in comparison to MG-63-
EV (n=6, p<0.001). 
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3.3.4 Functionality: IL-6 production following stimulation of SOCS3 DNA 
transfected MG-63 cells with IL-1β 
There were comparable data following transfection with SOCS3 (see section 3.2.22). 
Basal IL-6 production was dramatically increased in MG-63-SOCS3 cells compared 
with MG-63-Empty Vector (EV) cells (n=6, p<0.001). MG-63-SOCS3 cells also 
demonstrated enhanced production of IL-6 following IL-1β stimulation in comparison to 
MG-63-EV (n=6, p<0.001). These results are summarised in figure 3.14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Basal IL-6 production was significantly increased in MG-63-SOCS3 cells 
compared with MG-63-EV cells (n=6, p<0.001). MG-63-SOCS3 cells also demonstrated 
enhanced production of IL-6 following IL-1β stimulation in comparison to MG-63-EV 
(n=6, p<0.001). 
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3.3.5 Functionality: IL-6 production following stimulation of SOCS 1 DNA 
transfected MG-63 cells with IGF-I 
Basal IL-6 production was increased in MG-63-SOCS1 cells compared with MG-63-
Empty Vector (EV) cells (n=6, p<0.001). MG-63 SOCS1 cells did not demonstrate 
enhanced production of IL-6 following IGF-I stimulation in comparison to MG-63-Empty 
Vector. These results are summarised in figure 3.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Basal IL-6 production was increased in MG-63-SOCS1 cells compared with 
MG-63-EV cells (n=6, p<0.001). MG-63 SOCS1 cells did not demonstrate enhanced 
production of IL-6 following IGF-I stimulation in comparison to MG-63-EV (n=6, p=ns). 
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3.3.6 Functionality: IL-6 production following stimulation of SOCS 3 DNA MG-
63 cells transfected with IGF-I 
Basal IL-6 production was increased in MG-63-SOCS3 cells compared with MG-63-
Empty Vector (EV) cells (n=6, p<0.001). MG-63 SOCS3 cells did not demonstrate 
enhanced production of IL-6 following IGF-I stimulation in comparison to MG-63-Empty 
Vector. These results are summarised in figure 3.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Basal IL-6 production was increased in MG-63-SOCS3 cells compared with 
MG-63-EV cells (n=6, p<0.001). MG-63 SOCS3 cells did not demonstrate enhanced 
production of IL-6 following IGF-I stimulation in comparison to MG-63-EV (n=6, p=ns).  
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3.3.7 Functionality: OPG production following stimulation of SOCS 1 DNA 
transfected MG-63 cells with IL-1β 
Basal OPG production was not increased in MG-63-SOCS3 cells compared with MG-
63-Empty Vector (EV) cells. No significant differences in OPG secretion were seen in 
the SOCS1 transfected cells following IL-1β stimulation in comparison to cells 
transfected with EV. Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Basal OPG production was not increased in MG-63-SOCS3 cells compared 
with MG-63-EV cells (n=6, p=ns). No significant differences in OPG secretion were seen 
in the SOCS1 transfected cells following IL-1β stimulation in comparison to cells 
transfected with EV (n=6, p=ns). 
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3.3.8 Functionality: OPG production following stimulation of SOCS3 DNA 
transfected MG-63 cells with IL-1β 
Basal OPG production was not increased in MG-63-SOCS3 cells compared with MG-
63-Empty Vector (EV) cells. However, significant differences in OPG secretion were 
seen in the SOCS3 transfected cells following IL-1β stimulation in comparison to cells 
transfected with empty vector (n=6, p<0.001). Figure 3.18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Basal OPG production was not increased in MG-63-SOCS3 cells compared 
with MG-63-EV cells. However, significant differences in OPG secretion were seen in the 
SOCS3 transfected cells following IL-1β stimulation in comparison to cells transfected 
with empty vector (n=6, p<0.001). 
P<0.001 
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3.3.9   Functionality: JAK/STAT signalling pathway 
In this experiment, 3 separate clones of SOCS3 transfected cells - here designated 
3.1, 3.2 and 3.3 - were stimulated with IL-6 and the sIL-6R. The sIL-6R is the 
soluble form of the α subunit of the IL-6 receptor. Unlike other soluble cytokine 
receptors, it is an agonist - binding to IL-6 and stimulating JAK/STAT signalling via 
the gp130 subunit. It is added in this experiment as MG-63 cells respond poorly to 
IL-6 alone. Whole cell lysates were assessed for the activation of STAT3 (section 
3.2.24). In the SOCS3 expressing cells signalling via gp130/STAT3 appears intact, 
suggesting the increase in IL-6 production seen in SOCS3 transfected cells is not 
mediated via STAT3 and that transfected SOCS3 is not inhibiting the JAK/STAT 
pathway.  
 
 
 
 
Figure 3.19: STAT3 activation in MG63 cells over expressing SOCS3 DNA following 
stimulation with IL-6/sIL-6R suggests signalling via gp130/STAT3 is intact and that 
transfected SOCS3 may not be inhibiting the JAK/STAT pathway. (n=6, * = significant 
p<0.01). 
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3.4 Discussion 
These studies demonstrate that SOCS mRNA and protein are present in the human 
osteoblastic cell lines MG-63 and SaOS-2. Furthermore, the increased expression 
seen following stimulation with cytokines and growth factors is potentially compatible 
with their documented negative feedback function, acting to regulate uncontrolled and 
potentially harmful over-stimulation. The temporal pattern of SOCS expression in 
osteoblasts is consistent with studies performed in other cell types (Alexander and 
Hilton, 2004, Yoshimura, 2009). In general, upregulation occurred within 1 hour, 
peaked between 2 and 4 hours and diminished, without necessarily returning to 
baseline, by 8 hours. The constituitive expression of the four SOCS genes was higher, 
with a more pronounced response to stimulation, in MG-63 than in SaOS-2 cells. This 
is likely to reflect the different levels of basal cytokine activity exhibited by the cells, 
with, for example, the constituitive production of IL-6 higher by a factor of several 
thousand in MG-63 (3.4 ± 0.2 pg/106 cells [mean± SE] in SaOS-2 versus 2,898 ± 401 
pg/106 cells in MG-63) (Dovio et al., 2001). It is possible that a parallel increase in the 
baseline activity of the SOCS proteins is required in order to keep such autocrine 
signals in check.  
 
Of the growth factors and cytokines studied, GM-CSF had the least striking influence 
on SOCS mRNA expression. MG-63 cells express the GM-CSF receptor and display a 
JAK/STAT mediated proliferative response following ligand binding (Thacker et al., 
1994). Since the JAK/STAT apparatus is the classical target of SOCS inhibition, and 
GM-CSF has been shown to influence SOCS gene expression in other systems (Faderl 
et al., 2003), a more pronounced effect might have been expected. SOCS3 expression 
did start to increase at 1h and reach a two-fold increase by four hours, but effects on 
SOCS1 were small and those on SOCS2 and CIS barely detectable. This could be 
evidence that SOCS are not involved in the regulation of GM-CSF signalling in 
osteoblastic cells, though this would probably be an over-simplification of the 
relationship between relative SOCS expression and the amount of consequent 
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inhibition - the effect of SOCS has been shown to be highly sensitive in many in vitro 
and in vivo systems, a small increase in expression leading to powerful inhibition of 
JAK/STAT signalling. 
 
LPS is an integral cell wall component of gram-negative bacteria and is one of the 
mediators of endotoxic shock. It is recognised by TLR4, a member of the Toll-like 
receptor (TLR) group (Beutler and Poltorak, 2001). Ligand binding induces the 
sequential activation of several intracellular signalling molecules, including myeloid 
differentiating factor (MyD) 88 and TNFR-associated factor (TRAF) 6, with the 
subsequent recruitment of several downstream pathways, including c-jun NH2-terminal 
kinase (JNK), p38 mitogen activated protein kinase (MAPK) and NF-κB (Muzio and 
Mantovani, 2001). Despite the non-JAK/STAT nature of these signal transduction 
routes, the SOCS family, and SOCS1 in particular, have been shown to be an 
important regulatory mechanism, perhaps functioning to protect tissues against an 
overwhelming LPS response (Nakagawa et al., 2002). The effect of LPS on SOCS 
expression in MG-63 cells was most apparent for SOCS3 and CIS. Interestingly, the 
effect of LPS was minimal at one hour post-stimulation and became appreciable, 
though not significant, at 2h. This delay might reflect a secondary SOCS response to 
LPS induced autocrine cytokine release, rather than to LPS itself. This could also 
explain why the most obvious increase was seen with SOCS3 rather than SOCS1 as 
might have been expected. LPS powerfully augments IL-6 secretion in MG-63 cells and 
it is the regulation of IL-6/gp130 signalling that is increasingly recognised as one of the 
most important functions of SOCS3 (Croker et al., 2003).  Furthermore, it is very 
interesting to note that since the time the data under discussion were obtained, SOCS3 
has gradually emerged as a powerful regulator of LPS in many cell systems, 
particularly within the CNS (Qin et al., 2007, Brown et al., 2009, Yan et al., 2010). 
 
IL-1ß was one of the first non-JAK/STAT cytokines shown to upregulate SOCS genes, 
and in particular SOCS3. IL-1ß is a potent stimulator of bone resorption via RANK-L 
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and IL-6 production in osteoblastic cells. The present data show a trend to increased 
expression of all four SOCS genes in MG-63 cells, becoming significant at 4 hours for 
SOCS1 and SOCS3 and at 8 hours for SOCS2. The delay in upregulation of SOCS2 
by IL-1ß may again represent a secondary autocrine event. Further evidence for this 
comes from the absent SOCS2 response to IL-1ß in SaOS-2 cells. It is possible that 
the lower level of evoked cytokine secretion in these cells reduces the likelihood of a 
late autocrine response. Apart from SOCS2, the response to IL-1ß in SaOS-2 cells was 
similar to that in MG-63, with a trend to increased SOCS1, SOCS3 and CIS 
expression.  
 
The effect of IGF-I on SOCS gene expression is of particular interest. While IGF-I has 
been implicated in several aspects of cell function, including proliferation, 
differentiation, transformation and survival, reports of the effect of IGF-I on SOCS gene 
expression are scarce. The IGF-I receptor (IGF-IR) is a tetrameric type II receptor 
protein tyrosine kinase composed of two ligand-binding α-subunits and two 
transmembrane ß-subunits. Binding of ligand to receptor causes conformational 
change, ß-subunit cross-phosphorylation and the creation of binding sites for 
downstream signalling molecules (Chen et al., 1998). The major IGF-IR substrates are 
insulin receptor substrates (IRS) -1 and -2 and Shc, themselves able to recruit the 
Ras/MAPK and the phosphatidylinositide 3-kinase (PI3-kinase) pathways (O'Connor et 
al., 1997). MAPK signalling plays an important role in promoting cell growth and 
regulates a variety of genes, while PI3-kinase is involved in cell survival. Intriguingly, 
evidence suggests that the IGF-IR can induce activation of STAT3 as well as the 
phosphorylation of JAK1 and JAK2 (Zong et al., 2000). Although the mechanism of 
STAT3 activation is not established, several possibilities exist. Firstly, the activated 
receptor could associate with JAKs and phosphorylate STAT3. Secondly, JAKS may 
be activated to directly phosphorylate STAT3. Thirdly, JAKS could provide STAT3 
recruitment sites in the receptor complex, as is probably the case for JAK2 in response 
to growth hormone receptor activation. There is also evidence that the SOCS proteins, 
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particularly SOCS1 and SOCS3, are able to inhibit this IGF-I induced STAT3 activation 
(Dey et al., 2000) (Zong et al., 2000). The data presented here demonstrates a 
significant induction of SOCS1 and CIS by IGF-I in MG-63 cells and a trend to 
increased SOCS2 and SOCS3 in SaOS-2. This discrepancy between cellular 
phenotypes is consistent with an almost universal observation concerning the SOCS 
genes; in general the pattern of expression is dependent on cellular, not cytokine, 
identity. In addition, there is an inconsistency between the response to IGF-I in vitro 
and in vivo. In transfection models SOCS1 and SOCS3 are stronger inhibitors than 
SOCS2 and CIS, while in transgenic models it is the deletion of SOC2 that causes IGF-
I hyper-expression and gigantism and CIS over expression that causes growth 
retardation (Schaefer et al., 2001, Metcalf et al., 2000). 
 
As well as demonstrating the presence of SOCS mRNA in human osteoblastic cells, 
with expression increasing in response to a variety of osteotropic stimuli, a functional 
role for these genes in these cells is strongly suggested by the enhanced basal and IL-
1β stimulated IL-6 release following SOCS1 and SOCS3 over-expression, as well as 
the enhanced IL-1β stimulated OPG release following SOCS3 overexpression. 
Although SOCS expression, particularly SOCS3, is usually (and intuitively) associated 
with reduced basal IL-6 activity, the increases seen here are not without precedent. In 
rat skeletal muscle, exercise-induced increases in SOCS3 expression significantly 
elevate IL-6 production (Spangenburg et al., 2006). Interestingly, if SOCS3 is 
cotransfected into cultured myotubes with an NF-κB luciferase construct, NF-κB 
transcriptional activity is increased nearly 30-fold as is IL-6 promoter activity. However, 
if it is cotransfected with a mutated construct, no increase in IL-6 activity is seen. It is 
known that the IL-6 promoter contains a consensus NF-κB-binding site (Xiao et al., 
2004) and this could be required for SOCS3 induced increases in IL-6 promoter 
activity. This is compatible with previous data showing that overexpression of SOCS3 
in cultured macrophages results in heightened transcriptional activation of NF-κB (Park 
et al., 2003). The current finding of intact gp130/STAT3 signalling in cells successfully 
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transfected with SOCS3, but producing significant amounts of IL-6, would support the 
involvement of other pathways in osteoblastic cells. The coordination of the interplay 
between these genes remains uncertain, as they are often involved in relatively 
contradictory processes. The balance between cytokines with opposing functions is 
clearly important in many situations, not least in bone remodelling, with this balance 
likely to be the outcome of intricate cross talk between different intracellular 
transduction signals. The observation of an enhanced IL-6 response to IL-1β 
stimulation contrasts with previous studies suggesting SOCS3 deletion, rather than 
upregulation, is associated with an overzealous IL-6 response in this situation. Perhaps 
the most important example of this is the severe IL-1 mediated arthritis experienced by 
mice with SOCS3 partially knocked out (Wong et al., 2006). However, it is now 
recognised that IL-1 is able to directly induce SOCS3 expression in macrophages, 
rather than achieving this indirectly through stimulation of IL-6 production (Wong et al., 
2006), again suggesting the involvement of NF-κB signalling (Hayashi et al., 2002). 
Furthermore, in addition to classic gp130/STAT3 signalling, bone growth and 
remodelling is partially regulated by interactions between gp130 and the Ras/MAPK 
pathway (Sims et al., 2004). For example, mice carrying a point mutation that favours 
JAK/STAT signalling through the selective blockade of the Ras/MAPK pathway, display 
both increased bone turnover and decreased trabecular volume (Sims et al., 2004, 
Sims, 2009). SOCS3 has previously been shown to positively regulate the Ras/MAPK 
pathway (Cacalano et al., 2001) providing a additional route for it to potentially 
influence IL-6 stimulated bone turnover beyond a JAK/STAT paradigm.  
 
IL-1β is involved in the initiation of bone resorption (Kimble et al., 1994) and it’s signal 
to the osteoclast is generally processed via osteoblastic RANKL expression (Hofbauer 
et al., 1999c). This has made it difficult to understand its’ additional positive effect on 
OPG production (Pantouli et al., 2005). However, the latter may be dependent on 
phosphorylation of p38 and ERK, rather than NF-κB (Lambert et al., 2007). It is 
possible that forced expression of SOCS3 may regulate NF-κB signalling, thereby 
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favouring alternative pathways. This could support OPG, rather than RANK-L, 
production, and potentially act as a counter-regulatory measure during resorption. 
Alternatively, OPG could act as a survival factor via TRAIL or other pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 162 
Chapter 4 
The role of cytokines in human osteoblast survival: potential 
regulation by the suppressors of cytokine signalling (SOCS) 
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4.1 Background 
 
In addition to altering the balance between proliferation and activation of osteoblast and 
osteoclast precursors, the mass of skeletal tissue can be strongly influenced through 
the regulation of cellular longevity (Weinstein and Manolagas, 2000). During bone 
formation osteoblasts undergo an ordered developmental progression concluding with 
apoptotic cell death. The cellular and molecular pathways, control and overall 
significance of this process are yet to be fully understood, but the same cytokines and 
growth factors that stimulate osteoblast development appear fundamental to the 
regulation of subsequent apoptosis (Xing and Boyce, 2005). Evidence suggests that 
IGF-I exerts an important influence on senescence in cell types as diverse as cardiac 
myoblasts, neuronal cells, epithelial cells and osteoblasts (Hill et al., 1997, Vincent and 
Feldman, 2002). In the latter, IGF-I may inhibit caspase-3, one of several effector 
proteases, through upregulation of calbindin-D28k (Bellido et al., 2000). Such an anti-
apoptotic effect would help IGF-I fulfil it’s function as a key anabolic factor for the 
normal growth and maintenance of the skeleton (Zhao et al., 2000). SOCS proteins are 
increasingly recognised for their role in the processing and regulation of apoptotic and 
anti-apoptotic signals. This might serve a protective function; for example, SOCS3 
ameliorates both IL-1β and TNFα induced apoptosis in pancreatic ß-cells (Karlsen et 
al., 2001, Bruun et al., 2009); while SOCS1 suppresses the p38 MAP kinase regulated 
TNFα induced death of fibroblasts (Morita et al., 2000). In other systems, such as 
embryonic stem cells, SOCS expression may have a opposite effect, leading to a 
reduction in cell viability (Duval et al., 2000). The effect of IGF-I on SOCS gene 
expression in osteoblastic cells discussed in section 3.3.7 is of interest, as reports of 
the utility of IGF-I for inducing SOCS expression are relatively scarce. The downstream 
role SOCS proteins may play in the regulation of IGF-I functionality is currently 
unknown, but may potentially include an influence on apoptotic signalling and therefore 
cell death.  
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The bone resorbing activity of IL-1β is well described, particularly in common 
pathological states such as osteoporosis and rheumatoid arthritis (Strand and 
Kavanaugh, 2004). In an inflammatory context, the relationship between IL-1β and 
TNFα may play a particularly key role (Kobayashi et al., 2000) and this cytokine 
combination is demonstrably pro-apoptotic for osteoblastic cells (Tsuboi et al., 1999). 
IL-1β also stimulates apoptosis in other cell types, including pancreatic β cells 
(Vanderford, 2010), where it is, at least partially, under the control of SOCS3 (Karlsen 
et al., 2004). In osteoblasts, IL-1β also induces the release of OPG, a powerful anti-
resorptive factor, which possesses the potential to act as a survival factor through 
acting as a decoy receptor for TRAIL (Pantouli et al., 2005). The data presented in 
chapter 3 demonstrated the facility for IL-1β to induce SOCS1 and 3 expression in 
osteoblastic cells (chapter 3.3.7) and for SOCS1 and SOCS3 overexpression to 
enhance both basal and IL-1β stimulated IL-6 release (chapter 3.3.8-9). The functional 
implications of these are unknown, but may have relevance to cell survival. The 
increased IL-1β stimulated OPG release in the setting of SOCS3 overexpression 
(chapter 3.3.14) is potentially interesting, as it could provide a potential counter 
regulatory mechanism to block TRAIL mediated cell death.  
 
The studies in this chapter aim to explore the response of osteoblastic cells to the 
potential pro- and anti-apoptotic stimuli of IL-1β and IGF-I through the study of protease 
activity and DNA fragmentation. The potential utility of SOCS in the regulation of 
apoptotic pathways is studied through the targeted overexpression and knockdown of 
these genes.   
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4.2  Materials and methods 
4.2.1  Osteoblast-like cell lines and cell culture techniques 
Cell line and cell culture protocols were followed as described in section 2.2.1 – 2.2.4. 
 
4.2.2 In situ assays for caspase 3, 8 and 9 
MG-63 cells were seeded into 6 well tissue culture plates with 2 mL of medium. After 
24h the media was removed and refreshed with a further 2 mL. A blank plate (without 
cells) was also set up. To all plates the cell permeable inhibitor of the relevant caspase 
(table 4.1) was added to 3 wells whilst the remaining 3 wells were treated with the 
same volume of DMSO. IGF-I was added to all wells.  After a 15 min pre-incubation at 
370C in a humidified environment of air/CO2 (19:1), the cell permeable substrate of the 
relevant caspase was added to all wells Table 2.8) [all inhibitors and substrates from 
Calbiochem, Merck, Darmstadt, Germany]. After 4, 24 or 48 h incubation period 
fluorescence was detected at 380 nm excitation and 460 nm emission on a 
fluorescence plate reader (BMG Fluorostar, BMG Labtechnologies Ltd, Aylesbury, UK). 
Caspase activity was determined for each treatment as the difference between the 
mean fluorescence in the samples without the inhibitor, and those with the inhibitor. 
The caspase activity of each media solution without cells (blank plate) was then 
subtracted from the activity in the tissue culture plate to ensure that only cellular 
caspase activity was measured.  
 
4.2.3  In situ assay for calpain activity 
MG-63 cells were seeded into 6 well tissue culture plates with 2 mL of medium. After 
24 h the wells consisted of a monolayer of cells. The media was then removed and 
replaced with 2 mL of fresh media. A blank plate (without cells) was also set up. To all 
plates 50 µmol/L of the calpain specific inhibitor calpeptin (in DMSO) was added to 3 
wells whilst the remaining 3 wells were treated with the same volume of DMSO. At this 
point IGF-I (or other stimulus) was added to all wells, except those in the non-treatment 
groups. After a 15 min pre-incubation at 370C in a humidified environment of air/CO2 
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(19:1), 10 µL of the cell permeable calpain substrate N-succinyl-Leu-Leu-Val-Tyr-AMC 
(1 mmol/L in DMSO) was added to all wells. After an incubation (4, 24 or 48 h) period 
fluorescence was detected at 380 nm excitation and 460 nm emission on a 
fluorescence plate reader (BMG Fluorostar, BMG Labtechnologies Ltd, Aylesbury, UK). 
Calpain activity was determined for each treatment as the difference between the mean 
fluorescence in the samples without the calpain inhibitor, and those with the inhibitor. 
The calpain activity of each media solution without cells (blank plate) was then 
subtracted from the calpain activity in the tissue culture plate to ensure that only 
cellular calpain activity was measured.  
 
  
Substrate 
 
Inhibitor 
 
Caspase-3 
 
DEVD-AMC 
(final concentration 25 µM) 
 
DEVD-CHO 
(final concentration  2.5µmol/L) 
 
Caspase-8 
 
Z-IETD-AFC 
(final concentration 25 µM) 
 
IETD-CHO 
(final concentration 2.5 µmol/L) 
 
Caspase-9 
 
Ac-LEHD-AFC 
(final concentration 25 µM) 
 
LEHD-CHO 
(final concentration 2.5 µmol/L) 
 
Table 4.1: Concentrations of substrates and inhibitors for in situ assays of caspase-3, 8 and 9.  
 
4.2.4 Caspase-3 end-point Assay 
Cell lysates were prepared from cell pellets with 150 µl of mammalian extraction buffer 
(GE Healthcare Life Sciences, Little Chalfont, UK). Lysates were kept on ice with 
frequent mixing for 15 min before centrifugation (16000 g, 40C) to remove cell debris. 
Samples were then diluted 3:1 in running buffer, before being boiled for 5 min. 
Caspase-3 activity was measured using the fluorometric substrate Ac-DEVD-AMC as 
described previously. In summary, for each sample four replicates of 10 µL were 
 167 
assayed.  90 µL of caspase assay buffer was added to each sample well. Two 
replicates contained 50 µM of caspase-inhibitor (Ac-DEVD-CHO) in 2 µL and the 
remaining two containing the same volume of vehicle (DMSO). Each replicate 
contained 50 µM of the caspase substrate (Ac-DEVD-AMC). Fluorescence was 
measured on a microplate reader (Fluostar Galaxy; BMG Laboratory Technologies, 
Aylesbury, UK) with excitation at 380 nm and emission at 460 nm. Fluorescent 
readings from wells containing inhibitor were subtracted from the fluorescence in wells 
containing substrate and corrected for the amount of protein. Results were calculated 
as nmol AMC/min/mg total protein. Protein was measured by performing the Pierce® 
bicinchoninic acid protein assay (BCA) (ThermoScientific) using 25 µL of lysate (diluted 
1:1 in distilled H2O) according to the instructions of the kit insert for the 96-well format. 
 
4.2.5 Quantification of apoptotic cell death by DNA fragmentation assay 
Cell death was detected by a DNA fragmentation enzyme linked immunosorbent assay 
(ELISA), which quantifies the mono- and oligonucleosomes in the cytoplasmic fraction 
of cell lysates (Cell Death Detection ELISAPLUS; Roche Diagnostics, Lewes, UK). 
Cytosolic lysates extracted using 63.2mmol/L imidazole-HCL buffer, pH 7.3, containing 
10µmol/L digitonin, were diluted 20-fold in kit lysate buffer. 20 µL of the diluted cell 
lysate is placed into a streptavidin coated microtitre plate. 80 µL of a mixture of anti-
histone-biotin and an anti-DNA monoclonal antibody conjugated with peroxidase (anti-
DNA-POD) are added and the plate incubated for 2h at room temperature. During the 
incubation period, the anti-histone antibody binds to the histone component of the 
nucleosomes and simultaneously captures the immunocomplex to the streptavidin 
coated microtitre plate via its biotinylation. Additionally the anti-DNA-POD antibody 
reacts with the DNA component of the nucleosomes. The plate is then washed 3 times 
with incubation buffer before 100 µL of ABTS solution is added to each well and the 
plate incubated at room temperature for 10 min on a plate shaker (250 rpm). The plate 
is read at 405 nm. DNA fragmentation is expressed as an enrichment factor 
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(absorbance value for 24h experimental sample/absorbance value of 0h sample) from 
a time 0h baseline sample per mg of total lysate protein. 
 
4.2.6 Quantification of necrotic cell death by LDH assay 
 
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in all cells. It is 
rapidly released into the cell culture supernatant following damage to the plasma 
membrane. In this assay, LDH activity is calculated using an enzymatic test on cell free 
supernatants. The assay is based on a two-step principle: in the first step NAD+ is 
reduced to NADH/H+ by the LDH-catalysed conversion of lactate to pyruvate. In the 
second step, a catalyst (diaphorase) transfers H/H+ from NADH/H+ to the tetrazolium 
salt 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT), so 
reducing it to formazan, which can be detected using colorimetric measurements. LDH 
activity was measured in the incubation media prior to (background control) and at the 
end of the experiment (24h) using this assay (Cytotoxicity Detection Kit; Roche 
Diagnostics). Cytotoxicity (%) was calculated by the subtraction of the background 
control (media without cells) from the 24 h sample and expressed as a percentage of a 
positive control (2% Triton X-100 = 100% lysed cells), minus background control, 
corrected for total lysate protein. A background control is used for each separate 
treatment. 
 
4.2.7 Western blotting for fodrin breakdown products 
Fodrin is a universally expressed membrane associated cytoskeletal protein consisting 
of alpha and beta subunits. The protein is important for maintaining normal membrane 
structure and supporting cell surface protein function. Alpha fodrin is an important 
substrate of proteases and is cleaved during cell death. The full length 240kDa protein 
can be cleaved at several sites within its sequence by activated caspases generating N 
terminal 150kDa, C terminal 120kDa and 35kDa major products. It is also cleaved by 
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calpain yielding a 145KDa product. Cleavage of alpha fodrin leads to membrane 
dysfunction and cell shrinkage.  
 
Cell extracts were prepared as described in section 3.2.8. Ten µg of lysate protein was 
electrophoresed on a 10% polyacrylamide gel in the presence of SDS (section 3.2.10) 
before being probed with mouse anti α-fodrin diluted 1:1000 (Affiniti Research Products 
Ltd, UK). The secondary antibody (1:2000) was donkey anti-mouse labelled IgG 
conjugated to horseradish peroxidise (Santa Cruz Biotech, Autogen Bioclear, Calne, 
UK). Protein bands were visualised using chemiluminescence (ECL 
Chemiliminescence Detection System, Amersham, UK). 
 
4.2.8 Transfection of MG-63 cells with SOCS 1 and SOCS 3 DNA for gene 
overexpression experiments 
This was performed as per the methods outlined in section 3.2.22 
 
 
4.2.9  SOCS siRNA gene knockdown 
MG-63 cells were seeded into six-well plates in DMEM and left to adhere overnight to 
50% confluence. Media was then replaced with 1.6 mL of fresh media (with FCS but 
without antibiotics).  SOCS 1, SOCS 3, CIS and non-targeting control siRNA (20 uM) 
were diluted 1:100 with Opti-MEM I reduced serum medium (Invitrogen Life 
Technologies) and gently mixed. Lipofectamine (Invitrogen Life Technologies) was then 
diluted 1:100 with Opti-MEM I, mixed gently and incubated for 5min at room 
temperature. This was then combined 1:1 with the diluted siRNA (total volume 100 µL), 
mixed gently and left to incubate at room temperature for 20min to allow the siRNA: 
Lipofectamine complexes to form.   
 
Each cell culture well had 10 nM of siRNA added, before gentle mixing and incubation 
at 37˚C for 24h.  IL-1β (100 IU/mL) or control was added prior to a further 24h 
incubation. LDH activity as a marker of necrotic cell death was measured in the 
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incubation media at the start and the end of the experiment using a colorimetric assay 
(Cytotoxicity Detection Kit, Roche Diagnostics, Burgess Hill, UK), as described in 
section 4.2.5. Cytotoxicity (%) was calculated by the subtraction of the background 
control and expressed as a percentage of a positive control (2% Triton X-100). 
Caspase-3 activity was determined by end point assay, as described in section 4.2.4. 
STAT3 activity was determined using the TransAM kit (Active Motif) as described in 
section 3.2.24. 
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4.3 Results  
 
4.3.1  Effect of IGF-I on apoptosis in MG-63 cells:  caspase-3 activity at 24 h 
After being harvested and counted, MG-63 cells were seeded at a density of 0.3 x 106 
cells per well of a 6-well plate in 2 mL of medium and incubated at 37ºC for 24h. The 
cells were then refreshed in media containing a desired concentration of IGF-I and 
incubated for 24 or 48 h. In situ assays for caspase-3 were performed and cell lysates 
examined for DNA fragmentation. Unless otherwise indicated, all results are corrected 
for cellular protein. For each concentration of IGF-I n=6 and data are shown as mean ± 
SEM and analysed using Student’s t-test. 
 
 
At 24h, 10 ng/mL IGF-I caused a significant reduction in caspase-3 activity when 
compared to control (p<0.002). Caspase 3 activity was also reduced by 100 ng/mL 
IGF-I, but to a lesser extent. DNA fragmentation was reduced by both 10 ng/mL and 
100 ng/mL IGF-I, the latter reaching statistical significance (p<0.005) (figure 4.1). 
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Figure 4.1: Caspase-3 activity (corrected for cellular protein) in MG-63 cells (A) and DNA 
fragmentation (B) following 24h incubation with 0, 10 or 100 ng/mL IGF-I. A statistically 
significant reduction in comparison to control is denoted by *. n=6 for each concentration 
of IGF-I. 
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4.3.2 Effect of IGF-I on apoptosis in MG-63 cells:  caspase-3 activity at 48h 
At 48h, caspase-3 activity is greater in controls than at 24h. There is a reduction in 
caspase-3 activity with 10 ng/mL IGF-I, though this does not reach statistical 
significance. Activity was also reduced by 100 ng/mL IGF-I, but to a lesser extent. DNA 
fragmentation was reduced by both 10 ng/mL and 100 ng/mL IGF-I (figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Caspase-3 activity (corrected for cellular protein) in MG-63 cells (A) and DNA 
fragmentation (B) following 48h incubation with 0, 10 or 100 ng/mL IGF-I. n=6 for each 
concentration of IGF-I. No statistically significant differences were demonstrated. 
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4.3.3     Caspase-3 activity: effect of PI3-kinase inhibition 
A reduction in caspase-3 activity was seen following 24h incubation with 
10ng/mL IGF-I (p<0.05). This decrease was abolished in the presence of 100nM 
wortmannin, a phosphatidylinositol 3-kinase (PI3-kinase) inhibitor (figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Caspase-3 activity is significantly reduced following 24h incubation with 10 ng/mL 
IGF-I (n=6, p<0.05). The reduction is abolished in the presence of 100nM of the PI3-kinase 
inhibitor, Wortmannin.  
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4.3.4 IGF-I dose response: caspase-3 activity at 24 h 
 
Caspase-3 activity showed an incremental reduction at escalating concentrations of 
IGF-I (0, 2.5, 5, and 10 ng/mL IGF-I). At 10 ng/mL this reduction reaches statistical 
significance (p<0.001) (figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Caspase-3 activity (corrected for cellular protein) in MG-63 cells 
following 24h incubation with 0, 2.5, 5 or 10 ng/mL IGF-I. n=6 for each concentration 
of IGF-I. A significant difference was shown for 10ng/mL IGF-I (p<0.001). 
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4.3.5  Effect of IGF-I on apoptosis in MG-63 cells: caspase-8 and -9 activity 
 
The activity of both caspase-8 (p<0.01) (figure 4.5 A) and -9 (p<0.005 respectively) 
(figure 4.5 B) was significantly reduced after 24h incubation with 5 ng/mL IGF-I. In view 
of the high baseline apoptosis seen at 48h in preceding experiments, these studies 
were terminated at 24h. 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: A: caspase-8 and B: caspase-9 activity (corrected for cellular protein) in MG-
63 cells following 24h incubation with 0 or 5 ng/mL IGF-I. n=6 for each concentration of 
IGF-I. A significant difference was demonstrated in both cases (p<0.01 and p<0.005 
respectively). 
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4.3.6 Effect of IGF-I on apoptosis in MG-63 cells: DNA fragmentation 
 
There was consistent and dose-dependent reduction in DNA fragmentation following 
exposure to 5 or 10 ng/mL IGF-I.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: DNA fragmentation in MG-63 cells following 24h incubation with 0, 5 or 
10 ng/mL IGF-I. A statistically significant decrease in comparison to control is 
denoted by *. n=12 for each concentration of IGF-I. 
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4.3.7 LDH release 
As a further marker of cellular injury, LDH activity in cell supernatants was determined 
in all experiments. Representative results are shown in figure 4.7. No significant 
differences in LDH activity were detected in any of the preceding studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: LDH release (corrected for cellular protein) from MG-63 cells following 24h 
incubation with 0, 2.5, 5 or 10 ng/mL IGF-I. n=6 for each concentration of IGF-I. No 
significant differences were demonstrated. 
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4.3.8 Effect of IGF-I on apoptosis in MG-63 cells: calpain activity 
There was a significant increase in calpain activity when compared with controls after 
24 h incubation with 5 ng/mL IGF-I (p<0.01) (figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Calpain activity (corrected for cellular protein) in MG-63 cells following 
24h incubation with 0, 5 or 10 ng/mL IGF-I. n=12 for each concentration of IGF-I. A 
statistically significant increase in comparison to control is denoted by *. 
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4.3.10 Fodrin breakdown 
   
Western blotting for fodrin breakdown products in protein lysates from MG-63 
incubated for 24h ± 10 ng/mL IGF-I showed an increase in calpain cleavage products 
in the presence of IGF-I, not demonstrable in the presence of the specific calpain 
inhibitor, calpeptin (figure 4.9). 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Western blot for fodrin breakdown products in MG-63 cells after 24 h incubation with 
and without 10 ng/mL IGF-I in the presence or absence of calpeptin, a specific calpain inhibitor. 
Caspase-3 cuts fodrin to 150 and 120kDa and calpain to 145kDa. There is an increase in 
calpain activity in response to IGF-I that is not seen in the presence of calpeptin. 
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4.3.13 SOCS knockdown differentially attenuates IL-1β induced necrosis in MG 
63 cells 
IL-1β treatment greatly elevated the degree of necrotic injury in the control group [% 
cytotoxicity, ±SD, n=3] (P<0.0005). Basal cytotoxicity was reduced by SOCS1 
(P<0.0008) and SOCS3 (P<0.001) knockdown (KD), but was not affected by CIS KD. 
However, despite the lack of basal effect, IL-1β induced cytotoxicity was significantly 
reduced by CIS KD (P<0.001). SOCS3 KD afforded no protection from IL-1β induced 
cytotoxicity (figure 4.10 A-C).  
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Figure 4.10: Cytotoxicity in human osteoblastic cells treated with IL-1β.  IL-1β treatment greatly 
elevated the degree of necrotic injury in the control group [% cytotoxicity, ±SD, n=3] (P<0.0005). 
Basal cytotoxicity was reduced by SOCS1 (P<0.0008) and SOCS3 (P<0.001) knockdown (KD), 
but was not affected by CIS KD. Despite a lack of basal effect, IL-1β induced cytotoxicity was 
reduced by CIS KD (P<0.001). SOCS3 KD afforded no protection from IL-1β induced 
cytotoxicity SOCS 1 (A) and CIS (C), but not SOCS3 (B) knockdown resulted in significantly 
reduced necrotic injury.  
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4.3.12 SOCS knockdown differentially attenuates IL-1β induced caspase-3 
activity in MG 63 cells 
IL-1β treatment greatly elevated caspase-3 activity in the control group C (nM 
AMC/min/mg protein, ±SD, n=3). Control 103.8 ± 9.8, Control + IL-1β 195.7 ± 11.9 
(P<0.0005). SOCS knockdown (KD) significantly reduced caspase-3 activity in all 
groups (figure 4.11 A-C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P<0.0005 
P<0.0001 
A 
 184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Caspase-3 activity in human osteoblastic cells treated with IL-1β.  IL-1β treatment 
increased caspase-3 activity in the control group (nM AMC/min/mg protein, ±SD, n=3) 
(P<0.0005). SOCS 1 (A) (p<0.0001), SOCS 3 (B) (p<0.0002) and CIS (C) (p<0.0002) KD 
resulted in significantly reduced apoptotic injury after IL-1β.  
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4.3.13 SOCS knockdown differentially attenuates IL-1β induced STAT3 activity in 
MG 63 cells 
A downstream effect of IL-Iβ was evident from STAT3 activation (absorbance/mg 
protein) in the control groups, C, 0.37 ± 0.02, Control + IL-1β 0.56 ± 0.03 (P<0.001) but 
interestingly CIS-Knockdown (KD) prevented IL-Iβ induced activation, whilst SOCS3-
KD significantly elevated IL-Iβ induced STAT3 activity. STAT3 activity was similar in the 
SOCS1-KD group to control values (figure 4.12 A-C). 
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Figure 4.12: STAT3 activity in human osteoblastic cells treated with IL-1β.  A downstream effect 
of IL-Iβ was evident from STAT3 activation in the control groups (p<0.001). STAT3 activity was 
similar in SOCS1 KD group (A) as control. SOCS 3 KD significantly increased STAT3 activity 
(B) (p<0.01) whilst CIS KD prevented IL-β induced STAT3 activation (C) (p<0002). 
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4.4 Discussion 
Although osteoblast death is an important component of bone turnover in health and 
disease, the pathways that initiate and regulate the process are not yet fully 
understood. Although several growth factors, including FGF2, IL-6 and other gp130 
cytokines may have a role in osteoblast survival in vitro, their relevance to bone 
remodelling in vivo is uncertain (Hill et al., 1997, Debiais et al., 2004, Li et al., 2008). 
Furthermore, the signal transduction pathways responsible for the coordination of 
osteoblast apoptosis remain unclear.  
 
These studies confirm the dose dependent anti-apoptotic effect of IGF-I in human 
osteoblastic cells. This is consistent with previous studies (Hill et al., 1997, Gronowicz 
et al., 2000), as well as with it’s identified cell survival role in other systems (Himpe et 
al., 2008, Annunziata et al., 2011). These observations might also help explain the 
consequences of the relative IGF-I deficiency or resistance seen in low turnover 
skeletal disorders, such as renal adynamic bone disorder and age associated 
osteoporosis (Hoyland and Picton, 1999, Perrini et al., 2010). As may be expected, a 
reduction in the activity of the key effector protease caspase-3 following IGF-I exposure 
appears constant. IGF-I is known to upregulate the calcium binding protein calbindin-
D28k, which, in turn, binds and inhibits caspase-3 (Bellido et al., 2000). To date, the 
most clearly defined anti-apoptotic signal transduction pathways following ligand/IGF-
IR binding are via PI3-kinase (DiGirolamo et al., 2007). PI3-kinase is associated with 
the tyrosine kinase receptor and is activated by various growth factors, including 
insulin, PDGF, the IGF family and nerve growth factor (NGF). The fungal metabolite 
Wortmannin is a PI3-kinase inhibitor that was originally shown to inhibit the ability of 
NGF to prevent the apoptosis of rat phaeochromocytoma cells following serum 
starvation (Yao and Cooper, 1995). However, it should be noted that although 
wortmannin and other PI3-kinase inhibitors such as LY 294002 have provided helpful 
insights into PI3-kinase biology, they suffer from a lack of specificity that mandates 
caution when interpreting in vitro mechanisms (Davies et al., 2000). Wortmannin also 
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inhibits other members of the PI3-kinase superfamily, including the protein kinases 
ataxia telangiectasia mutated, mammalian target of rapamycin (mTOR) and DNA 
dependent protein kinase (Chen et al., 2008). This lack of substrate specificity has also 
contributed to their failure to advance to clinical use in cancer therapy (Gupta et al., 
2003). More recently, several novel PI3-kinase inhibitors differing in their isoform 
specificity have been developed. These include the pyridinylfuranopyrimidine PI-103 
and the imidazopyridines PIK-75 and PIK-90 (Knight et al., 2006). PI3-kinase is now 
also known to play a role as a negative regulator of caspase-3 activation in other 
systems (Fujita et al., 1998, Schneider et al., 2008). The amelioration of the anti-
apoptotic effect of IGF-I by PI3-kinase inhibition in the present studies suggests that 
this pathway is important for IGF-I functionality in osteoblastic cells. It is therefore 
interesting to note that increased basal tyrosine phosphorylation, which would blunt the 
IGF-IR signalling through PI3-kinase, is seen in osteoporotic subjects (Perrini et al., 
2008). PI3-kinase activates the protein Akt/PKB which, in turn, phosphorylates and 
inactivates several pro-apoptotic proteins, including Bad and other members of the Bcl-
2 family (Peruzzi et al., 1999, Bai et al., 1999). In its non-phosphorylated state, Bad 
locates at the mitochondrial membrane and interacts with Bcl-2, preventing its anti-
apoptotic function. Akt/PKB also prevents the progression of the caspase cascade 
through the phosphorylation of caspase-9 (Kermer et al., 2000, Chen et al., 2011). The 
significant reduction in caspase-9 activity following IGF-I exposure demonstrated in 
these studies is consistent with this mechanistic observation. In addition, the 
concomitant decrease in caspase-8 activity is compatible with previous observations 
that the extrinsic pathway is active during cell death in MG-63 cells (Jilka et al., 1998, 
Lin et al., 2008) as well as other human osteoblastic cells (Brama et al., 2011). 
Caspase-8 can also activate the mitochondrial pathway via the bcl-2 protein Bid, so 
multiple pathways and pathway interactions are likely to be in operation (Li et al., 
1998). Akt/PKB may also inhibit apoptosis through the activation of NF-κB (Chang et 
al., 2003). Akt phosphorylates I-κB, facilitating the translocation of NF-κB to the nucleus 
where it initiates the transcription of cell survival genes (Karin and Delhase, 2000, 
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Madrid et al., 2000). NF-κB was originally thought to be pro-apoptotic, as many 
cytokines that reduce cell survival, such as TNFα, induce it’s activation (Beg and 
Baldwin, 1994). However, it is clear that NF-κB can prevent apoptosis, whilst it’s 
inhibition may potentiate cell death (Wang et al., 1996).  
 
The cysteine protease calpain was originally described as a mediator of necrotic cell 
death, though a role in caspase independent apoptosis and autophagy is now widely 
accepted (Wang, 2000, Harwood et al., 2005, Demarchi and Schneider, 2007). The 
significance of the IGF-I induced increase in calpain activity in the present studies is 
unclear, although two putative explanations can be offered. Firstly, calpain shares 
many common substrates with caspase-3, so the reduction in caspase-3 activity may 
leave a surfeit of substrate (in this study, the synthetic fluorogenic peptide N-succinyl-
Leu-Leu-Val-Tyr-AMC) available to calpain, with a consequent increase in apparent 
activity (Harwood et al., 2003). Secondly, ligand binding to IGF-IR leads, possibly via 
Akt/PKB, to a rapid activation of voltage dependent calcium channels (Blair et al., 
1999). A potential downstream effect of this could be an increase in calcium-dependent 
calpain activity. There is evidence that calpain plays a role in the proliferation and 
differentiation of osteoblastic cells (Kashiwagi et al., 2011) and it therefore possible that 
the preservation of these activities, rather than a cell survival function, dominates the 
calpain response to IGF-I in this context. However, the enhancement of fodrin 
breakdown would suggest that the calpain is active at the cell membrane and therefore 
involved as an effector of injurious signalling. It has been shown that calpain can 
negatively regulate p53 dependent apoptosis (Atencio et al., 2000, Benetti et al., 2001) 
and that it can degrade NF-κB inhibitors, with the resultant activation of NF-κB 
dependent survival pathways (Han et al., 1999, Demarchi et al., 2005). This is thought 
to play a role in the resistance to anti-tumour therapy (Mlynarczuk-Bialy et al., 2006). 
Accordingly, calpain activity may be increased by IGF-I in these osteoblastic cells in 
order to fulfil an anti-apoptotic function. The increase in fodrin breakdown may be 
explained as a manifestation of the positive effect of both IGF-I and calpain on normal 
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cell growth, homeostasis and repair. Alternatively, calpain may increase to promote cell 
death following IGF-I exposure, but be effectively counterbalanced by the promotion of 
other anti-apoptotic pathways, including those utilising alternative proteases, such as 
the caspases. 
 
SOCS proteins have been recognised for their role in the processing and regulation of 
apoptotic and anti-apoptotic signals. This may be protective, such as the amelioration 
by SOCS3 of IL-1β induced cell injury in pancreatic ß-cells (Karlsen et al., 2001, Bruun 
et al., 2009); or produce a reduction in cell viability, such as seen with SOCS1 and 
SOCS3 overexpression in embryonic stem cells (Duval et al., 2000). The effect of IGF-I 
on SOCS gene expression in osteoblastic cells demonstrated in section 3.3.1 is of 
interest, as reports of the utility of IGF-I for inducing SOCS expression are relatively 
scarce. The downstream role SOCS proteins may play in the regulation of IGF-I 
functionality is currently unknown, but could potentially include an influence on 
apoptotic signalling and therefore cell survival. While it is possible that conventional 
pathways downstream of IGF-IR, such as PI3-kinase, may also be influenced by SOCS 
(Himpe and Kooijman, 2009), there is also evidence that IGF-I may additionally signal 
through JAK/STAT and be more directly susceptible to SOCS regulation. For example, 
SOCS inhibit IGF-I induced STAT3 activation (Dey et al., 2000, Zong et al., 2000). 
There are several putative mechanisms for this STAT activation through IGF-IR. Firstly, 
after activation by IGF-IR, JAKS could directly phosphorylate STAT. Secondly; 
activated IGF-IR could associate with JAK to phosphorylate STAT, with a STAT-
binding site generated by activated IGF-IR or JAK. Thirdly, JAKS could provide STAT 
recruitment sites within the receptor complex. The negative regulation of STAT3 by 
SOCS3 has been further investigated in the context of IGF-I mediated neuronal 
survival (Yadav et al., 2005). Of note is that IGF-I has also been shown to regulate 
survival through PI3-kinase in these cells, underlining the presence of multiple survival 
signals downstream of IGF-IR (Kenchappa et al., 2004). Although the present studies 
in osteoblastic cells did not demonstrate that the overexpression of SOCS1 or SOCS3 
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could regulate the anti-apoptotic effect of IGF-I, as measured by either caspase-3 
activity or DNA fragmentation (data shown in appendix 3), this is not the case in other 
systems such as neuronal cells. In neuroblastoma cells, SOCS3 was found to co-
localise and associate with IGF-IR after IGF-I stimulation, thereby inhibiting STAT3 
activation. SOCS3 overexpression reduced their sensitivity to the anti-apoptotic effects 
of IGF-I, with an 80% decrease in cell survival following IGF-I stimulation (Yadav et al., 
2005). However, when primary cortical neuronal cells were made to overexpress 
SOCS3, there was no demonstrable difference in cell survival, as was the case in MG-
63 osteoblastic cells. 
 
IL-1β was one of the first non-JAK/STAT cytokines shown to upregulate SOCS genes, 
particularly SOCS3. IL-1β is pro-apoptotic for osteoblastic cells (Tsuboi et al., 1999)  
and other cell types, such as pancreatic β cells (Vanderford, 2010). The latter appears, 
at least partially, under the control of SOCS3 (Karlsen et al., 2004). The data presented 
in chapter 3 demonstrated the ability of IL-1β to induce SOCS1 and SOCS3 expression 
in osteoblastic cells (chapter 3.3.1) and for SOCS1 and SOCS3 overexpression to 
enhance both basal and IL-1β stimulated IL-6 release (chapter 3.3.3-4). The functional 
implications of these observations are unknown, but could have potential relevance to 
the regulation of cell survival. The increased IL-1β stimulated OPG release in the 
setting of SOCS3 overexpression (chapter 3.3.8) is potentially interesting, as it could 
provide a potential counter regulatory mechanism to block TRAIL mediated cell death 
(Pantouli et al., 2005). In the present studies, IL-1β consistently and significantly 
increased the degree of both necrotic and apoptotic cell death in osteoblastic cells, as 
measured by LDH release and activity of caspase-3 respectively. Caspase-3 was 
chosen for these studies, as it is a key effector caspase in both extrinsic and intrinsic 
pathways involving caspases 8 and 9 respectively. The SOCS knockdown results 
collectively indicate that SOCS have a role in the regulation of this process and that it 
may be mediated by different SOCS proteins depending on the type of cell death 
involved. All three of the SOCS studied appeared involved in the regulation of the 
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apoptotic protease cascade, with knockdown of SOCS1, SOCS3 and CIS all 
significantly reducing basal caspase-3 activity. However, whereas CIS knockdown 
failed to reduce basal necrosis, unlike SOCS1 and SOCS3 knockdown, it did reduce 
IL-1β induced cytotoxicity. Furthermore, SOCS3 knockdown did not affect IL-1β 
induced necrosis. So, in this system, SOCS3 would appear to have a pro-apoptotic and 
anti-necrotic role, while CIS differentially influences cytokine induced, but not basal, 
necrosis. Both of these are almost certainly oversimplifications. In addition, SOCS3 
knockdown significantly elevated IL-1β induced STAT3 activity, suggesting that 
although there is evidence in other cell systems for SOC3 interaction with JAK 
independent pathways such as MAPK/Ras pathways following IL-1β stimulation, it is 
JAK/STAT signalling that dominates in this particular context. There are precedents for 
these observations; for example, overexpression of SOCS1 or SOCS3 in LIF 
stimulated embryonic stem cells leads to a reduction in cell viability (Duval et al., 2000). 
LIF is analogous to IL-1β, in that its effects on cell proliferation, differentiation and 
apoptotic signalling are mediated differentially by both JAK/STAT and MAPK/Ras 
pathways, although almost certainly with a degree of synergy (Kummer et al., 1997, 
Burdon et al., 2002). In this regard, it is interesting that CIS knockdown had the 
opposite effect to SOCS3, significantly inhibiting IL-1β induced STAT3 activation. This 
again underlines the intricacies and interdependencies necessary to maintain a 
balance between cytokine signalling and cytokine functioning (Forrai et al., 2006). 
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CHAPTER 5      
Final discussion and conclusions  
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The studies presented in this thesis describe several aspects of the function of human 
osteoblasts. In the intervening years since the experimental work was undertaken this 
cell lineage has come under increasing scrutiny, not only for its role in skeletal health 
and disease, but also for the relevance of its systemic interactions in other contexts. 
This expanding body of knowledge has helped to explain many historical observations 
concerning bone and its biology and has already offered several potential targets for 
novel therapeutic interventions.  
 
Osteoblasts are derived from mesenchymal stem cells that reach bone via vascular 
channels associated with remodelling sites. Once they arrive at the remodelling 
surface, they progress through pre-osteoblastic, matrix producing and, eventually, 
osteocytic stages. The sequential expression of several important transcription factors, 
including runt-related transcription factor 2 (Runx2), formerly Cbfa-1, and osterix, are 
now well described throughout this growth and differentiation (Komori et al., 1997) 
(Nakashima et al., 2002). The significance of the various endocrine, autocrine and 
paracrine factors that influence osteoblastic development, including IGFs, PTH and 
BMPs has continued to be elucidated (Qin et al., 2003, Zuo et al., 2012). For example, 
the action of PTH and BMPs is now known to be closely associated with the activation 
of the recently described Wnt signalling pathway (Westendorf et al., 2004, Monroe et 
al., 2012). Mature osteoblasts produce the various regulators of matrix mineralisation, 
such as osteocalcin, and express RANK-L for osteoclast recruitment (Mellis et al., 
2011). The fate of these cells is to either terminally differentiate into osteocytes or to 
die through apoptosis (Manolagas, 2000). Osteocytes are the most abundant cell in 
bone and their death following skeletal micro-damage is thought to be the key event in 
the initiation of subsequent osteoclastic bone resorption (Zhao et al., 2002, Kurata et 
al., 2006, Cardoso et al., 2009). Dying cells can promote osteoclast differentiation 
through the release of apoptotic bodies that express M-CSF and RANK-L (Kogianni et 
al., 2008). Such observations have confirmed that osteoblast viability is a fundamental 
tenet of bone homeostasis. Furthermore, the ability to resist apoptosis may be a key 
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determinant of whether a matrix producing osteoblast is able to progress towards an 
osteocytic phenotype (Verborgt et al., 2002). This progression was previously viewed 
as a passive process, proceeding as individual cells were enveloped and encased by 
osteoid (Franz-Odendaal et al., 2006). However, it is now seen as active and regulated, 
with protection from apoptosis possibly afforded by autophagy, the process where 
lysosomal degradation recycles cellular products (Xia et al., 2010, Bonewald, 2011). In 
addition, the different forms of cell death may be important; for example, the promotion 
of necrosis with diphtheria toxin following forced osteocytic expression of the toxin 
receptor in mice causes osteoclast activation (Tatsumi et al., 2007). The death of 
osteocytes is now recognised in disorders associated with skeletal instability, including 
osteoporosis, with consequent impairment of the ability to sense micro-damage and 
initiate repair (Weinstein et al., 2000, Kitase et al., 2010, Bonewald, 2011). Osteocyte 
apoptosis can be promoted by treatment with corticosteroids, as well as by oestrogen 
withdrawal; the latter mediated by IL-1 and TNF-α (Emerton et al., 2010). Known 
inhibitors of osteocyte apoptosis include oestrogen, bisphosphonates, calcitonin and 
calbindin-D28k (Bonewald, 2007). However, although resisting apoptosis may help 
prevent bone loss in some circumstances, it may be detrimental in others where 
apoptosis is necessary to initiate the normal housekeeping repair of the micro-damage 
caused by the large mechanical loads continuously placed upon the skeleton. This 
means that the regulation of apoptotic processes in osteoblastic cells has developed 
into a key focus of bone related research, giving several of the observations in this 
thesis particular resonance and potential for future exploration. 
 
The isolated mature osteoblast cannot simultaneously perform all the functions 
necessary to advance bone formation, so subpopulations of cells at various 
differentiation stages, including osteoprogenitor cells, matrix secreting mature 
osteoblasts and osteocytes must be maintained within the skeletal microenvironment in 
order to provide the functional heterogeneity required for bone generation (Aubin, 
2001). This means that, although it can provide valuable insights, the utility of cell 
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culture based in vitro research is quite restricted in its capacity to reflect the overall 
phenotypic diversity present in vivo. The experiments described in this thesis were 
performed in osteosarcoma cells originally derived from malignant bone tumours and 
therefore subject to all the inherent limitations of such an approach. To ameliorate 
potential inconsistencies to some extent, many of the studies were carried out 
simultaneously in both MG-63 and SaOS-2 osteosarcoma cells. Such cells have 
multiple verifiable osteoblastic characteristics, but, almost by definition, are prone to 
exhibit abnormal cellular function, particularly with respect to their proliferation kinetics 
and production of osteoid (Scheven et al., 2002, Pautke et al., 2004, Shapira and 
Halabi, 2009). MG-63 populations, in particular, can be phenotypically heterogeneous, 
with both mature and immature osteoblastic features represented (Clover and Gowen, 
1994). In addition, contact inhibition is often impaired, so they may not be restricted to 
a monolayer in culture (Pautke et al., 2004). However, osteosarcoma cells are 
ubiquitous and valuable in bone cell research, principally because cultures of primary 
osteoblasts are extremely difficult to initiate and maintain. Such primary cultures are 
derived from healthy donor tissue, but quite marked variation is usual between cells 
from different subjects (Katzburg et al., 1999). In addition, purification techniques are 
complicated and can lead to phenotypic inconsistencies (Clover and Gowen, 1994). 
Most importantly from a practical perspective, primary cells can be maintained for only 
3-4 passages before they experience significant drift in their osteoblastic character. 
 
The developing appreciation of the complexity of skeletal biology, particularly with 
respect to the initiation and regulation of bone formation and resorption, has helped 
inform a reassessment of many common bone disorders, including renal 
osteodystrophy (Sprague, 2010). Furthermore, it has begun to explain the apparent 
mismatch between the heterogeneous clinicopathological manifestations of this (and 
other) disorders and the relatively limited pathophysiological rationalisation afforded 
through the conventional framework of abnormal vitamin D and/or PTH metabolism. 
Although the skeleton may appear a static tissue or organ, its biology is in fact 
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extremely intricate and vibrant at the cellular level. The concept of bone remodelling, 
the closely regulated process of osteoclastic resorption and osteoblastic formation, 
originated four decades ago and our current refined, if incomplete, understanding of the 
process has formed the basis of the treatments for osteoporosis in widespread clinical 
use (Frost, 1969, Marie and Kassem, 2011). The term basic multicellular unit (BMU) is 
traditionally used to describe the spatial relationships of osteoclastic and osteoblastic 
subpopulations within a remodelling cavity. However, this is now known to be part of a 
specialised vascular structure, designated the bone remodelling compartment (BRC) 
(Hauge et al., 2001). It is the BRC that is responsible for translating micro-damage into 
coupled osteoclast and osteoblast activity through the signalling of the osteocyte 
network (Eriksen, 2010). The enclosure of regulatory factors within a structure that is 
distinct from the rest of bone allows control of the process without intrusion from the 
many growth factors present in the nearby marrow space. This regulation is 
fundamental, as changes in the balance between resorption and formation will have 
rapid deleterious consequences through either net bone loss or gain, both of which will 
impact on bone strength. Unfortunately, this spatial relationship also provides an ideal 
location for the seeding of malignant metastases (Mundy, 1997). Of note, 
bisphosphonates are now widely deployed to reduce the number of skeletal 
secondaries in several solid organ cancers as well as multiple myeloma. This effect 
has been attributed to the inhibition of angiogenesis, but it may simply reflect the 
reduced number of BRCs and amount of bone accessible to the tumour following the 
use of these agents (Polascik, 2009).  
 
Low bone turnover states are characterised by a decrease in the number of BRCs, 
while high turnover states are characterised by an increase. The normal remodelling 
cycle lasts approximately 200 days, but can be reduced to 100 days in 
hyperparathyroidism, thyrotoxicosis and other high turnover states. Conversely, it may 
exceed 1,000 days in adynamic bone disorder, hypothyroidism and other low turnover 
states (including after treatment with a bisphosphonate) (Eriksen et al., 1984b, Eriksen, 
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2010). Osteoblasts are active for longer, with osteoclastic resorption of a remodelling 
cavity, or lacuna, occurring over a period of 30-40 days, with osteoblastic formation 
replacing this over approximately 150 days (Eriksen et al., 1984a, Eriksen et al., 
1984b). In many disorders, including osteoporosis, osteoblastic refilling of the lacuna is 
impaired, leading to net bone loss (Eriksen et al., 1990). The mechanisms underlying 
cell coupling during this process remain only partly understood, although our 
comprehension has improved greatly over the last decade. Prior to this the prevailing 
view was that the release of growth factors, like IGF-I and other cytokines, embedded 
within the bone matrix during the osteoclastic phase maintained equilibrium by exerting 
control over subsequent formation (Mohan and Baylink, 1996). However, it is now 
recognised that osteoblastic bone formation can advance without preceding 
osteoclastic resorptive activity (Karsdal et al., 2007).  
 
Unfortunately, this quiet revolution in our understanding of bone biology over the last 
ten years has, on the whole, bypassed the clinical renal community. The majority of 
clinicians continue to think from the narrow perspective of surrogate biological markers, 
such as serum PTH, and are generally supported in doing so by national and 
international guidelines, despite the paucity of evidence that underpins them. Although 
the latest KDIGO clinical practice guidelines have generally been accepted and 
adopted internationally (including in the UK) they contain only two 1A graded pieces of 
evidence, and both of these relate to aspects of paediatric, rather than adult, practice 
(Moe, 2009) (Steddon and Sharples, 2011). Abnormal skeletal structure and function 
are virtually ubiquitous in CKD and progress as GFR deteriorates, becoming especially 
prevalent in patients dependent on dialysis (Goldsmith and Cunningham, 2011). 
Furthermore, extraskeletal calcification, particularly vascular, is now firmly established 
as a detrimental consequence of CKD, with growing evidence of significant interplay 
between the skeleton and the circulation (Tomlinson and Cunningham, 2009). In 
general, PTH and other markers in clinical use are poor at supporting decision-making 
in relation to skeletal turnover and integrity. It is easy to overlook the fact that PTH is 
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primarily representative of parathyroid activity, not bone remodelling (Qi et al., 1995). 
The current recommendation of PTH measurement every three months will allow 
assessment of its concentration for 0.003% of the patient’s year, which is clearly 
divorced from any meaningful assessment of the state of a patients’ skeletal health 
(Garrett, 2012). It is interesting that the clinical biomarker in current use with the closest 
relationship to bone turnover is generally underappreciated and therefore underutilised. 
Bone derived alkaline phosphatase is a relatively effective marker of osteoblastic 
activity and is associated with both bone mineral density and fracture risk in dialysis 
patients (Haarhaus et al., 2009, Drechsler et al., 2011). However, its use is not routine, 
perhaps reflecting concerns regarding cross-reaction with liver-derived alkaline 
phosphatase.  
 
Over the years, bone histomorphometry has provided a useful insight into bone 
physiology, particularly with respect to remodelling (Kulak and Dempster, 2010). 
Information acquired using tetracycline double labelling as a time marker have been 
extremely valuable, because it demonstrates the cellular activity of osteoclasts and 
osteoblasts and bone formation (Ott, 2009). However, the histomorphometrical analysis 
of bone biopsy material is now rarely undertaken in clinical practice, further dissociating 
clinicians from the consideration of skeletal health as an end-point of clinical decisions. 
The cellular processes unfolding at the level of the skeleton, such as those presented 
in this thesis, as well as the far-reaching systemic consequences of these, are currently 
poorly conceptualized. This is despite the significant increase in prevalence of low 
turnover, or adynamic, bone disorder; a syndrome that takes its definition from a 
decrease in osteoblast and osteoclast numbers and reduced bone formation (Frazao 
and Martins, 2009). This increase in adynamic bone has been driven by multiple 
factors, including an ageing CKD population, the prevalence of diabetes related CKD 
and, perhaps more controversially, higher calcium loading as part of current treatment 
strategies (Andress, 2008). Whatever its cause, this increase mandates a broader 
clinical appreciation and understanding of underlying bone physiology and 
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pathophysiology. 
 
This is given additional importance when the systemic consequences of CKD-MBD, 
including, vascular calcification and excess cardiovascular morbidity and mortality, are 
taken into consideration. Osteoblasts appear to regulate serum phosphate through the 
expression of factors such as phosphate-regulating gene with homologies to 
endopeptidases on the X chromosome (Phex), dentix matrix protein 1 (DMP-1) and 
FGF-23 (Thompson et al., 2002, Feng et al., 2006, Liu et al., 2006). Phex and DMP-1 
both act to downregulate FGF-23 expression, which facilitates renal phosphate 
reabsorption and the maintenance of normal bone mineralisation (Feng et al., 2009). In 
the absence of either Phex or DMP-1, FGF-23 is elevated in both the osteoblast and 
the circulation, leading to excess renal phosphate wasting and, eventually, 
osteomalacia and rickets (Amatschek et al., 2010, Rowe, 2012). Such observations 
have led to the suggestion that the osteoblast network should be considered as a form 
of endocrine system, given that it has important remote targets including the kidney 
(Feng et al., 2006, Bonewald, 2011). Osteoblast derived FGF-23 may have wider-
reaching importance than the control of renal phosphate handling (Martin et al., 2012). 
Its concentration is elevated in patients with CKD and continues to rise as GFR 
deteriorates (Fliser et al., 2007), an increase that is strongly associated with both 
cardiovascular disease and vascular calcification (Gutierrez, 2010, Bernheim and 
Benchetrit, 2011). It remains to be seen how FGF-23 interacts with tissues other than 
the kidney, but further clarity around these lines of communication should provide 
important insights, not only into disorders of phosphate homeostasis, but also the 
relationship of cardiovascular disease to CKD. In addition, there is increasing evidence 
for close interaction, and perhaps common lineage, between vascular endothelial cells 
and osteoblasts; for example, endothelial cells can promote differentiation of 
mesenchymal stem cells towards an osteoblastic phenotype (Kaigler et al., 2003). Both 
endothelin and vascular endothelial derived growth factor (VEGF) appear involved in 
this cardiovascular and skeletal cross talk (Brandi and Collin-Osdoby, 2006). 
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Osteoblasts express the VEGF receptor and can also express VEGF itself during 
differentiation (Tombran-Tink and Barnstable, 2004). 
 
There has long been speculation that a component, or more likely components of the 
uraemic environment could impede, or disturb aspects of normal cellular function as 
kidney dysfunction progresses (Wills and Jenkins, 1976, Massry, 1977). For bone, it 
has been inferred from the abnormal serum concentrations of many growth factors in 
CKD patients, such as the demonstrable excess of the key resorptive cytokine IL-6, 
that such aberrations have the potential to disrupt the remodelling cycle (Herbelin et al., 
1991). The initial studies presented in this thesis aimed to explore the hypothesis that 
uraemia might exert an influence on the local regulation of bone remodelling through 
altered osteoblastic release of either IL-6, OPG, or both. The most important findings 
were that haemodialysis patients had significantly higher concentrations of IL-6 than 
healthy subjects and that incubation of human osteoblastic cells with untreated sera 
from healthy individuals significantly raised osteoblastic IL-6 production above that 
induced by sera from uraemic subjects. Furthermore, treatment with dialysis did not 
restore the capacity of uraemic serum to augment IL-6 release. In contrast, osteoblastic 
OPG production was no different after incubation with healthy or uraemic serum. These 
findings support the premise that non-dialyzable constituents of uraemic serum might 
influence bone turnover through modified osteoblastic cytokine signalling and therefore 
contribute to the dysregulation of bone turnover characteristic of osteodystrophy. In 
addition, apparent removal by charcoal stripping, but not heat treatment or dialysis, 
suggests that candidate molecules are more complex, perhaps hydrophobic; for 
example steroids, than those susceptible to simple heat denaturation or removal across 
standard haemodialysis membranes. Indeed, the fact that the bone and mineral 
complications of kidney disease are more prevalent, more severe and more difficult to 
treat in dialysis patients emphasizes the known limitations of dialysis therapies in the 
correction of many aspects of the uraemic milieu.  
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The uraemic state is a multi-faceted disorder, meaning that uraemic serum is an 
unpredictable experimental instrument that is susceptible to multiple confounding 
factors; including concurrent inflammation, differing concentrations of circulating 
hormones as well as the possible effects of co-existing co-morbid conditions. Not only 
did this have to be taken into consideration during the interpretation of results, but it 
also guided subsequent experiments in chapters 3 and 4 toward exploration of the 
cellular regulation of osteoblastic cytokine signalling, rather than toward attempts to 
identify those factors in uraemic setting that may interfere with it. The considerable 
heterogeneity of uraemia means that pooled uraemic serum is not likely to replicate the 
complicated and often constantly changing metabolic features of advanced CKD. It will 
also not allow meaningful representation of patient groups classified according to the 
severity of their renal failure or the modality of their dialysis treatment. For example, it 
is known that peritoneal dialysis is a risk factor for low turnover bone disease (Andress, 
2008). With hindsight, the uraemic serum experiments could have been structured to 
include comparisons between sera obtained from patients treated with the different 
dialysis modalities, as well as from patients with advanced CKD who had not yet 
commenced dialysis treatment. Uraemic serum is also likely to be affected by the 
patient’s drug treatments. Many drugs have a prolonged half-life in dialysis patients and 
could be present in considerable excess in serum. The effect of these drugs, as well as 
their retained metabolites, on in vitro systems is unknown, but could be significant. 
Furthermore, in many cases the drug regimens will include active vitamin D sterols, the 
receptor for which is expressed on human osteoblastic cells. Even within dialysis 
modality, it would have been possible, and perhaps more appropriate, to separate 
patients according clinical estimates of bone turnover, using PTH concentration, 
alkaline phosphatase and concurrent treatments as a guide. Such an approach has 
been undertaken by other investigators, including for studies involving SOCS, where 
differential expression of SOCS mRNA has been found according to dialysis modality; 
for example, significantly higher CIS expression in lymphocytes from pre-dialysis and 
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peritoneal dialysis patients, but not from haemodialysis patients (Rastmanesh et al., 
2009).   
 
At the time the data presented was obtained, the growing body of evidence for the 
importance of cytokine signalling in bone health meant that the relatively recently 
described SOCS family of cytokine regulators appeared a novel and interesting group 
to investigate further. Although our understanding of SOCS in many cell systems has 
advanced significantly since their discovery fifteen years ago, the study of their function 
within osteoblasts, and skeletal tissue in general, remains in its relative infancy. Indeed, 
the present studies were the first to demonstrate their presence and inducibility in 
human osteoblastic cells. It is interesting to note that SOCS1 is now believed to 
undertake an important regulatory role in the late stages of osteoblast differentiation, 
given the importance now attributed to cell maturation through matrix-producing and 
osteocytic stages, particularly in light of renewed interest in the latter as a regulatory 
cell for remodelling (Abe et al., 2006). 
 
It is also interesting that SOCS have progressively come under scrutiny in the uraemic 
state, particularly with respect to their association with growth hormone resistance, 
poor erythropoietin response and, more recently, a potential role in CKD progression 
(Rabkin et al., 2005, Tan and Rabkin, 2005, Liu et al., 2011). The initial work presented 
here with conventional RT-PCR showed promise, but results were disappointingly 
inconsistent. Subsequent fluorescence-based kinetic ‘real-time’ PCR significantly 
improved reproducibility and enabled the collection of more robust quantitative data. 
Unfortunately, the detection of SOCS protein proved extremely difficult due to the 
paucity of high-quality commercially available SOCS antibodies at the time. This was 
an experience shared with other laboratories with an interest in this area. In terms of 
mRNA, SOCS were found to be both constitutively expressed and inducible to different, 
and in some cases, surprising degrees by osteotropic cytokines and growth factors. In 
general, the sequential pattern of expression was consistent with a negative feedback 
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function, presumably acting to regulate uncontrolled and potentially harmful over-
stimulation. With hindsight, and given contemporary understanding of the complexities 
of SOCS function, this is an over-simplification of the relationship between relative 
SOCS expression and feedback inhibition. In many systems the effect of SOCS has 
been shown to be highly sensitive, with very small differences in expression leading to 
powerful inhibition of JAK/STAT and other interdependent pathways. The effect of IGF-
I on osteoblastic SOCS1 and CIS gene expression is of particular interest. Reports of 
the effect of IGF-I, traditionally a ‘non-JAK/STAT’ cytokine, on SOCS expression 
remain scarce (Ahmed and Farquharson, 2010). The departure from a strict JAK/STAT 
paradigm for SOCS functionality is also demonstrated by the increased SOCS3 and 
CIS expression following osteoblastic stimulation with LPS. At the time, this finding was 
unexpected, but it is interesting to note that since these data were obtained, SOCS3 
has become recognized as a potent regulator of LPS in many cell systems, particularly 
the CNS(Ramgolam and Markovic-Plese, 2011, Strebovsky et al., 2012). IGF-I induced 
SOCS expression also provides an important reminder of the limitations of in vitro data 
when extrapolated to whole systems or organisms. In transfection models, SOCS1 and 
SOCS3 appear the stronger inhibitors of IGF-I, but in transgenic animals deletion of 
SOC2 causes IGF-I induced gigantism, while CIS over-expression causes growth 
retardation (Alexander and Hilton, 2004).  
 
Beyond inducible expression, a functional role for SOCS was suggested by enhanced 
IL-6 release following SOCS1 and SOCS3 over-expression, as well as the enhanced 
IL-1β stimulated OPG release following SOCS3 overexpression. The finding of intact 
gp130/STAT3 signalling in cells transfected with SOCS3 and producing significant 
amounts of IL-6 supports the involvement of other non-JAK/STAT pathways, as has 
now been demonstrated in many non-osteoblastic cell systems (Cassatella et al., 1999, 
Mansell et al., 2006). In fact, balanced cytokine signalling is likely to depend on 
complex cross talk between numerous intracellular signals, including SOCS, JAK/STAT 
and others pathways, including Ras/MAPK. The isolated study of SOCS functionality is 
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therefore likely to raise as many questions as it answers and further studies would 
need to acknowledge and explore these interdependencies from the outset. 
 
Subsequent experiments utilised apoptotic and necrotic cell death as functional end 
points to determine the role, if any, of SOCS in this crucial component of bone 
remodelling. The anti-apoptotic effect of IGF-I in osteoblastic cells was confirmed, 
underscoring the importance of relative IGF-I resistance to low turnover skeletal 
disorders such as renal adynamic bone disorder (Cao et al., 2007). A reduction in DNA 
fragmentation as well as protease activity, including caspase-3 were consistent 
following IGF-I exposure, although a potential lack of specificity of protease substrates 
should be acknowledged in all the caspase assays presented. It would also have been 
interesting and highly desirable to have explored apoptotic end points in more detail 
with techniques such as viability staining, fluorescence microscopy and quantitation of 
annexin V binding using flow cytometry had the time and techniques been available.  
 
SOCS have been increasingly recognized for their role in the processing of apoptotic 
and survival signals (Sutherland et al., 2007, Yan et al., 2008, Horndasch and Culig, 
2011a). In the present studies, SOCS overexpression did not demonstrably affect 
osteoblast survival and it would be interesting to repeat this and further explore the 
reasons underpinning it; for example, through examination of SOCS-IGF-IR interaction 
and STAT activation under these circumstances. SOCS gene knock down suggested 
that cytokine induced cell loss is mediated differentially depending on the type of cell 
death involved. SOCS1, SOCS3 and CIS all appeared relevant to the protease 
cascade, with reduced basal caspase-3 activity. However, whereas CIS knockdown 
failed to reduce basal necrosis, unlike SOCS1 and SOCS3 knockdown, it did reduce 
IL-1β induced cytotoxicity. Furthermore, SOCS3 knockdown did not affect cytokine-
induced necrosis. It would be interesting to explore these observations further in the 
context of the new knowledge concerning the importance of the different types of 
osteoblastic cell death and their potential relationship to the initiation of osteoclastic 
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bone resorption (Tatsumi et al., 2007, Xia et al., 2010, Bonewald, 2011). As compelling 
as these results are, the possibility of off-target effects of SOCS siRNA not seen with 
control siRNA should be acknowledged. Such effects occur when an siRNA is 
processed by the RNA silencing complex, causing downregulation of unintended 
bystander targets with consequent alterations in the expression of many genes.   
 
The data presented in this thesis add to our knowledge surrounding the cells and 
growth factors involved in the bone remodelling process. Our understanding of 
osteoblast and osteoclast signalling and its regulation is the foundation for the 
development of therapies able to influence bone mass and integrity. Until quite 
recently, these efforts have primarily been focused on the development of drugs that 
can prevent bone loss, usually by targeting bone resorption. Examples of such ‘anti-
catabolic’ agents include oestrogens, selective oestrogen receptor modulators 
(SERMS), bisphosphonates and, more recently, RANK-L inhibitors (Riggs and Parfitt, 
2005). However, the expanding overview of osteoblast biology has started to 
encourage the development of ‘anabolic’ agents that aim to increase bone formation. 
Such anabolic therapies may increase osteoblastic bone formation by promoting 
osteoblast differentiation or preventing their apoptosis (Khosla et al., 2008). The data 
presented here reaffirm the potent anti-apoptotic property of IGF-I for osteoblastic cells, 
a property which are likely to be important for the maintenance of normal bone mass 
(Giustina et al., 2008). In addition, considerable interest remains in the potential for this 
growth factor to be used as an anabolic agent. The concentrations of growth hormone, 
IGF-I and certain IGF binding proteins (IGFBP) are altered in both osteoporosis and 
ageing (Yamaguchi et al., 2006, Amin et al., 2007) In addition, reduced serum IGF-I 
levels are associated with decreased bone strength, while ageing appears to produce 
receptor mediated relative skeletal resistance to IGF-I (Giustina et al., 2008). In animal 
models of osteoporosis, administration of IGF-I promotes bone formation and 
ameliorates bone loss (Fowlkes et al., 2006). PTH is currently the only approved 
anabolic therapy for osteoporosis and exerts its action, at least in part, through the 
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enhanced local production of IGF-I (Jilka, 2007). This therapeutic use of PTH is based 
on the observation that intermittent, rather than sustained PTH administration 
advances bone formation over bone resorption (Compston, 2007). In this situation it 
promotes osteoblastic cell proliferation and extends their longevity through an anti-
apoptotic effect. It also inhibits the Wnt antagonist sclerostin to enhance Wnt signalling 
pathways (Westendorf et al., 2004, Kramer et al., 2010). An alternative approach would 
be to stimulate endogenous PTH secretion using calcium-sensing receptor antagonists, 
or calcilytics (Arey et al., 2005, Kumar et al., 2010). The near future is likely a new 
generation of therapeutic agents that exert their effect through the osteoblast (Marie 
and Kassem, 2011). For example, canonical Wnt signalling has become a key drug 
target. Activation of the canonical Wnt/β-catenin pathway promotes osteoblast 
proliferation and differentiation at the expense of adipocyte differentiation (Bodine and 
Komm, 2006). Consequently, activation of the Wnt signalling with glycogen synthase 
kinase 3 inhibitors produces enhanced bone formation, density and strength in 
osteopenic mice (Clement-Lacroix et al., 2005, Kulkarni et al., 2006). However, given 
concerns regarding the implications of Wnt signalling in cancer development, indirect 
targeting through the inhibition of Wnt antagonists currently shows the most promise 
(Enders, 2009). One such approach is the inhibition of the osteoblastic protein 
sclerostin, a negative modulator of bone formation (Poole et al., 2005). Systemic 
injections of a monoclonal antibody to sclerostin increase bone formation, bone mass 
and strength in osteopenic animals and to lead to an increase in markers of bone 
formation in postmenopausal women (Li et al., 2009, Paszty et al., 2010, Padhi et al., 
2011).  
 
Collectively, the studies presented in this thesis provide several insights into 
osteoblastic cytokine signalling and its regulation under both normal and uraemic 
conditions. Importantly, they contribute to the relatively small number of studies 
concerning the presence and function of the SOCS family in human osteoblastic cells, 
including potential involvement in aspects of cell survival. These findings add to the 
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body of knowledge regarding the coupling of osteoblastic bone formation and 
osteoclastic resorption within the remodelling cycle in both healthy and uraemic bone.  
 
The last decade has seen impressive advances in our understanding of local and 
systemic biology of cells of osteoblastic lineage. The next will hopefully see the benefits 
of this new knowledge realized through the development of meaningful diagnostic and 
therapeutic advances that transfer to the clinical setting. Ultimately, one would hope 
that all clinicians will soon have the tools available to stimulate a more sophisticated 
understanding of the complexity, function and importance of bone tissue and to assist 
them to successfully preserve the skeletal and cardiovascular health of their patients. 
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Appendix 1 Supplementary data chapter 2 
 
Appendix 1.1 Standard curves for IL-6 and OPG DuoSet ELISA 
Development kits  
 
 
 
 
Figure A.1.1 Typical standard curve for IL-6 Duoset ELISA (R&D Systems, Abingdon, UK). 
The relevant sample values were found in the sensitive part of the response curve (above 
300pmo/L). 
 
 
 
 
 
Figure A.1.2 Typical standard curve for OPG Duoset ELISA (R&D Systems, Abingdon, 
UK). The relevant sample values were found in the sensitive part of the response curve 
(above 500pmo/L). 
Absorbance 
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Appendix 2 Preliminary data chapter 3 
 
Appendix 2.1  Verification of MG-63 cytokine response 
 
Effect of IL-1ß stimulation on IL-6 mRNA expression  
 
Preliminary experiments were aimed at confirming the previous observation that IL-1ß 
stimulation augments IL-6 production in MG-63 cells. After harvesting and counting, 
MG-63 cells were plated at a density of 0.5 x 106 cells per well of a 6-well plate in 3 mL 
medium and incubated at 37ºC for 24h in a humidified incubator with an air to CO2 mix 
of 19:1. The cells were then serum starved for 12h, before incubation with either 100 
IU/mL IL-1ß in serum free media or serum free media alone. Cells were harvested at 
times 0, 15, 30, 60, 120 and 240 min, with subsequent mRNA extraction, cDNA 
synthesis and PCR amplification using IL-6 specific primers (forward primer 5’-
CTGCTCCTGGTGTTGCCT-3’, reverse 5’-CCTGCAGCCACTGGTTCT-3’, 35 cycles of 
93ºC for 60s, 60ºC for 60s and 72º for 60s, followed by a further 10min at 72ºC for final 
primer extension). The integrity of RNA for each specimen was verified using human 
GAPDH primers. Results confirmed the IL-6 response of MG-63 cells. Representative 
results are shown in figure A.2.1. 
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Figure A.2.1: Effect of IL-1ß stimulation on IL-6 mRNA expression in MG-63 cells. Gel lanes 
marked with a plus (+) contain products from IL-1ß stimulated cells, while those marked with a 
minus (-) contain (unstimulated) controls. The X-Y plot shows the result of densitometric 
analysis, with IL-6 mRNA production increasing above controls in the IL-1ß stimulated cells 
after 60 min and remaining elevated thereafter. n=1 for each time point. 
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Appendix 2.2 Optimisation of SOCS PCR conditions 
Linearity of cycle number  
Optimisation of the RT-PCR procedure was performed with respect to the number of 
amplification cycles to ensure a linear relationship between the amount of RNA 
template and the optical density of the PCR band generated. Results are shown in 
figure A.2.2. GAPDH and SOCS2 remain linear throughout. SOCS3 is linear between 
cycles 25 to 30 and plateaus thereafter. CIS is linear between cycles 28 and 35. In 
subsequent amplifications 28 cycles were used for SOCS2 and SOCS3 and 30 for CIS. 
Twenty-eight or 30 cycles were used for GAPDH, depending on the (simultaneously 
amplified) amplicon of interest. 
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Figure A.2.2: Optimisation of SOCS PCR conditions: linearity of cycle number. In 
order to ensure a linear relationship between amount of RNA template and optical 
density of the PCR band generated, optimisation of the RT-PCR procedure was 
performed with respect to the number of amplification cycles. 
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Effect of total RNA amounts  
The effect of different total RNA amounts on SOCS detection was investigated by 
varying the starting concentration of RNA template. This was achieved by increasing 
the volume of cDNA (0, 1, 2, 3 and 4 µL) used in PCR amplification (total RNA input 
was kept constant in all first strand reactions). All amplifications were performed using 
the optimum cycle number determined above. For GAPDH, SOCS3 and CIS the 
relationship between the amount of starting cDNA and amount of PCR product is 
approximately linear. For SOCS2 the relationship is no longer linear above 2µL of 
starting product. These results are shown in figure A.2.3. In subsequent reactions 2 µL 
of cDNA were used for SOCS3 and CIS and 1 µL for SOCS2. One or 2 µL of cDNA 
were used for GAPDH, depending on the (simultaneously amplified) amplicon of 
interest  
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Figure A.2.3: Optimisation of SOCS PCR conditions: effect of total RNA amount. The 
effect of different total RNA amounts on SOCS detection was investigated by varying 
the starting concentration of RNA template. This was achieved by increasing the 
volume of cDNA (0, 1, 2, 3 and 4 µL) used in PCR amplification. 
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Appendix 2.3  Effect of serum supplementation on SOCS3 expression 
To investigate the influence of serum supplementation of media on basal SOCS3 
expression, MG-63 cells were grown under the following conditions for 4h: serum free 
media, charcoal stripped 5% FBS or 5% FBS. Charcoal stripping removes many 
growth factors and cytokines that could potentially influence SOCS expression. Results 
are shown in figure A.2.4. No differences were seen in basal SOCS3 mRNA 
expression following 4h exposure to either serum free, serum supplemented, or 
charcoal stripped serum supplemented media. This implies that the effect of media as 
a potential confounding factor could be discarded in subsequent experiments. 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure A.2.4: Effect of media with and without serum supplementation on 
SOCS3 expression. No differences were seen in basal SOCS3 mRNA 
expression following 4 hours exposure to either serum free, serum 
supplemented, or charcoal stripped serum supplemented media. 
 
 
Se
ru
m
 F
re
e
5%
 C
S-
FB
S
5%
 F
BS
Se
ru
m
 F
re
e
5%
 C
S-
FB
S
5%
 F
BS
SOCS3 GAPDH
Se
ru
m
 F
re
e
5%
 C
S-
FB
S
5%
 F
BS
Se
ru
m
 F
re
e
5%
 C
S-
FB
S
5%
 F
BS
 293 
Appendix 2.4 Regulation of SOCS expression by cytokines: stimulation of 
MG-63 cells with IL-1ß and IGF-I 
Following the initial detection of SOCS mRNA in the MG-63 cell line, experiments were 
designed to examine any regulation of expression of SOCS mRNA by the cytokines IL-
1ß and IGF-I. After being harvested and counted, MG-63 cells were plated at a density 
of 0.5 x 106 cells per well of a 6-well plate in 3 mL medium and incubated at 37ºC for 
24h. The cells were then growth arrested in serum starved media for 12 hours, before 
stimulation with IL-1ß (100 IU/mL) or IGF-I (10 ng/mL) for time points between 0 and 
24h. An additional untreated sample was collected at each time point. mRNA was 
isolated from the cells followed by cDNA synthesis and PCR amplification with SOCS 
specific primers. The integrity of RNA for each specimen was verified using human 
GAPDH primers.  
 
Results for IL-1ß are shown in figures A.2.5 (SOCS2) and A.2.6 (SOCS3) and for IGF-I 
in figure A.2.7 (SOCS2 and 3). Due to difficulties experienced in cross experiment 
comparison, representative results are shown. Up to 60min following IL-1ß stimulation 
there were no differences in SOCS2 expression between control and stimulated 
groups. After 60min there was a modest rise in expression in the stimulated arm, this 
was most pronounced at 24h, and 30min following stimulation with IL-1ß there was a 
rise in SOCS3 expression in both the control and stimulated groups. This was more 
pronounced in the stimulated group and persists until the end of the experimental 
period. The reason for the increase in the unstimulated group is unclear, but could 
indicate that there is a certain amount of basal variability in SOCS expression, perhaps 
in response to autocrine factors.  
 
No consistent pattern of expression was seen in either SOCS2 or SOCS3 following 
stimulation of MG-63 cells with IGF-I.  Results for CIS mRNA expression in response to 
either IL-1ß or IGF-I were inconsistent and therefore difficult to interpret.   
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Figure A.2.5: SOCS2 expression following stimulation of MG-63 cells with IL-1ß (100 
IU/mL). Up to 60min there are no differences between control and stimulated groups. 
After 60min there is a modest increase in SOCS2 expression in the stimulated cells 
with respect to controls, though expression in both groups has fallen compared to 
baseline. The difference in expression is most pronounced at 24h. 
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Figure A.2.6: SOCS3 expression following stimulation of MG-63 cells with IL-1ß (100 
IU/mL). After 30min there is a rise in SOCS3 expression in both the control and 
stimulated groups. This is more pronounced in the stimulated group and persists until 
the end of the experiment. 
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Figure A.2.7: SOCS3 (A) and SOCS2 (B) expression following stimulation of MG-63 
cells with IGF-I (10ng/mL). The SOCS2 PCRs in B are run duplex with GAPDH. In 
these representative experiments and repeats, no consistent pattern of expression 
was seen following stimulation. 
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Appendix 3 Supplementary data chapter 4 
 
Appendix 3.1  Effect of SOCS1 and SOCS3 overexpression on caspase-3 
activity and DNA fragmentation with and without treatment with IGF-I  
In these studies, IGF-I has no effect on caspase-3 activity (figure A.3.1a) and DNA 
fragmentation (figure A.3.1b), respectively, in the presence of empty vector. This 
should have acted as a positive control. In the absence of such an effect, no 
conclusions can be drawn from the lack of effect following over-expression of SOCS-1 
and SOCS-3. It is interesting to note the much higher basal caspase activity and cell 
death in these experiments. Such variability is a feature of biological assays, but might 
also indicate that the cells were undergoing unusually high basal apoptosis for 
unspecified reasons during this experiment; e.g. the cells had reached over-
confluence. 
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Figure A.3.1a Caspase-3 activity in cells overexpressing SOCS1 and SOCS3 compared with 
empty vector (EV) controls, with and without 24h incubation with 10ng/mL IGF-I. n=6 for each 
group. No statistically significant differences were demonstrated. 
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Figure A.3.1b DNA fragmentation in cells overexpressing SOCS1 and SOCS3 compared with 
empty vector (EV) controls, with and without 24h incubation with 10ng/mL IGF-I. n=6 for each 
group. No statistically significant differences were demonstrated. 
 
 
 
 
 
 300 
Declaration 
This thesis is my own work, with collaborative work fully acknowledged. It has not 
previously been presented to another institution for a higher degree. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‘There is nothing so fatal to character than half finished tasks’ 
David Lloyd George 
